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Rheumatoid arthritis (RA) is a chronic inflammatory disease of synovial joints. Accumulating 
evidence implicates the pathogenic role of the urokinase plasminogen activation system (uPAS) 
in RA and experimental arthritis models. Collagen-induced arthritis (CIA) is one of the most 
widely used and clinically relevant models of RA for the evaluation of novel anti-arthritic 
therapeutic candidates. Urokinase plasminogen activator-directed monoclonal antibodies have 
shown ameliorating effects in a mouse model of CIA. Previous efforts in our laboratory 
produced novel amiloride analogues as inhibitors of human uPA with improved selectivity over 
other trypsin-like serine proteases (TLSPs). The lead compound, BB2-30F, completely 
eliminated metastasis in uPA-driven mouse xenograft cancer models, suggesting the potential 
for its use in inflammatory disease models such as RA where uPAS is upregulated. As evident 
from the literature, the CIA model in rats more closely recapitulates human RA than equivalent 
models in mice. This motivated our selection of rat CIA for testing the effects of BB2-30F in 
this disease model. However, the uPAS has not been characterised in rat CIA. Thus, the overall 
objectives of the study were to characterise uPAS in female Lewis rat CIA and then to 
investigate the in vivo efficacy of BB2-30F compared to the standard of care treatment 
methotrexate (MTx).  
The first chapter describes inflammation and inflammatory diseases focusing on RA and the 
role of uPAS in clinical and experimental arthritis. In addition, different types of experimental 
arthritis models and their relevance to human RA are discussed. 
Chapter 2 focuses on the materials and methods used throughout the project. This includes the 
optimised methods of emulsification of collagen, arthritis scoring, blood collection and 
processing, tissue harvesting and tissue processing for histology and immunohistochemistry of 
fibrin(ogen) and uPA receptor (uPAR), fluorogenic and chromogenic biochemical assays for 
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uPA activity, casein and gelatin zymography, microCT analysis, auto-CII autoantibodies 
ELISA assay, and cytokine analysis. Methods for statistical analysis of data are also described. 
Chapter 3 focuses on induction, optimisation and characterisation of CIA models in Lewis rats. 
CIA was generated and optimised in rats (12 weeks of age) by immunisation with bovine 
collagen type II (CII) emulsified in incomplete Freund's adjuvant (IFA), followed by booster 
immunisation 7 days later. Clinical and arthritic paw scores and paw thickness were 
significantly higher in CIA versus sham control (received normal saline instead of CII-IFA 
emulsion) animals. Increased anti-CII autoantibodies and inflammatory cytokines in CIA rats 
validated the model as expected and in agreement with previous studies. The endpoint anti-CII 
antibodies titre was a good indicator of model induction, but no correlation between the 
antibodies titre and disease severity was seen. Additionally, histological findings such as 
cartilage destruction, pannus formation and immune cell infiltration and morphological changes 
(as seen on microCT images) confirmed joint damage consistent with RA.  
Chapter 4 describes the use of a uPA-specific chromogenic assay for rat serum and tissue analysis 
and validation of the measurement of uPA in these biological samples using BB2-30F. 
Significantly increased uPA activity was observed in joint tissue homogenates and serum from 
arthritic rats compared to sham controls. uPA activities in tissue homogenates from CIA rats 
showed a moderate to strong correlation to disease severity. Casein-plasminogen and gelatin 
zymography showed higher uPA and MMP-2/-9 activities, respectively, in tissue homogenates 
from arthritic rats than non-arthritic rats. Furthermore, uPAR expression was higher in CIA rat 
joints than in sham control rats as assessed by western blot and immunohistochemistry and 
showed a strong correlation with disease severity. Fibrin(ogen) immunohistochemistry showed 
that fibrin(ogen) clots were present in the inflamed joints but not in the sham control rats, 
mirroring similar deposits observed in clinical RA. Overall, uPA activities in the CIA rats were 
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higher than sham controls, suggesting a pro-pathogenic role for uPAS in the model and its 
suitability for testing uPAS-directed therapeutics.  
Chapter 5 then describes the therapeutic effects of BB2-30F compared to MTx in the rat CIA 
model. The data show that short-term treatment with BB2-30F was ineffective in reducing 
clinical & histological scores or serum cytokines levels. On the other hand, MTx showed 
modest effects on histological scores and differing effects on multiple inflammatory cytokines 
in serum, as well as lower cumulative and average paw scores when compared to the vehicle-
treated group. MTx effectively reduced serum inflammatory cytokines, including IFN, MCPI, 
TNF-α, IL-12p IL-1b and IL-10. Interestingly, there was no significant difference in IL-6 
concentration across any groups. Thus, although MTx did not show improvements in clinical 
scores at the given dose and treatment period, there was sufficient evidence to indicate an anti-
inflammatory response in the model. The chapter also discusses the potential reasons for the 
failure of BB2-30F to ameliorate the disease.  
The final chapter discusses the overall findings of the thesis and the contribution of the work to 
the existing body of literature. The chapter also discusses the key parameters determined during 
the CIA induction, challenges associated with model induction and how to overcome them. 
Moreover, the relevance of uPAS in the rat CIA model in the framework of clinical arthritis 
and in CIA models in other species is reiterated. Finally, a discussion of the limitations of the 
study is presented with an emphasis on addressing the issues and how to mitigate these 
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CHAPTER 1 Introduction 
 
Part of this chapter (specifically section 1.6) includes material that has been published by the 
candidate and will be acknowledged accordingly. 
Reference 
Buckley, B.J., Ali, U., Kelso, M.J. and Ranson, M., 2019. The Urokinase Plasminogen 
Activation System in Rheumatoid Arthritis: Pathophysiological Roles and Prospective 
Therapeutic Targets. Current Drug Targets, 20(9), pp.970-981
2 
 
Rheumatoid arthritis (RA) is an autoimmune disease characterised by chronic inflammation in 
the joints. Although the exact immunopathogenic pathways are yet to be fully understood, 
many contributing processes have been investigated as pathogenic targets. This chapter aims 
to describe the pathophysiology of inflammation, experimental models, and current treatments 
for RA. Furthermore, this chapter will delve into the wealth of experimental and clinical 
evidence implicating a role for the urokinase plasminogen activation system (uPAS) in 
inflammatory arthritis. 
1.1 Inflammation 
Inflammation is an essential part of the immune system providing a protective response against 
invading danger, including infectious pathogens, tissue injuries and other noxious stimuli 
(Medzhitov, 2010).  The classical signs of inflammation, such as redness, heat, and swelling, 
have been known to humankind since time immemorial. The triggering stimulus may range 
from an exogenous substance to endogenous cells or proteins. In addition to the primary role 
of inflammation in defence also helps maintain homeostasis and the tissue healing processes 
(Lehnardt, 2010).  
The precise mechanisms involved in inflammation are yet to be completely defined, but 
extensive work has studied the cellular and molecular processes underpinning acute and 
chronic inflammatory diseases. An interested reader may refer to the comprehensive literature 
on the topic (Scrivo et al., 2011, Medzhitov, 2010). Whereas a localised inflammation caused 
by infections (acute inflammation) is partly understood, comparatively little is known about 
inflammation in chronic autoimmune diseases that appear to be triggered by malfunctioning of 
the immune system (e.g., diabetes, cardiovascular diseases and rheumatoid arthritis) (Scrivo et 
al., 2011, Gong et al., 2020, Speca and Dubuquoy, 2017). In contrast to acute inflammation, 
chronic inflammation is not necessarily due to injury or infection. The inflammatory processes 
in healthy inflammation (e.g., wound healing and tissue repair) become aberrant and potentially 
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harmful in chronic disease states.  The primary role of an inflammatory response is to increase 
blood flow, maximising the supply of blood components like plasma and leukocytes to the 
affected area. This increased supply of blood components helps tissue fight against the invading 
threat and repair itself from damage. The specific inflammatory pathways vary greatly 
depending on the nature of the initiating stimuli (Greten and Grivennikov, 2019). The helper T 
cells (Th-cells) and B-cells cause the activation of neutrophils and their recruitment to the 
affected area. B-cells produce antigen-specific antibodies, which causes antigen recognition 
and neutralisation and trigger other inflammatory cells (e.g., neutrophils) to the affected area. 
T-cells activate helper T-cell 1 (Th1), promoting extravasation of neutrophils to the inflamed 
site to clear the antigen (Figure 1.1). 
During infection, inflammation is triggered by the innate immune system through the action of 
various receptors, such as nucleotide-binding oligomerisation-domain (NOD protein)-like 
receptors (NLRs) and toll-like receptors (TLRs) (Barton, 2008, Nathan and Ding, 2010, Greten 
and Grivennikov, 2019). Macrophages and mast cells residing in tissues help recognise 
infectious agents at earlier stages and produce various inflammatory mediators, such as 
cytokines, chemokines, eicosanoids and proteolytic cascade (Oishi and Manabe, 2018). These 
mediators' primary effect is a rapid increase in blood vessels' permeability, enabling plasma 
protein and leukocytes to easily pass into the extravascular interstitial spaces. The leaky 
endothelial junctions selectively let plasma, protein and white blood cells enter interstitial 
spaces. The filtrate is known as exudate, a key source of inflammatory material in the affected 
area. The endothelial-cell selectins with protein integrins and chemokines receptors on 
leukocytes are believed to offer this type of selective permeability of blood vessels (Pober and 
Sessa, 2007). After reaching the affected tissue, neutrophils are activated by cytokines (e.g., 
tumour necrosis factor (TNF) and interleukins (ILs)) secreted by tissue-resident cells or direct 
contact with the pathogen. Following activation, neutrophils release various toxic species, 
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including reactive nitrogen species (RNS), reactive oxygen species, specific proteinases, 
elastases, cathepsin G, IL-1 and IL-6 and TNF, that function to kill the invading pathogen 
(Nathan, 2006). The non-specific nature of these effectors often causes significant collateral 
damage to the host (Nathan, 2002). A successful inflammatory response ideally results in 
eliminating the pathogens and follows a resolution and repair phase. The transition from 
inflammation to resolution requires a control mechanism mediated by the balance between pro-
inflammatory prostaglandins to anti-inflammatory lipoxins (Dennis and Norris, 2015, Das, 
2016). 
In contrast to the pro-inflammatory mediators, like prostaglandins, lipoxins promote 
monocytes recruitment and inhibit neutrophils. The recruited monocytes, in turn, facilitate 
tissue remodelling and repair (Serhan and Savill, 2005). In addition to lipoxins, other classes 
of lipid mediators, i.e., resolvins and protectins, and growth factors including transforming 
growth-β (TGF-β) play a vital role in the resolution and tissue repair phases of inflammation 
(Serhan, 2007, Serhan and Savill, 2005, Das, 2016).  
Failure of an inflammatory response to eliminate and resolve a pathogen may lead to persistent 
inflammation that begins to acquire new features. Instead of neutrophil infiltration, 
macrophages and T-cells may be activated. If these effectors combined, efforts are still 
ineffective in eliminating the pathogen, the formation of granulomas and tertiary lymphoid 
tissues occurs, indicating the chronic state of inflammation (Drayton et al., 2006). Granulomas 
are formed when macrophages fail to engulf pathogens, where several layers of macrophages 
wall off invaders. This sequestration marks a final attempt of macrophages to protect the host 
from the invading pathogen.  Following this, a state of chronic inflammation can occur due to 
the persistent pathogen and autoimmune responses of the immune system (Serhan and Savill, 
2005, Drayton et al., 2006). Besides, B-cells activation results in antigen-specific antibodies.  
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Systemic symptoms of chronic inflammation appear when there is excessive production of 
inflammatory mediators following failure to resolve an acute inflammatory response 
completely. The secretion of C-reactive protein and coagulation factors (acute phase protein) 
by the liver and other inflammatory cytokines causes the production of prostaglandins by brain 
endothelial cells. These mediators act on the central nervous system to produce symptoms like 
fever and pain (Hopkins, 2007, Garami et al., 2018). Cells of the innate and adaptive immune 
system express transmembrane receptors known as pattern recognition receptors (PRRs), 
which help initiate inflammatory stimuli by the immune system. These PRRs provide a basis 
to the immune system in sensing the presence of any invading infectious substance or any 
cellular damage (Ito et al., 1992, Joosten et al., 2008). 
1.2 Chronic inflammation and chronic inflammatory diseases 
As discussed earlier, an inflammatory response is a controlled process and terminated once the 
potential danger is over and the tissue damage is repaired (Figure 1.1). This controlled 
response is called the resolution of inflammation, where the inflammatory response reverts 
rapidly to a normal homeostatic state. The resolution process is complex, and many anti-
inflammatory mediators play roles, such as glucocorticoids, interleukin-10 IL-10, and TGF-β 





Figure 1.1: Process of inflammation and its aftermaths. When encountered by the immune 
system through antigen-specific T-cells, external antigen or autoantigen triggers either the T 
cells pathway or B cell pathway for its removal. The activated B cells release antigen-specific 
antibodies, which complement the system causes the recruitment of neutrophils to the site and 
the activation of macrophages to clear the antigen. In parallel, the T-cell pathway activates Th1 
cells, which also cause activation and recruitment of macrophages. In the case of external 
antigen, when the inflammatory process is successful, the antigen is cleared. In the case of 
autoantigen, the process continues as there is no clearance of the autoantigen. Adapted from 
(Kumar et al., 2004, Ryan and Majno, 1977, Majno and Joris, 2004) 
 
Unresolved inflammation is one of the common features of various types of inflammatory 
diseases such as diabetes, obesity, neurodegenerative, asthma, cancer, and RA (Nathan and 
Ding, 2010). The most common factors in chronic inflammatory diseases are the failure to 
remove triggering stimuli and persistent cell injury (Kumar et al., 2004, Ryan and Majno, 1977, 
Majno and Joris, 2004). The pathogenesis does not result from the pathogen, but damage to 
host tissue cause ongoing inflammatory response (Nathan, 2002, Nathan and Ding, 2010, 
Libby, 2007). The following will focus on RA as an example of chronic inflammatory disease. 
1.3 Rheumatoid arthritis (RA) 
Arthritis is a broad diagnosis that describes any inflammatory condition in joints characterised 
by swelling, pain, and stiffness (and, in severe cases, complete immobility) (Gough et al., 
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1994). Arthritis may be autoimmune, inflammatory, infectious, metabolic, and degenerative 
(Brewerton, 1988). RA is one of the most common types of inflammatory arthritis, where 
persistent inflammation in the synovium causes hypertrophy of soft tissues (known as pannus), 
which is a common characteristic in RA (Cassim et al., 2002). A comparison between normal 
and arthritic knee is shown (Figure 1.2). As one of the most common and debilitating chronic 
inflammatory diseases, RA affects approximately 1% of the world population (Clough, 2009), 
with an annual incidence rate of about 20-50 new cases per 100,000 people worldwide 
(Belostocki and Paget, 2001).  
 
Figure 1.2: Normal and RA knee joints. A normal knee joint has clear synovium, intact 
cartilage, and no exudates in the joint. On the contrary, when affected by RA, the synovial 
membrane becomes hyperplastic (pannus), immune cells and proteins extravasate into the 
synovium causing cartilage destruction. Adapted from (Strand et al., 2007)  
 
Based on the Australian Bureau of Statistics 2014–15 National Health Survey data, about 
407,900 Australians, or approximately 2% of the population, have RA (Knox et al., 2008, 
survey, 2014). Furthermore, RA is more prevalent in females and positively associated with 
increased age. One of the most common biochemical markers of RA is antigen collagen type 
II (CII) antibodies, rheumatoid factor (RF) (Waaler, 1940) and anti-citrullinated protein 
antibodies (ACPAs) (Young et al., 1979).  Both the former antibodies have been widely used 
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as markers for the diagnosis of RA. However, ACPAs are regarded as superior to RF, based on 
their increased sensitivity in the early stages of the disease (Aggarwal et al., 2009). Multiple 
variables, including genetic predisposition and environmental factors, have shown to contribute 
to RA progression (McInnes and Schett, 2007).  
The characteristic activation of synovial cells, synoviocytes, is accompanied by infiltration of 
lymphocytes and macrophages. The synovial space is filled with synovial fluid that 
accommodates large numbers of infiltrated neutrophils in a single day during the course of RA 
disease (Hollingsworth et al., 1967) (Figure 1.2). These neutrophils have a half-life of ~4 hours 
but play an essential role in chronic synovitis. In the synovium, cytosolic peptidyl arginine 
deaminase released by neutrophils is activated in response to extracellular Ca2+ released by 
neutrophils as they die. This enzyme then converts the guanidine side chain of L-arginine 
residues to ureido residues forming citrulline in certain proteins. This is apparent when 
rheumatoid-associated autoantibodies react with the citrullinated proteins (Uysal et al., 2009). 
Therefore, several therapeutic interventions to alter the synovial cellularity and subsequent 
damage to the joint have been investigated.  
1.3.1 Current treatment options for RA and their limitations 
While there is no treatment available to eradicate RA, many drugs have played a key role in 
reducing morbidity and disease progression. Non-steroidal anti-inflammatory drugs (NSAIDs) 
and colchicine are useful in treating symptoms in RA. The class of drugs to manage RA is 
known as disease-modifying antirheumatic drugs (DMARDs) and can be classified into small 
molecule and biological DMARDs (Table 1.1). Early diagnosis and intervention have key 
importance in the successful treatment of RA. Methotrexate (MTx), an antimetabolite that 
interferes with the biosynthesis of pyrimidines and purines, is useful in the treatment of RA. 
MTx alone or in combination with other DMARDs has been a mainstay drug for more than 50 
years, successfully reducing RA progression and joint destruction (Smolen et al., 2014).  The 
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biologic DMARDs include anti-TNF antibodies, IL inhibitors and immunosuppressant drug 
leflunomide (Table 1.2). Targeting specific mediators and pathways (Figure 1.3) aimed to shift 
the paradigm to more targeted therapy and improve overall outcomes in RA; however, their 
use is limited by certain limitations and makes MTx preferable in uncomplicated RA. The 
perceived efficacy, low cost and long history of clinical use make MTx the drug of choice and 
mainstay in the initial and uncomplicated RA cases; however, the risk of liver and renal 
toxicities are significant concerns associated with its use. 
Furthermore, when used in combination, MTx has been shown to increase bacterial infection 
rates related to certain biological DMARDs (e.g., anti-TNFα). Hydroxychloroquine, another 
small molecule DMARD, has been shown to affect eyesight probably through altered 
metabolism of melanin in rods and cones cells, and therefore, routine eyesight monitoring is 
required throughout treatment (Bernatsky et al., 2007, Richter et al., 2016). The biological 
DMARDs are not an answer to treat all inflammatory diseases either, as their efficacy varies 
among individuals presumably due to the variable target expression (Wijbrandts and Tak, 2017, 
Cui et al., 2013). Moreover, the biological DMARDs have additional risk due to 
hypersensitivity reactions in some patients and requiring a professional setup for its 
administration.  
Table 1.1: Examples of currently available therapeutics for the treatment of RA. TNF= 
tumour necrosis factor. Adapted from (Pisetsky, 2017). 
Class  Examples of DMARDs 
Small molecules MTx, sulfasalazine, hydroxychloroquine, 
leflunomide, azathioprine, tofacitinib, 
tacrolimus 
Biologic TNF Blockers (e.g., adalimumab, etanercept, 
infliximab), anti-IL-6 receptor (tocilizumab), 
anti-CD-20 (rituximab) and T-Cells co-







Figure 1.3:  Inflammatory cascade in RA and molecular targets blocked by DMARDs. 
Solid rods in the figure show the critical points blocked by molecular targets agents.  ADA 
adalimumab, IFX infliximab, GLM golimumab, LEF leflunomide, TCZ tocilizumab, ABT 
abatacept, CZP certolizumab pegol, MTX methotrexate, TOF tofacitinib, IL-1β interleukin-1β, 







Table 1.2: Summary of currently available RA treatment options, drug doses and frequencies 
of administration, monitoring required and major adverse drug reactions (ADRs).  
DMARDs Dose frequency Monitoring Major ADRs Ref. 
MTx 7.5 mg weekly 
(Maximum 25mg per 
week) 
With folic acid 1mg 










Sulfasalazine Orally 500mg daily 
taper up weekly basis 
to 1000mg twice daily 




Mansky et al., 
2009) 
Hydroxychloroquine Orally, 200-400 mg 












50 mg weekly SC 
3 mg/kg IV at 0, 2, 
and 6 weeks, THEN q 
8 Weeks thereafter 










(Flouri et al., 
2014) 
Anakinra 100 mg SC qDay CBC, E+C, 
LFT 








Leflunomide 100 mg orally once a 
day for 3 days 
Maintenance: 20 mg 
orally once a day 
CBC, LFT Anemia, neutropenia, 
and severe liver injury 













Azathioprine 1 mg/kg/day IV/PO 
initially in a single 
daily dose or divided 
q12hr 




et al., 2008) 




Hair loss, risk of a 
secondary tumour, 
weight loss and 
allergic reactions 
(Teles et al., 
2017) 
D-Penicillamine Initial: 125-250 
mg/day PO 
Maintenance: May be 
increased by 125-250 
mg/day q1-3Months 









LFT, Liver function test, CBC, complete blood count. B.P, Blood pressure, serum E+C 




1.3.2 Methotrexate as a mainstay treatment in RA 
MTx was first synthesised and described as an analogue of folic acid (pteroylglutamic acid) 
and was shown to inhibit the rate-limiting enzyme dihydrofolate reductase (DHFR) in the 
synthesis of tetrahydrofolate (THF) (Seeger et al., 1949). The product of the DHFR pathways, 
THF acts as a single carbon donor during multiple biochemical reactions involved in the 
biosynthesis of purine and pyrimidines and ultimately DNA and RNA synthesis, which is 
essential for cell division (Brown et al., 2016). Thus MTx, by inhibiting DHFR, ultimately 
inhibits purine synthesis and cell mitosis and effectively treats neoplastic diseases (Morand et 
al., 2020, Abolmaali et al., 2013).  
The rationale for using MTx in RA is its potential to inhibit the proliferation and infiltration of 
lymphocytes, monocytes (Cutolo et al., 2000), and other inflammatory cells to the inflamed 
joints with lesser doses than required for DHFR inhibition (Cutolo et al., 2001). The utility of 
MTx in RA treatment is not linked to direct cytotoxic effects as anti-inflammatory efficacy was 
observed below the doses required for the antineoplastic effects (5 -30 mg for RA vs. 1000-
5000 mg for anticancer) (Cronstein, 2010, Czarnecka-Operacz and Sadowska-Przytocka, 
2014).  Several studies reported that MTx improved disease indicators in RA patients (Williams 
et al., 1985, Andersen et al., 1985, Cronstein, 2005). While multiple mechanisms have been 
proposed for MTx efficacy in RA, the most relevant ones are discussed here (Figure 1.4). 
During the biosynthesis of inosine monophosphate (IMP), an intermediate product 5-
aminoimidazole-4-carboxamide ribonucleotide (AICAR), an analogue of adenosine, is 
generated. AICAR potently stimulates adenosine monophosphate-dependent kinase (AMPK) 
activity in the intracellular region of many cell types (e.g., T cell). Acadesine, a nucleoside 
form of AICAR, enters the cell and inhibits AICAR-transformylase, an essential enzyme 
required to convert AICAR to formylated AICAR (FAICAR). FAICAR is the precursor needed 
for the biosynthesis of IMP and purine. MTx at low doses (as used in RA regimens) inhibits 
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the enzyme AICAR-transformylase, causing the accumulation of AICAR and inhibits the 
formation of FAICAR and ultimately IMP and purine. AICAR has also been shown to enter 
the de novo synthesis pathway of adenosine by inhibiting adenosine deaminase, causing a 
build-up of adenosine and adenosine triphosphate (ATP). Although MTx has been shown to 
reduce the formation of thymidine residues and tetrahydrofolate (THF) by inhibiting 
thymidylate synthase (TYMS) and DHFR in T-cells, respectively, these mechanisms are not 
central in the anti-inflammatory effects of MTx (Segal et al., 1990, Sramek et al., 2017). The 
daily folate supplementation to suppress the side effects does not alter the anti-inflammatory 
efficacy of MTx, suggesting that DHFR inhibition may not be the primary mechanism through 
which MTx reduces inflammation in RA (Friedman and Cronstein, 2019, Sramek et al., 2017). 
The clinical effectiveness and various associated mechanisms have been proposed since then 
and are still evolving (Kremer et al., 1994, Gerards et al., 2003, Friedman and Cronstein, 2019), 
and these have been studied in multiple animal models of RA. 
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Figure 1.4: Anti-arthritic and antineoplastic mechanisms of action of MTx. Folate 
transport-1 helps in the uptake (FOLT-1) of MTx into the cell. MTx in intracellular space 
triggers the release of endogenous adenosine by inhibiting AICAR conversion to FAICAR, 
which in turn inhibits adenosine deamination by adenosine deaminase to inosine. Adenosine is 
a strong endogenous anti-inflammatory molecule exerting anti-inflammatory signalling 
through G protein-coupled adenosine receptors. The direct anti-proliferative effects of MTx 
may in part be helpful in reducing the inflammatory process by reducing the number of 
lymphocytes produced and that infiltrate into the inflamed synovia. Other mechanisms of MTx 
linked to its anti-inflammatory efficacy are suppression of pro-inflammatory cytokines, such 
as interferon-gamma (IFN-γ), TNF-α and Interleukins (IL-4, IL-6 and IL-13) (Wessels et al., 
2008, Friedman and Cronstein, 2019). MTx also decreases intracellular reactive oxygen species 
(ROS) and makes T cells more sensitive to apoptotic pathways (Strauss et al., 2002).  
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1.4 Experimental models of RA 
Animal models have provided an efficient platform to study disease pathology and the safety 
and efficacy of new therapeutic interventions. Given their usefulness in drug screening for 
efficacy and toxicity, the United States Food and Drug Administration (FDA), in consultation 
with the pharmaceutical industry, has developed the guidance document "critical path initiative 
and its influence on new drug development". This document describes how to modernise the 
process of drug development with particular emphasis on the safety of new molecular entities 
(NME) before introducing them to human subjects (Woodcock and Woosley, 2008). 
Furthermore, these guidelines provide a complete path from basic research to post-market 
surveillance of any drug (Woodcock and Woosley, 2008). In addition to various in vitro assays, 
preclinical studies have become an essential part of drug development. Therefore, an animal 
model with a close resemblance provides an opportunity to explore the pathophysiology of the 
disease, effects, and toxicities of treatments.    
The essential criteria for selecting animal species are driven primarily by availability, 
affordability, house reproductive capacity, ease of handling, and pathogenic resemblance to the 
clinical disease (Fox, 2015). A key consideration is how well-established clinical hallmarks 
from the relevant human disease are reproduced by the model and outcomes observed in the 
human disease. Multiple species, including rodents, monkeys, dogs, pigs, and zebrafish, have 
been used in modelling various disease states (Fox, 2015). The ease of handling, reproductive 
capacity and ease of genetic manipulations with inbred strains availability make rodents one of 
the most widely studied and used animal species (Fox, 2015). Like other diseases, animal 
models of inflammatory diseases have faced criticism for their underlying pathologies being 
different from human disease and partial disease-reflective nature (Choy, 2012). Multiple 
experimental models of arthritis have been developed to study RA. These models can 
principally be classified as (i) spontaneous and (ii) immunogen-induced arthritis models. 
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1.4.1 Spontaneous arthritis models 
Although a range of rodents is known to develop arthritic pathology spontaneously, attention 
has been paid to certain species of mice due to their predictable rates of disease induction and 
ease of genetic manipulation (Pouton and Haynes, 2007). Transgenic mouse models have 
provided a means to study the role of specific genes and their interaction with other factors in 
the pathogenesis of the disease, such as K/BxN and transgenic TNF mouse models (Keffer et 
al., 1991, Kouskoff et al., 1996) summarises different types of rodent models with their 
relevance and difference to RA). The K/BxN model expresses mutant T-cell surface receptor 
causing the immune system to misrecognise the body's own major histocompatibility complex 
class II (MHC-II), ultimately resulting in autoimmune arthritis. Transgenic TCR KRN and Ag7 
allele of the MHC class II mice spontaneously produces pathology resembling in some aspects 
(e.g. multiple joint involvement and spontaneous nature) of human RA. 
Interestingly, donor serum from these mice can trigger arthritis in recipient wild-type mice, and 
the model is known as the serum transfer mode (Kouskoff et al., 1996). Another commonly 
used spontaneous model is the TNF-transgenic mouse model. TNF is a superfamily of proteins 
critical for cell signalling and immune responses to the pathogen (Zhang and Yao, 2016). The 
primary activities of TNF are acting as endogenous pyrogen, initiating cachexia, apoptotic cell 
death and inflammation (Kircheis et al., 1992). The transgenic alternation to the gene of TNF 
Tg in mice exhibits pathology recapitulating many of the RA features. The first TNF Tg mice 
were developed in 1991, and the model lacked the essential post-transcriptional elements 
causing excessive transcription and translation of TNF (Keffer et al., 1991). The arthritic 
pathology is triggered as a result of the exuberant production of TNFα.  The TNF Tg may range 
from a single-copy strain, such as Tg(TNF)3647, to those featuring multiple transgene copies 
models, such as Tg(TNF)197. Although not an ideal autoimmune disease model, TNF Tg 
models have many common features with human RA, such as synovial hyperplasia, joint 
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erosion, immune cells infiltration and systemic inflammation. While the multiple transgenic 
copies models are suited to study the acute phases of arthritis due to their short onset, the single 
transgenic copy models are relatively better for progressive stages and chronicity of the disease 
(Adeyemo, 2018, Celvin, 2019, Süß et al., 2015). These models provide a reliable platform for 
in vivo efficacy screening of the selective TNF-targeted therapies (Douni et al., 2004, 
Kaymakcalan et al., 1998, Wu et al., 2019). 
SKG is another example of a transgenic model where a point mutation on zeta-chain-associated 
protein kinase 70 (ZAP 70) causes abnormal cell signalling. ZAP 70 plays a vital role in cell 
signalling, and any mutation in these genes causes abnormal immune response through T-cells 
(SKG strain). The abnormal immune response causes inflammation in multiple organs, 
including joints (Sakaguchi et al., 2003). However, gut flora is essential in initiating this 
response as mice with ZAP 70 mutation under germ-free condition do not exhibit arthritis 
(Rehaume et al., 2014). The manifestation of inflammation in organs other than joints makes 
the model relatively non-specific for arthritic studies. In these models, inflammation 
appearance also depends on gut flora resulting in variable inflammation outcomes.  
Severe combined immune deficiency (SCID) is a congenital syndrome causing loss of T- and 
B-cell functions and loss of immunity (Bosma and Carroll, 1991). SCID mice are severely 
immunocompromised, tolerating human synovial tissue implanted as xenografts making the 
human/SCID (h/SCID) chimeric mice model of arthritis. The h/SCID models provide 
experimental insight into the arthritic human synovial tissues and in vivo fibroblast mediated 
cartilage in mice (Geiler et al., 1994). Although the spontaneous models exhibit some RA 
features, such as joint inflammation, their utility as a drug screening model is limited by their 
specific and known pathophysiology.  
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1.4.2 Immunogen-induced arthritis models 
In contrast to spontaneous models, arthritic pathology in immunogen-induced models is 
induced by antigen or immunogen. The antigen or immunogen may range from collagen to 
components of the bacterial cell wall. The similarities of the latter to the human RA are limited 
to their exacerbation and remission during the reactivation phase of the model (Bevaart et al., 
2010). As this bacterial cell wall induced model is primarily monoarticular and the primary site 
of immunisation is not systemic, it may not reflect most of the critical features of human RA 
(Bevaart et al., 2010). This section, therefore, will focus on adjuvant-induced arthritis and 
collagen-induced arthritis as these more closely resemble human RA (Van Den Berg et al., 
2007, Brand et al., 2007).  
1.4.2.1  Adjuvant-induced arthritis (AIA) 
Freund's adjuvant (FA) is an immunogenic mixture prepared by emulsifying antigen in mineral 
oil, used as an immune booster and was first described by Jules Freund in the 1940s (Freund 
and McDermott, 1942, Freund and Walter, 1944, Freund et al., 1948, Freund et al., 1945). 
There are two variants of the preparation, the complete Freund's adjuvant (CFA), containing 
inactivated dried components from mycobacteria and the incomplete Freund's adjuvant (IFA), 
which does not have the bacterial components. The emulsified FA mixture can elicit a robust 
immunogenic response and enhance the immune response to other co-administered antigens. 
The repeated administration of mycobacterial components may cause severe pathology, such 
as localised necrosis, and therefore, the IFA is preferred where possible (van Eden et al., 1996, 
Hossain et al., 2001, Liu et al., 2009). Lipton and Freund later showed that CFA causes 
inflammation in the central nervous system (CNS) in rats and found that the immunisation may 
elicit autoimmune diseases in rats and mice (Lipton and Freund, 1953, Freund and Lipton, 
1955). Stoerk, on the other hand, was able to show specific immunogenic lesions in rat joints 
after immunisation with CFA and spleen tissues (Stoerk et al., 1954). However, Pearson 
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showed that CFA was the arthritogenic component of the immunisation and not the spleen 
tissue, and therefore, led to the foundation of adjuvant arthritis pathology in rodents (Pearson 
and Wood, 1959).  As MHC and non-MHC genes' role are critical in this model, the genetic 
background used affects the incidence and severity of the model. Rapid onset and progression 
of polyarthritis are the characteristics of AIA in rats (Hegen et al., 2008). Some of the important 
similarities of AIA to human RA are the permanent joint destruction, immune cells infiltration 
and swelling of the joints involved. Although both humoral and cell-mediated immune 
responses are involved in AIA pathology, T-cells have been widely found in the joints. 
Cytokine expression in joints varies with different phases of arthritic phenotype; the earlier 
stages are characterised by TNF, IFN and interleukin-17 (IL-17), but as the inflammation 
progresses, it increases in IL-4, and IL 6 expression is observed. The other cytokines involved 
in the disease are IL-1β, IL-21, TGF-β and monocyte chemotactic protein 1 (MCP1) (Pearson 
and Wood, 1959). Although these models have some similarities to RA, the absence of 
autoantibodies, gastrointestinal tract, and skin involvement limit their use in clinical drug 
screening (Bevaart et al., 2010).   
1.4.2.2 Collagen Induced Arthritis (CIA) 
Though the CIA is inducible in primate and non-primates, rats and mice are the most common 
species used in the CIA model (Brand, 2005). The ease of induction, relatively better 
reproducibility and reliability make this model one of the most commonly used polyarthritis 
models (Trentham et al., 1977, Myers et al., 1997, Kannan et al., 2005).  CIA can be induced 
in rats by injection of type II collagen (CII) emulsified in either CFA or IFA (Cathcart et al., 
1986). In susceptible strains of mice, CII/CFA emulsion causes severe polyarthritis developed 
over a few days (3-6) that lasts for weeks (Courtenay et al., 1980). The CII used in 
immunisation can be either from the murine origin (autologous) or from other species, such as 
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pig and bovine (heterologous) (Larsson et al., 1990, Holmdahl et al., 1985, Rosloniec et al., 
2010, Williams, 2004b). CIA induced with autologous collagen has a delayed onset, lower 
penetrance; however, arthritic symptoms last longer. A similar pathology was reproduced in 
mice (DBA/1) by immunisation with bovine CII, but not collagen I, and this model requires a 
second booster on day 21. The investigators also reported that male mice are more susceptible 
to the CIA than their female counterparts (Courtenay et al., 1980). As CII is the only primary 
type of collagens that constitutes the cartilage matrix, arthritogenicity resulting from CII 
immunisation is not surprising (Brand et al., 2004). The disease progression pattern in males 
immunised with homologous CII in CFA exhibited arthritic symptoms (but not female), 
capturing many features of clinical RA, including a gradual onset, intermittent remission and 
relapse from the disease (Holmdahl et al., 1985, Holmdahl et al., 1986). The CII autoantibodies 
have variable titers in different mice species injected with the same amount of CII antigen and 
were also present in mice without clinical arthritis (Wooley et al., 1981). The wide variability 
in anti-CII autoantibodies suggests that it may not be an exclusive pathogenic and an outcome 
parameter in CIA in mice. The other limitation with mouse CIA models is its dependence on 
specific MHCII haplotypes, such as MHCII I-Aq, with mice having these specific alleles 
susceptible to the immunogenic pathology caused by CII immunisation (Gonzalez-Gay et al., 
1995, Nandakumar et al., 2011).  Watson et al. found that Th1-associated IgG2a-type 
antibodies trigger the complement system and are primarily involved in the inflammatory 
process during the development of the CIA in mice. The antibodies were only present in 
arthritic mice but not in non-arthritic mice (Watson and Townes, 1985). Holmdahl and 
colleagues found that passively transferred CIA immune serum from arthritic mice with CIA 
cause CIA like pathology, which laid the foundation of collagen antibody-induced arthritis 
(CAIA) (Holmdahl et al., 1990, Burkhardt et al., 2002). The development of arthritis in mice 
upon exogenous anti-collagen antibodies and lack of arthritic pathology development in B-
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cells deficient mice demonstrate the vital role of anti-CII autoantibodies in mouse CIA 
(Holmdahl et al., 1990, Burkhardt et al., 2002, Svensson et al., 1998). Arthritogenic 
monoclonal antibodies from arthritic mouse and human IgG in sera from RA patients recognise 
and bind to surface epitopes of intact collagen protein but not to the denatured form (Burkhardt 
et al., 2002, Bäcklund et al., 2002). Overall, CIA models in general, have a close resemblance 
to human RA and is associated with antibody-mediated immunity similar to RA.   
1.4.2.2.1 Histological and clinical features of CIA and their relevance to human RA 
Synovitis positively correlates with the onset and severity of pathology and is a hallmark of 
CIA in rats and mice (Brand et al., 2004, Tsai et al., 2007). The progression of inflammation 
from the acute phase to the chronic is intricate. The simplified pattern follows as immune cells 
infiltrate into the synovium, causing edema, pannus formation and cartilage destruction as seen 
in human RA (Holmdahl et al., 2002).  Osteoclasts, and the small number of CII-specific CD4+ 
T cells, pannus is an essential chemotaxis source and platform for immune cell adhesion and, 
therefore, promotes bone cartilage destruction in the CIA model in a similar way as in RA 
(Latham et al., 2005, Arai et al., 1996, Williams, 2004a). 
1.5 Extracellular matrix (ECM) as a building block for connective tissue 
Cartilage is a major type of connective tissue in the body and is comprised of cellular (e.g., 
chondrocytes) and the non-cellular matrix, also known as extracellular matrix (ECM), 
providing rigidity and resistance to compression. The ECM of the cartilage is one of the 
important targets of autoinflammatory damage in the RA. The primary role of ECM is to 
provide a physical scaffold to which cells can embed and to regulate cellular processes, such 
as cell differentiation, proliferation, adhesion, migration, in the local environment (Figure 1.5) 




Figure 1.5: Important biological functions of ECM: ECM provides a physical scaffold for 
cellular integration in connective tissues. The essential functions include modulating cell 
morphogenesis, cell differentiation and growth, angiogenesis, tissue remodelling during 
normal tissue development and physiological stresses (such as in response to acute injury). 
These physiological roles may turn detrimental if abnormal or unregulated ECM remodelling 
occurs, triggering the pathogenesis of cancer, inflammatory diseases and blood homeostasis 
disorders.  Adapted from (Ghanemi et al., 2020, Jarvelainen et al., 2009). 
 
Each tissue in the body has an ECM with a unique composition of fundamental components of 
ECM, i.e., water, polysaccharides, and proteins, engendered during the tissue-development 
process through a tightly regulated and dynamic biochemical communication between the cells 
and surroundings. The important cellular components of ECM include fibroblasts, epithelial 
cells, and adipocytes. Moreover, the fundamental elements and nature of ECM in a specific 
tissue is unique and is temporally and spatially regulated (Harburger and Calderwood, 2009, 
Frantz et al., 2010, Humphries et al., 2006, Hynes and Naba, 2012). ECM is majorly composed 
of fibrous protein (secreted by non-activated fibroblasts and adipocytes) and proteoglycans 
(PGs), such as hyaluronic acid and decorin (Jarvelainen et al., 2009, Schaefer and Schaefer, 
2010, Rozario and DeSimone, 2010). Different types of collagens, fibronectins, elastins and 
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laminins comprise a major part of the fibrous protein network (Jarvelainen et al., 2009, 
Schaefer and Schaefer, 2010). Among the fibrous proteins, collagen is the most common ECM 
constituent and makes up to 30% of most animals' total protein composition.  The structure and 
function of ECM is a crosstalk between cellular and non-cellular components of ECM; for 
instance, the non-activated fibroblasts secrete elastin, collagens (type I and III) and PGs and 
regulate their consolidation to form a tensile structure (Paszek and Weaver, 2004).  
The structure and functions of ECM are dynamic and adaptive to any change in the 
microenvironment through remodelling. This is also true of cartilaginous ECM. The tightly 
regulated ECM remodelling takes place either by enzymatic or non-enzymatic processes, as 
the cells constitutively synthesise and degrade ECM by proteolysis and chemical modifications 
(post-translational modifications) (Rozario and DeSimone, 2010). Dysregulation of these 
processes results in pathologies such as RA. A key proteolytic system affecting ECM 
remodelling is the plasminogen activation system. 
1.6 Plasmin(ogen)/Plasminogen Activation System (PAS) and proteolysis of ECM 
Findings from clinical and experimental studies have long implicated the urokinase 
plasminogen activation system (uPAS), which ultimately generates plasmin, in the 
pathogenesis of RA (Buckley et al., 2019). The PAS has been shown to be involved in 
coordination, adhesion and detachment of inflammatory cells, including macrophages in 
underlying ECM. The main components of the PAS include plasminogen, plasmin, the 
plasminogen activators, urokinase-type plasminogen activator (uPA) and tissue-type 
plasminogen activator tPA. Plasminogen is an inactive zymogen of plasmin that requires 
enzymatic cleavage of a single peptide bond at Arg560-Val561 for activation. The two types 
of plasminogen activators, i.e., tPA and uPA, are structurally distinct and differ in their tissue 
localisations, tPA being the predominant PA in the blood responsible primarily for fibrinolytic 
processes and uPA in the viscera responsible primarily for tissue remodelling and cell 
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migration (Binder et al., 2002, Baker and Strickland, 2020). Urokinase-type plasminogen 
activator is secreted as a heavily glycosylated single-chain zymogen (also known as pro-uPA) 
that requires proteolytic cleavage at Lys158-Ile159 to enable catalytic activity (Ichinose et al., 
1986). After binding to its cognate cell surface receptor uPAR, pro-uPA is more efficiently 
converted via proteolysis into active two-chain uPA by multiple enzymes, including plasmin 
in a feed-forward loop, which controls the activation of cell surface co-
localised plasminogen to plasmin (Figure 1.6). Here, bound plasmin is protected from 
inhibition by endogenous inhibitors and subsequently cleaves a range of multiple downstream 
extracellular targets, including ECM proteins, latent matrix metalloproteinases (MMPs) and 
growth factors (Danø et al., 1985, Vassalli et al., 1991). Several physiological inhibitors of 
PAS exist, including plasminogen activator inhibitor-1 (PAI-1), plasminogen activator 
inhibitor-2 (PAI-2) (Andreasen et al., 1997, Saksela and Rifkin, 1988) and endogenous 
inhibitors of soluble plasmin like α2-macroglobulin, α1-antitrypsin, and α2-antiplasmin 
(Figure 1.6) (Judex and Mueller, 2005, Travis and Salvesen, 1983). 
Plasmin has been shown to directly degrade ECM by proteolysis of major components, such 
as glycoproteins, laminin, fibronectin, proteoglycans, and elastin (Andreasen et al., 2000, 
Mignatti and Rifkin, 1993, Kwaan, 1992). As mentioned above, plasmin also in-directly 
degrades other ECM components by activating latent (pro-MMPs) to MMPs, which degrade 
collagen, elastins and other proteinous ECM components (Lu et al., 2011). Mainly, due to their 
collagenase activities, MMP2 and MMP9 are more relevant in the context of cartilage ECM 
destruction (Baramova et al., 1997, Ramos-DeSimone et al., 1999). The activated plasmin and 
MMPs cause a highly proteolytic pericellular environment where the broad-scale remodelling 
of ECM occurs, causing degradation of cartilage in the case of RA (Harris, 1993, Huber et al., 




In the extracellular fluid, plasminogen binds to fibrin(ogen) and specialised receptors on the 
cell surface, known as plasminogen receptors (PlnR). In addition to PAIs, there exists a 
protease nexin-1 (PN-1), which is known to regulate the activity of uPA (Ranon and 
Andronicos 2003). Further protease activated-receptor (PAR)-2 activated by plasmin is 
considered the primary mediator in the activation of synovial fibroblasts and the release of 
cytokines and invasion (McCulloch et al., 2018). Both PAR-1 and PAR-2 show significantly 
higher expression in RA synovium than in normal tissues (Xue et al., 2012). 
The chronic activation of the PAS in RA leads to the progressive and irreversible destruction 
of joint tissue (Figure 1.6). This suggests that targeting the early initiation of plasminogen 
activation is a promising therapeutic approach to prevent irreversible damage to cartilage bone.  
The evidence outlining the important role of activated PAS and downstream mediators in RA 





Figure 1.6: The roles of uPAS in tissue remodelling of the knee joint in RA. Pro-uPA binds 
to the surface uPA receptor (uPAR) and is activated to uPA, which in turn efficiently activates 
plasminogen to plasmin. Plasmin can directly degrade some ECM components and activates 
latent forms of growth factors and various pro-MMPs (including the collagenases MMP-2 and 
MMP-9) to their active forms, which degrade ECM and facilitates immune cell infiltration into 
the inflamed synovium. Upregulation/ineffective inhibition of this system leads to unregulated 
ECM remodelling and cartilage destruction, resulting in morphological changes characteristic 
of the arthritic joint. Plasmin also converts uPAR-bound pro-uPA to uPA in a forward feedback 
loop. Anti-plasmin (A.P.) inhibits released plasmin but is ineffective against surface bound 
plasmin. The uPA-uPAR complex also causes intracellular signalling to promote cell 
proliferation and adhesion. PAI-1 and PAI-2 covalently bind to uPA, and the complex is 
internalised, where the uPA-PAI complex is degraded, and uPAR is recycled to the cell surface. 
EC, extracellular IC, intracellular. In a normal knee joint, the pathway is tightly regulated, and 





1.6.1 Plasminogen Activation System in RA 
With respect to clinical data, there are several studies on the expression of PAS components in 
patients with RA (reviewed by (Buckley et al., 2019)). From a clinical perspective, tPA was 
observed at a higher concentration in non-inflammatory osteoarthritis patients than in normal 
subjects (Ronday et al., 1996). However, in the case of inflammatory synovial membrane from 
RA patients, an elevated expression (corresponding mRNAs and antigen) of uPA and 
significantly reduced tPA activity was observed (Ronday et al., 1996, Busso et al., 1997). These 
findings have been supported by biopsy results showing an elevated antigenic level of uPA, 
uPAR and PAI-1 compared to the corresponding plasma levels of these in synovial fluid taken 
from a normal knee. Conversely, the levels of tPA remained unchanged or decreased (Saxne et 
al., 1993, Brommer et al., 1992b, Alain et al., 1992, Belcher et al., 1996a). Interestingly the 
synovial fluid taken from RA patients exhibited increased levels of uPA with or without 
decreased tPA compared to traumatic injury patients or normal knee samples, indicating a 
possible association of uPA levels with disease severity (Brommer et al., 1992a).   
uPA/uPAR-mediated cell surface proteolysis and uPAR-mediated signalling events promote 
inflammatory joint disease, indicating that disruption of this key proteolytic/signalling system 
may provide a novel therapeutic strategy to limit clinical arthritis (Mondino and Blasi, 2004, 
Slot et al., 1999). It has been shown that most of the cell types in the inflamed synovium can 
express uPA and uPAR (to a variable extent), such as synovial fibroblasts, polymorphonuclear 
cells, mononuclear cells, chondrocytes, and osteocytes (Guiducci et al., 2005a). Inflammatory 
mediators such as TNF-α and interleukin 1α (IL-1α) are believed to upregulate uPA expression 
while downregulating tPA. While it is likely that localised plasminogen activation by uPA 
proteolytic activity is the primary means by which uPAS contributes to RA pathogenesis, it is 
possible that plasminogen-independent cell signalling via uPAR also plays a role, such as the 
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mitogenic, adhesive and migratory responses, are plasmin-independent (Guiducci et al., 2005b, 
Waltz and Chapman, 1994, Rabbani et al., 1992).  
Besides the role of uPAR in RA, uPA plays a crucial role in fibrin degradation (Zacharski et 
al., 1992, Weinberg et al., 1991). One of the common features of RA is the intra-articular 
accumulation of fibrin, resulting in aggregate formation in the synovial fluids known as rice 
bodies (Zacharski et al., 1992, Weinberg et al., 1991, Harris, 1993). These fibrin deposits help 
in regulating the intra-articular balance between fibrinolysis and coagulation (So et al., 2003). 
The fibrin degradation matrix through PAS releases D-dimer, a useful measure of fibrinolysis 
in RA (Bloom et al., 2009, Weinberg et al., 1991, Bloom et al., 1998, Carmassi et al., 1994, So 
et al., 2003). The simultaneous presence of uPA and D-dimer in RA synovial fluid suggests 
ongoing fibrinolysis mediated by uPA (Zacharski et al., 1992, Weinberg et al., 1991, Harris, 
1993, So et al., 2003). Moreover, a correlation between decreased uPA and extravascular fibrin 
deposition has been found in other inflammatory diseases, including the inflammatory lung 
injury model (Olman et al., 1995) and septic shock (Yamamoto and Loskutoff, 1996). D-dimer 
and other fibrin degradation products act as chemoattractant, promoting inflammatory cells' 
migration to the synovium. 
Furthermore, insufficient nutrient uptake can cause localised hypoxia and concomitant acidosis 
in synovial fluid, exacerbating the local inflammatory responses. The fibrin meshwork in 
extravascular regions provides a temporary scaffold for inflammatory cells to adhere to (Altieri, 
1993, Kim et al., 2011b, Wells, 2008). When injected into the joints, fibrin induces 
inflammatory arthritis in rabbits previously immunised with human fibrin (Dumonde and 
Glynn, 1962).   
In contrast to uPA, tPA expression levels and activity are generally decreased in RA (Ronday 
et al., 1996). Similarly, tPA proteolytic activity was undetectable in articular cartilage from RA 
patients undergoing total knee arthroplasty (Kikuchi et al., 1996). Only one study found 
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significantly increased tPA antigen levels in RA relative to OA samples, where uPA, uPAR 
and PAI-1 antigen levels were raised significantly (Belcher et al., 1996b). This downregulation 
of tPA expression may be localised to arthritic joints as circulating tPA, along with PAI-1, are 
significantly increased in blood samples from RA patients and correlate with a greater risk of 
hypertriglyceridaemia and insulin resistance (Dimitroulas et al., 2013). This pattern contrasts 
with OA, where tPA activity is strongly dominant over uPA or in healthy synovium where uPA 
activity is undetectable (Busso et al., 1997). In the RA synovium, high levels of uPA activity 
are observed throughout the entire synovial membrane, whereas in OA, tPA activity is confined 
to the luminal face of the vascular endothelium (Busso et al., 1997). As such, the prevalence 
of uPA over tPA in the affected joints appears to differentiate the reactive arthritis, like RA and 
Sjögren's syndrome, from OA, where tPA expression predominates (Slot et al., 1999). As the 
primary physiological role of tPA is to facilitate fibrin clearance via its direct binding to fibrin 
clots (Urano et al., 2018), downregulation of fibrin turnover has severe implications in RA (So 
et al., 2003). As mentioned above, detectable fibrin deposition is a diagnostic characteristic of 
RA joints (Galvez et al., 1992) and is believed to promote sustained inflammation and tissue 
damage in the synovial space (reviewed (Busso and Hamilton, 2002)). Indeed, the balance 
between uPA/tPA expressions appears to play a key role in the dysregulation of fibrin clearance 
in diseased synovium and the wider extravascular coagulation observed in joints of RA patients 
(Buckley et al., 2019). 
1.6.2 uPAS-mediated effects in animal models of RA 
We have published a detailed review of studies concerning the consequence of manipulating 
various components of the uPAS in mouse models of RA (Buckley et al., 2019), and key 
findings are summarised below.  
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Decreased uPAR expression in synovial fibroblast has found to be associated with a significant 
reduction in invasion of human cartilage in vitro and RA symptoms in SCID mice (Serrati et 
al., 2011). 
These studies were based on the targeted deletion of specific PAS components; some results 
have shown that targeted deletion of uPA, tPA or plasminogen caused an accumulation of fibrin 
and exacerbation of joint inflammation (Cook et al., 2002, Busso et al., 1998).  However, other 
studies have shown that deletion of plasminogen or uPA produces milder disease than the wild-
type control (Li et al., 2005a, Cook et al., 2002). Moreover, fibrin has been found to induce 
inflammation in joints with silicone rubber prostheses (Gordon and Bullough, 1982), and 
spontaneous fibrin deposition has been reported on surfaces of implanted joints (Gordon and 
Bullough, 1982, Tang and Eaton, 1993). Although a precise answer to these mixed and 
contrasting findings regarding the role of fibrin deposition and uPA is yet to be found, these 
may be attributable to the differences in pathophysiology seen in different RA models 
(Thornton et al., 2017, Li et al., 2005a, Cook et al., 2002). Tranexamic acid (an inhibitor of 
plasmin formation) reduced arthritic progression in the septic arthritis model of arthritis, 
suggesting the role of plasminogen in inflammation (Kłak et al., 2010). TNF-driven Tg197 
model mice showed region-specific results in the animal where an exacerbation of the 
symptoms was reported in paw joints with entirely diminished pathological spectrum in the 
knee joints, suggesting the possibility of a joint-specific role of the PAS system in arthritis 
(Raghu et al., 2014).  
As discussed, plasmin can activate latent forms of specific MMPs (Kim et al., 2012) and 
therefore can cause indirect degradation of ECM of the synovial joint (Knauper et al., 1996, 
Nagase et al., 1990, Werb et al., 1977, Eeckhout and Vaes, 1977) through different 
mechanisms, such as intracellular signalling via PAR-1 in association with integrin 9 
(Majumdar et al., 2004), complement system activation (Li et al., 2005a), activation of the 
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latent form of growth factors, such as TGF (Rifkin et al., 1999, Jenkins, 2008) and release of 
insulin-like growth factor-1 IGF-1 (Campbell and Andress, 1997). On the other hand, uPAR 
also has roles independent of localised uPA proteolytic activity through stimulating cell 
signallings, such as cell proliferation, adhesion, differentiation, and migration (Odekon et al., 
1992). The uPAR is anchored to the cell surface via a glycosylphosphatidylinositol (GPI) 
linker. Interestingly having no intracellular or transmembrane domain, uPAR is capable of cell-
mediated signalling, possibly due to association with integrin and other uPAR-associated 
proteins (Yuan and Huang, 2007). It has been shown that activated neutrophils in exudates act 
as an important source of soluble uPAR (suPAR). The activated neutrophils release a 
chemotactically active form of suPAR, which may contribute to the recruitment of formyl 
peptide receptors expressing leukocytes at the site of inflammation (Pliyev and Menshikov, 
2010). The anti-uPA mAbs are in the preclinical development phase for the treatment of RA 
(Almholt et al., 2020). 
1.6.2.1 uPAS in AIA and Septic Arthritis  
The contrasting roles of PA in localised trauma models versus systemic RA models have been 
a subject of debate for over two decades (see (Hamilton, 2008) for review). Many investigators 
have shown that uPA appears to play a protective role, as uPA-/- mice show significantly worse 
pathology in acute antigen-induced monoarticular RA models (Yang et al., 2001). Furthermore, 
PAI-1-/- mice show mild symptoms and decreased fibrin deposition in response to AIA 
compared to the wild-type control (Van Ness et al., 2002), supporting the notion that uPA 
activity is protective in these models via increased fibrinolysis. Similarly, tPA deficiency in 
the acute mBSA/IL-1 monoarticular model (Yang et al., 2001) and Plg deficiency in the classic 
AIA model (Busso et al., 1998) resulted in the worsened disease characterised increased fibrin 
deposition with the joints. These findings demonstrate plasmin-mediated fibrinolysis as an 
essential protective mechanism in models involving the intraarticular administration of mBSA. 
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Similar results have been reported in a monoarticular septic arthritis model, where Plg-/- mice 
show reduced clearance of bacteria and necrotic tissue from affected joints. However, in 
contrast to AIA, differences in fibrin deposition between Plg-/- and WT mice were not seen, 
suggesting that the protective effects of Plg were not a direct result of fibrinolytic capacity in 
this model (Guo et al., 2008). Furthermore, inhibition of Plg cell surface binding using 
tranexamic acid exacerbates arthritic symptoms from systemically administered 
Staphyloccocus aureus (Klak et al., 2010). It was recently shown that exogenous PAI-1 (natural 
inhibitor of uPA and tPA) administration reduced arthritic symptoms in the septic arthritis 
model in mice, delineating the importance of plasmin mediated joint destruction (Sultana et al., 
2019). 
1.6.2.2 uPAS in CIA and systemic models of polyarthritis 
CIA models differ from AIA, where a humoral immune response is not required for the 
manifestation of pathology (Wong et al., 2006), despite the observation of immune complex 
formation in this model (Fischetti et al., 2007).  In CIA models, Plg itself is essential for the 
initiation of symptoms, with Plg -/-/DBA1 mice showing no signs of arthritic disease following 
collagen immunization (Li et al., 2005a, Li et al., 2005b). Similarly, Plg-/-/DBA1 mice are 
insensitive to the administration of CII autoantibodies (i.e., CAIA), with full disease severity 
able to be restored by the daily administration of exogenous human Plg, suggesting a role for 
Plg in the effector phase of inflammation (Li et al., 2005b).  
While not wholly ameliorative of CIA symptoms, uPA -/- mice typically show only mild signs 
in the CIA model and significantly decreased disease incidence than WT (Cook et al., 2002, Li 
et al., 2005a, Li et al., 2005b). The extent of symptom amelioration is gene-dependent (i.e., 
uPA-/- < uPA+/- <WT) and is affected by the number of backcross generations on to a 
susceptible genetic background (higher the number of generations, the milder the symptoms). 
uPA deficient mice backcrossed onto C57BL/6 mice 8 times showed minimal CIA symptoms 
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(mean clinical score at endpoint = 1.5 ± 0.6, WT = 4.1 ± 1.2) and complete resistance to arthritis 
mediated by serum transfer from KxBN mice or CAIA (Cook et al., 2010). Bone marrow 
chimera experiments revealed that uPA produced by a bone marrow-derived cell lineage was 
required to elicit disease symptoms (C56BL6→uPA-/-) in the CIA model, while the reciprocal 
engraftment (uPA-/-→ C56BL/6) showed that uPA from all other host sources is not sufficient 
to cause disease (Cook et al., 2010).  From this, it was proposed that monocyte/macrophages 
were the most likely source of pro-arthritic uPA, given that lymphocytes are not required for 
disease induction in either the CAIA or KBxN models (Cook et al., 2010).  
The essential nature of the uPAS function in CIA induction was further demonstrated in a 
recent report on the DBA1 background. uPA-/- DBA1 mice showed virtually no clinical arthritic 
symptoms and very mild histological scores following CII immunisation (Almholt et al., 2018). 
Significant decreases in incidence, symptom severity and microscopic disease in knees were 
also observed for uPAR-/- crosses, although to a lesser extent than for uPA-/- mice. Consistent 
with a diminished inflammatory response, significant decreases in paw mRNA levels for key 
inflammatory cytokines were observed for both genotypes, along with minimal fibrin 
deposition in joint sections. Humoral and T-cell responses were found to be unaffected in both 
genotypes, except for decreased IgG2a titres in uPA-/- mice following the CII challenge. 
Similar to observations in uPA-/-/C57BL/6 mice (Cook et al., 2010), bone marrow chimera 
experiments revealed a similarly crucial role for bone marrow-derived uPAR expression for 
CIA pathology (Almholt et al., 2018). WT animals reconstituted with bone marrow transplants 
from uPAR-/- mice (uPAR-/- → DBA1) showed significant decreases in arthritis incidence and 
severity relative to WT chimeras (DBA1→DBA1). Reciprocal chimeras (DBA1→uPAR-/-) 
demonstrated that uPAR competency within bone marrow-derived cells is needed to elicit 
disease. However, the resulting arthritis symptoms showed a lower incidence and were milder 
than in control mice. Again, monocytes/macrophages were suggested as the myeloid cell 
34 
 
lineage most likely responsible for the requisite expression of pro-pathogenic uPAR.  Aside 
from the known pro-inflammatory role of macrophages in rheumatoid arthritis (Udalova et al., 
2016), this hypothesis supports observations that macrophage uPA and uPAR expression are 
induced by inflammatory cytokine exposure (Hamilton and Slywka, 1981, Yoshida et al., 1996, 
Gyetko et al., 1992, Gyetko et al., 1993). Macrophages accumulate in diseased synovium 
(Mulherin et al., 1996), where they mediate joint-specific inflammation via the local expression 
of pro-inflammatory cytokines (like TNFα) (Udalova et al., 2016, McInnes and Schett, 2007) 
and proteases linked to clinical RA progression (e.g., MMP-9) (Kinne et al., 2000). Indeed, 
selective macrophage depletion has been investigated as a strategy for the clinical treatment of 
RA (Kinne et al., 2007, Barrera et al., 2000), supported by studies in the CIA mouse model 
where systemic targeting of macrophages (Li et al., 2012) or synovial macrophage-like cells 
ameliorates disease progression (Van Lent et al., 1998). Furthermore, macrophage cellularity 
in arthritic joints decreases in response to clinical pharmacotherapy (Haringman et al., 2005).  
In contrast, tPA-/- mice show considerably worse pathology in CIA, characterized by increased 
clinical scores, joint fibrin deposition and IL-1β expression (Cook et al., 2002). Thus, 
differential effects of tPA and uPA KO suggest that tPA is the primary mediator of fibrinolysis 
in systemic (CIA) and acute and localised (AIA) arthritis models. In comparison, uPA, through 
its expression in concert with uPAR by infiltrating myeloid cells, appears to play a decisively 
pro-arthritic role in multiple systemic immune complex-mediated models of RA, a part 
mediated primarily through downstream Plg activation (Cook et al., 2002). 
1.7 Rationale and Aims  
As indicated above, upregulated uPAS expression and activity in the clinical scenario suggests 
a pathogenic role in RA. Previous work in this area shows the potential for validating the uPAS 
as a therapeutic target in RA, specifically in uPA proteolytic activity in the diseased joints. The 
targeting of plasminogen activators like uPA has already been investigated as a therapeutic 
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approach to inhibit proteolytic joint destruction in RA using anti-uPA active site monoclonal 
antibodies (mAbs) in mice. In this study, Almholt et al. showed that when uPA proteolytic 
function was disrupted by antibody neutralization, the arthritic and histologic scores were 
diminished in the mouse CIA model (Almholt et al., 2018). The Ranson and Kelso laboratories 
have developed highly potent and selective active site inhibitors of uPA derived from the 
clinically used potassium-sparing diuretic amiloride (Buckley et al., 2018). The lead compound 
BB2-30F (also referred to as AA1-41; (Buckley et al., 2021)) (Figure 1.7) also showed a robust 
in vivo efficacy in xenograft mouse models of cancer and is non-toxic at therapeutic doses 
(Buckley et al., 2018). Given the primary role that uPA overexpression plays in the clinical 
development of RA and the established in vivo uPA inhibitory activity of BB2-30F, there was 










Figure 1.7: Properties of BB2-30F (AA1-41) versus amiloride. BB2-30F is a very potent 
and moderate inhibitor of human and murine uPA, respectively, while amiloride displays 
moderate human and murine uPA inhibitory activity (Ki = inhibition constant; IC50 = 
concentration of inhibitor causing 50% inhibition of the enzymatic reaction). BB2-30F has high 
selectivity over other trypsin-like proteases (TLSPS). Amiloride is a potent epithelial Na+ 
channel (ENaC) inhibitor, while BB2-30F is ENaC inactive, thus eliminating the diuretic or 
antikaliuretic effects otherwise associated with amiloride. The plasma half-life (t1/2) of BB2-
30F in rodents is very similar to that of amiloride. Adapted from (Buckley et al., 2018, Buckley 
et al., 2021). 
 
CIA is a highly relevant model of human RA, and the implications of the uPAS in mouse CIA 
resembles those of human RA. Within the framework of CIA, rat CIA shows a more remarkable 
resemblance to human RA than its mouse counterpart. Previously, no work has been done on 
uPAS in the rat CIA model. Therefore, it was deemed judicious to investigate the pathogenicity 
of the uPAS in rat CIA as a new model for testing the effects of uPA-targeted and established 
therapeutics.  MTx has been a gold-standard drug in the treatment of uncomplicated RA and 
was used in this model as a positive control. As no small-molecule uPA inhibitors have been 
investigated in arthritis models, we aimed to test the therapeutic potential of uPA protease 
inhibition using BB2-30F in the rat CIA model and to determine the effect of short term MTx 
treatment on uPAS in this model.  
Amiloride  
Human uPA 
(Ki = 2433 nM/IC50 = 3954 nM) 
Murine uPA  
(Ki = 2,313nM/ IC50=3310 nM) 
t1/2 (h) = 6.6 (mice)/7.3 (rats) 
BB2-30F 
Human uPA  
(Ki = 53 nM/IC50= 86 nM) 
Murine uPA  
(Ki = 1,611 nM/ IC50= 2305 nM) 
t1/2 (h)= 7.4 (mice)/6.8 (rats) 
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The specific aims of the thesis were to: 
1. develop, characterise, and optimise the rat CIA model (Chapter 3) 
2. characterise the uPAS in the rat CIA model (Chapter 4) 

















2.1 Ethical approval for in vivo experiments 
All experiments involving animals were approved by the Animals Ethics Committee (AEC) at 
the University of Wollongong (approval number AE18/02). All procedures, including 
intradermal injection, intraperitoneal (i.p) injection, blood collection, general anesthesia and 
euthanasia, were performed according to standard operating procedures approved by the AEC 
(AE18/02). 
2.2 Animals and housing 
Female Lewis 8–12 weeks old rats (100-150 g) were sourced from Animal Resources Centre, 
Perth, Australia, and housed in the animal facility at the University of Wollongong. Rats were 
acclimatised to the environment and investigators by daily handling. During the acclimation 
period, unrestricted access to the standard diet (Specialty Feeds Irradiated Rodent Diet) and 
water was provided. During the symptomatic period, Specialty Feeds Irradiated Rodent Diet, 
Nutrigel (mixed with water and food pellets to make a paste), DietGel Recovery and 
watermelon to the animal on the cage floor to provide as easy access for the animals. Soft 
bedding (Bed-R-Nest pucks, paper towels and tissues) was supplied in the base of the top deck 
of the cage (Tecniplast GR1800DD) along with the enrichments (Wooden chew block, tunnels, 
and cardboard houses) to reduce discomfort caused by the floor during the disease.  
2.3 Generation of Rat Collagen Induced Arthritis (CIA) model 
2.3.1 Collagen II emulsion preparation 
A stable emulsion of immunisation-grade collagen type II (Chondrex USA, Catalog # 20021) 
is essential for appropriate immunisation. The CII emulsion was prepared according to the 
Chondrex protocols (https://www.chondrex.com/documents/Rat%20CIA.pdf) with minor 
changes to optimise the stability of the emulsion. Lyophilised bovine CII was prepared at a 
concentration of 2 mg/mL in 0.05 M acetic acid at 4 °C overnight to produce a clear solution 
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and sterilised by filtering through a 0.22 µm filter under aseptic conditions in a biological safety 
cabinet (BSC). The aliquots were either used immediately or stored at -80 °C for later use. 
The emulsion assembly was set up in the BSC and was sterilised with ethanol spray followed 
by ultraviolet (UV) light for 1 hour prior to use. The emulsion preparation assembly consisted 
of a homogeniser (Bio-Gen PRO200, ProScientific) with a 0.7 cm blade held in a stand, the 
beaker containing ice-cold water and a 10 mL syringe (Becton Dickinson) with the plunger 
removed and attached 3-way stopcock (Becton Dickinson) (Figure 2.1). An equal volume of 
incomplete Freund's adjuvant (IFA) (Sigma-Aldrich) was added to the syringe held in the 
assembly; another 5 mL syringe was used to draw collagen solution (equal volume), which was 
slowly added to the IFA dropwise with the homogeniser on at low speed (3,000 rpm). Once the 
collagen solution was added dropwise, the solution was left to cool down for 2 minutes. 
Subsequent homogenisation was carried out in 2-minute spells of homogenisation at high speed 
(15,000 rpm) followed by 2-5 minutes of cooling time. Meanwhile, the emulsion was tested 
for stability by putting a single droplet on the surface of the water in a beaker. A quick 
dispersion of the emulsion indicated instability, while intact droplet floating with no diffusion 






Figure 2.1: Emulsion preparation assembly. The assembly was set up under sterile 
conditions in a BSC, and the emulsion was prepared in a 10 mL syringe held in ice-cold water. 
 
Once the stable emulsion was prepared, the syringes were connected through a 3-way stopcock, 
ensuring no leakage in the tubing. The emulsion was drawn into another 10 mL syringe attached 
to the stopcock and was kept on ice. The desired quantity of emulsion was then drawn using 
the Hamilton glass syringe to administer for immunisation. 
 
2.3.2 Immunisation with CII emulsion and blood collection 
On the day of immunisation, the animals were placed under a warming lamp to improve arterial 
visibility and for a smooth recovery from anaesthesia, with body temperatures checked using 
an infrared thermometer. The animals were removed from cages, weighed, and paw scores 
(details below) were taken prior to anesthesia under isoflurane 1-3% with O2 1-2 L/min. Once 
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rats were anesthetised, an arterial tail prick was performed, blood (150 μL) was collected from 
the tail artery in a non-citrated 3 mL Vacutainer (Becton Dickenson). The rats were then 
administered 200 µL (equivalent to 200 µg of CII) emulsion via intradermal injection at the 
base of the tail, approximately 1 cm away from the flank using a Hamilton Glass syringe (1 
mL) (pre-sterilised by autoclaving). The formation of a white bleb in the skin indicated 
successful intradermal injection. The animals were given 0.9% NaCl saline (5 mL) 
subcutaneously on the back and were placed in an oxygen chamber for a smooth recovery from 
general anaesthesia. The animals were monitored for the appearance of any allergic or adverse 
reaction to the immunisation procedures. A booster dose of the freshly prepared CII emulsion 
of CII (100 µL equivalent to 100 µg of CII) was given 7 days later under general anaesthesia. 
In CII unchallenged (sham control) animals, similar procedures were followed, except 0.9% 
saline was administered instead of CII emulsion on days 0 and 7. All animals were monitored 
for the appearance of arthritic signs, wellbeing, and any untoward effect of immunisation.  
There were two possible endpoints to the study, i.e., scientific endpoint where the treatment 
regimen was continued for the desired period (maximum of 10 days after the booster 
immunisation) or the humane endpoint based on scores (Figure 2.2) whichever arose first. At 





Figure 2.2: CIA Induction and animal monitoring. CIA Rats were acclimated to the animal 
house, and researchers handling them for seven days prior to immunising. On the day of 
immunisation, under general anaesthesia (GA), blood was collected, and 200 µg of CII 
emulsion was injected intradermally (ID) at the base of the tail, followed by another booster 
immunisation on day 7 with 100 µg of CII via the same route and technique as the primary 
immunisation. Baseline photographs were taken, and the rats were monitored, and any sign of 
arthritis was recorded. The treatment was started once the rat reached an individual arthritic 
score of 2 and was continued until the endpoint (either x days post booster or if the animal 
reached a humane endpoint based on weight loss and/or clinical score prior). Animals were 
then sacrificed in a CO2 chamber and blood, and tissues were collected for further analysis ID 
Intradermal injection. The animals were monitored every day for the appearance of symptoms.  
 
2.3.3 Clinical assessment of arthritic and clinical scores 
The arthritic scoring criteria was adapted as previously described with few modifications for 
HEPs (Mossiat et al., 2015, Scales et al., 2016). The extent of paw swelling, redness and the 
number of joints involved were considered for arthritic scores. Arthritic scoring criteria was 
defined as following: 
• 0 for no inflammatory manifestations 
• 1 redness or mild swelling in one joint  
• 2 moderate swelling and redness and or two joints involved 
• 3 swelling and redness in multiple joints with preserved anatomical demarcation  
• 4 maximal swelling, loss of anatomical demarcation, ankyloses of paws 
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In addition to arthritic scores, bodyweight, body condition and hydration status were used to 
determin the composite clinical scores and to determine the overall general wellbeing of the 
animal. The monitoring was performed throughout the model every second day till the 
appearance of symptoms (days 0-12) and every day thereafter. 
2.3.3.1 Arthritic scores 
The fore and hind paws of the animals were assessed for the appearance of any sign of 
inflammation, such as redness and swelling and were scored accordingly (Figure 2.3). 
Following the appearance of arthritic symptoms, a daily arthritic score was recorded as per the 
scoring system described in section 2.3.3. 
2.3.3.2 Paw thickness measurement 
The rats were restrained, and the bilateral rear paw measurements just below the knuckles were 
taken using a digital vernier calliper. The procedure was performed with care and not more 
than 3 times in 7 days to minimise procedure-related discomfort and pain.  
2.3.3.3 Clinical scoresd 
A composite score of arthritic scores accompanied by animal wellbeing scores, such as body 
condition, coat condition and weight loss, were formed to determine the overall outcomes of 
the disease induction on animals and take the non-arthritic aspects and their impacts on the 
model into account. The scoring was done every second day till the appearance of inflammatory 
signs and then every day thereafter by the scorer unaware of the immunisation group. The 
overall clinical score of equal to or more than 14 or individual arthritic paw scores of 4 was 




Figure 2.3: Animal wellbeing and arthritic scoring sheet. The data was updated on a daily 
basis.  
 
2.3.3.4 Blood collection and processing for serum 
Blood samples (about 150 μL) on day 0 (prior to immunisation) were collected from the tail 
artery under general anesthesia. In pilot-I, blood samples were collected 9 days after the initial 
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immunisation to validate anti-CII autoantibodies. For the endpoint analysis, blood samples 
were collected immediately after euthanasia by cardiac puncture. The blood was collected into 
Vacutainer (Becton Dickinson) with no additives and was let coagulate for 20 minutes at room 
temperature followed by centrifugation at 4,000 rpm in a 4 °C centrifuge. The supernatant 
serum was collected,  aliquoted in 100 μL samples and stored at -80°C for later analyses 
(Figure 2.4).   
2.4 Tissue harvesting and processing 
Immediately after euthanasia and blood collection,  right limbs (front and hind) were resected 
with a sharp bone cutter and freed from the skin and excess tissues and snap-frozen in liquid 
nitrogen for tissue homogenisation pre-labelled container and then stored at -80°C. The left 
limbs were harvested and fixed either in Decalcifier-I (for histology) or 10% neutral buffered 
formalin (for microCT imaging).   
2.4.1 Tissue homogenisation 
The snap-frozen tissues were taken out of the -80 ℃ freezer and placed in liquid nitrogen in a 
mortar, and crushed with a pestle to powder form. The powder was reconstituted in a 
homogenisation buffer (8 mL), and the mixture incubated on ice for 30 minutes. Further 
homogenisation was then carried out using Biogen PRO200 homogeniser (ScientificPRO) 
initially at low speed (3,000 rpm) for 2 minutes and at high speed (12,000 rpm) for 2 minutes, 
followed by cooling in ice-cold water, before this step was repeated 4 times for 2 minutes each 
at high speed (12,000 rpm). The homogenate was then centrifuged in a pre-cooled 
centrifugation machine at 4,000 rpm for 10 minutes at 4 ℃. The supernatant was collected and 
assayed for total protein quantification using the Pierce™ BCA Protein Assay Kit (Thermo 
Scientific) as per the manufacturer's instructions, and aliquots were frozen at -80 ℃. No 
protease inhibitors were added to the tissue homogenates to avoid any interference during 
















Figure 2.4: Tissue and blood collection and processing for analysis. After euthanising the animal, blood was collected in a non-citrated 
vacutainer and coagulated at room temperature for 20 minutes. Serum was separated, centrifuged, and aliquots were stored in a -80 ℃ freezer. 
Right limbs (fore and hind) were collected and immediately placed in liquid nitrogen. They were then homogenised in tissue lysis buffer, 
centrifuged, and aliquots stored in -80 ℃ freezer. Left limbs (fore and hind) were collected and immediately placed in Decalcifier-I for fixation 
and decalcification (For microCT analysis, the samples were fixed in 10% buffered neutral formalin and were decalcified after imaging). Tissues 
were cut and processed, embedded in paraffin, and sectioned to prepare slides for histology and immunohistochemistry. 
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2.4.2 Tissue preparation for histology 
Limb tissues were initially placed in the Decalcifier-I for 2 days in 20× volume of that of tissue 
weight. The decalcifier was changed every day. The joints were then sliced horizontally (about 
250 µm each) for more efficient decalcification. The tissues were washed in running water for 
up to 30 minutes, and then the decalcification was continued in decalcifier-II assessed by 
inserting a needle into the joint and observing no hindrance and also the absence of precipitates 
in the decalcifier-II.  
After the decalcification process, the tissues were washed under running tap water for about 1 
hour. The tissue was then dried and put into labelled tissue cassettes. The tissue processor 
(Leica Biosystem) was set to the default rat protocols for overnight tissue processing. The 
processed tissue was then taken out the next day and was embedded in paraffin using the Leica 
Embedding platform (Leica Biosystem).  
The paraffin-embedded tissues were sectioned using a Microtome (Leica Biosystem). Briefly, 
serial 4-6 µm sections were made and mounted on lysine-coated slides, which were allowed to 
dry on a slide dryer setting 6 for 4-6 hours. The slides were then either used for Histology or 
IHC staining. 
2.4.3 Hematoxylin and Eosin (H&E staining) 
H&E staining was performed on a Linear Stainer (Leica Biosystems). The sections were 
deparaffinised in citrulline (2 changes, 2 minutes each) followed by dehydration in 100% 
ethanol (2 changes, 2 minutes each). The sections were then rehydrated in 95% ethanol for 2 
minutes and then 70% ethanol for 2 minutes. The sections were then washed in running tap 
water for 2 minutes and then subjected to Harris hematoxylin solution for 10 minutes. The 
section was then rewashed in running tap water for 3 minutes and then differentiated in 1% 
acid alcohol for 2 seconds, followed by washing under running tap water for 1 minute and 30 
seconds. The sections were then placed in bluing solution (0.2% ammonia water) for 30 
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seconds and washed again for 3 minutes. The sections were then moved to 95% ethanol for 3 
minutes and then to Aqueous Eosin solution for 2 minutes. Dehydration of the sections was 
then carried out by 95% ethanol (2 changes, 2 minutes each) and then in 100% ethanol for 1 
minute. The sections were then cleared with citrulline (a xylene substitute) and covered with a 
coverslip and mounted with mounting media. 
2.4.4 Safranin-O fast green staining 
The Safranin-O, 1% solution, was prepared by dissolving 2.5 grams of safranin-O in 250 mL 
of deionised water. The 0.02% fast green solution was prepared by dissolving 0.05 g of Fast 
Green in 250 mL of deionised water. 1% acetic acid solution was prepared by dissolving glacial 
acetic acid 1 mL in 100mL of 70% ethanol. The sections were deparaffinised in citrulline (2 
changes, 2 minutes each) followed by dehydration in 100% ethanol (2 changes, 2 minutes 
each). The sections were then rehydrated in 95% ethanol for 2 minutes, followed by 70% 
ethanol for 2 minutes. The sections were then washed in running tap water for 2 minutes and 
then subjected to Harris hematoxylin solution for 10 minutes. The section was then rewashed 
in running tap water for 3 minutes and then differentiated in 1% acid alcohol for 2 seconds, 
followed by washing under running tap water for 1 minute and 30 seconds. The sections were 
then taken into 0.02% fast green solution for 1 minute then transferred without washing to the 
1% acetic acid alcohol for 25 seconds. Again without washing, the sections were taken into 1% 
Safranin-O solution for 15 minutes. The sections were then rinsed with 95% ethanol and then 
100% ethanol 3 minutes each. The sections were then cleared with citrulline and covered with 
a coverslip and mounting media.  
2.4.5 Immunohistochemistry (IHC) 
Sections were deparaffinised in citrulline (2 changes, 3 minutes each) and then washed under 
running tap water for 5 minutes. Antigen retrieval was performed using a heat-induced antigen 
retrieval method by placing slides in freshly prepared sodium citrate buffer (10 mM sodium 
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citrate, 0.05% Tween 20, pH 6.0) for uPAR detection or Tris-EDTA buffer (10 mM tris base, 
1 mM EDTA solution, 0.05% Tween 20, pH 9.0) for fibrin(ogen) detection in a water bath set 
at 95 oC for 1 hour. 
A circle was then drawn around the section on the slide using a hydrophobic PAP pen (Abcam, 
Cat# ab2601) and allowed to dry. IHC assays were carried out using a commercially available 
IHC DAB-staining kit (R&D Systems Cat# RDSCTS005). The slides were incubated with 1-3 
drops of blocking solution for at least 15 minutes to block non-specific interactions, drained, 
and excess serum was wiped from sides. The slides were then incubated with 1-3 drops of 
avidin blocking reagents for 15 minutes and were rinsed in the wash buffer provided. Excess 
buffer was wiped away gently, and slides were then incubated with biotin blocking reagent (1-
3 drops) for 15 minutes, followed by rinsing with washing buffer, and any excess was wiped 
away from sides and with care. Primary antibody solutions (either anti-uPAR (Abcam, Cat# 
ab103791) or recombinant antifibrinogen antibodies (Abcam, Cat# ab189490), raised in 
rabbits)  were prepared in dilution buffer, and the slides were incubated with primary antibodies 
(3-4 drops) at 4 °C overnight. The next day, the slides were washed with wash buffer 3 times 
5 minutes each and were drain to remove any excess buffer. The slides were then incubated 
with 3-4 drops of biotinylated secondary antibodies for 1 hour at room temperature. The 
samples were then rinsed with wash buffer 3 times 15 minutes each and drained to remove the 
excess buffer. The samples were then incubated with HSS-HRP for 30 minutes and rinsed with 
wash buffer 3 times 2 minutes each. The desired volume (estimated as the number of slides 
times 150 μL required for each slide) was freshly prepared by adding 1 drop of chromogen to 
1.5 mL of chromogen buffer. 1-5 drops of the chromogen solution were added to each sample 
and incubated for up to 20 minutes; the colour intensity was checked under a microscope. The 
samples were then washed with wash buffer 3 times 10 minutes each and were counterstained 
with hematoxylin and mounted with a coverslip and aqueous mounting solution. 
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Simultaneously, mouse liver (tissue sourced from another experiment through approved tissue 
sharing protocols in place) and kidney were incubated with the same antibodies as per the 
manufacturer recommendation as positive controls.  In parallel, slides were incubated with 
irrelevant IgG isotype to control for non-specific binding of primary antibodies as a negative 
control.   
2.5 Micro-computed tomography (microCT) imaging 
MicroCT images were taken using Skyscan (Bruker microCT Systems) housed at UOW, 
following the manufacturer's specific protocols for rat bone with slight modifications.  Briefly, 
the rat rear knees were taken out of the neutral buffered formalin, dried superficially on a paper 
towel and with a paper tissue and then wrapped in cling-wrap to avoid drying out during 
scanning. The cling-wrapped tissue was then placed in a plastic container and mounted 
vertically on the tissue stand inside the scanning chamber.  
The variables were set as X-ray voltage 70 kV, X-ray current 120 µA, Filter 1 mm aluminium, 
Image pixel size 8-10 µm, camera resolution medium 2000-pixel field width, tomographic 




2.6 Western blotting analysis 
In order to to remove fat content from tissue, homogenate samples were thawed on ice before 
being heated to 75℃ for 5 minutes, cooled and then centrifuged at high speed (16,000× g) at 
℃ for 10 minutes. The total protein concentration in the supernatants was re-estimated by BCA 
protein assay. Aliquots of the supernatants containing the protein extracts were then denatured 
by heating at 95℃ for 10 minutes with 5× reducing SDS-PAGE loading buffer. The protein 
extracts (25 µg, unless specified otherwise) were then resolved on SDS-PAGE (7.5%) gels. 
Proteins were transferred to the Immobilon®  PVDF membrane (Sigma-Aldrich) before being 
stained with Ponceau-S (Sigma-Aldrich) for loading control analysis of blot images taken with 
the Amersham Imager 600 (GE Healthcare, Chicago, IL, USA) using the colourimetric imaging 
method. The Ponceau-S was then washed away with PBST, and the membrane blocked in 10% 
skim milk powder containing Tris-buffered saline with 0.2% Tween (TBST) for 1 hour at room 
temperature. Membranes were rinsed with TBST and then incubated overnight at 4℃ with 
primary antibodies (rabbit anti-uPAR, Abcam cat# ab103791) prepared according to 
manufacturer recommendation in (1:300 in 5% skimmed milk/TBST) with minor 
modifications made to optimise the concentration for each primary antibody. Blots were 
washed extensively with TBST and incubated with secondary antibodies (HRP-conjugated 
goat anti-rabbit IgG antibodies (Cell Signaling, Cat#7074)) (1:5000 in 5% skimmed 
milk/TBST) for an hour at room temperature. After extensive washing with TBST followed by 
a rinse in TBS, the blots were probed with SuperSignal™ ECL reagents (Catalog #34095 
Thermo Scientific). The chemiluminescent images were captured on  Amersham Imager and 
were subjected to densitometric analysis using ImageJ to determine band intensity relative to 
protein loading control.  
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2.7 Casein-plasminogen zymography for uPA activity in tissue homogenates 
Casein zymography was performed as described by Bajou et al., with a slight modification to 
optimise sensitivity for THs (Bajou et al., 2002). Briefly, casein 1 mg/mL solution was 
prepared by soaking 1 gram casein in 60 mL Milli-Q water for 20 minutes then heating to 65℃ 
on a magnetic stirrer 1 mL of CaCl2 (1M) was added to the mixture and stirred. A few drops 
of 10M NaOH were added to the mixture, and stirring was continued till a clear solution was 
obtained. The pH of the solution was adjusted to 8.5 by slowly adding a few drops of 5M HCl. 
The volume was made up to 100 mL with Milli-Q water, and the solution was filtered. The 
casein solution was always freshly prepared on the same day of use. A 7.5% polyacrylamide 
resolving gel (1 mm) was prepared to contain human plasminogen (25 µg/mL final 
concentration), and casein (0.7 mg/mL final concentration). The stacking gel (no plasminogen) 
was poured on the top. The THs samples (30 µg) were incubated with 5× loading buffer  (4% 
SDS, 20% glycerine, and 0.01% bromophenol in Milli-Q water) for 10 minutes on ice and 
electrophoresed at 85 volts (constant voltage). After electrophoresis, the gels were imaged 
before removing the molecular weight protein marker lane. The gel was re-natured using 
renaturation buffer (containing 2.5% Triton X-100, 50 mM Tris HCl, 5 mM CaCl2, and 1 µM 
ZnCl2) 3 times for 30 minutes each. The zymograms were then developed in developing buffer 
(containing 1% Triton X-100, 50 mM Tris HCl, 5 mM CaCl2, and 1 µM ZnCl2 in Milli-Q water) 
at 37℃ overnight. The zymogram was then stained with coomassie blue (See Appendix A) for 
1 hour. The gels were then destained until light bands on the dark blue background were visible. 
Images were taken, and densitometry was performed to quantify the band intensity using Gel 
Doc XR+ System (Bio-Rad). 
2.8 Gelatin zymography for MMP activities in tissue homogenates 
Gelatin zymography was performed as described by Toth et al. (Toth et al., 2012). Briefly, a 
7.5% acrylamide resolving gel (1 mm) containing freshly prepared gelatin (1 mg/mL) was 
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prepared with a stacking gel (no gelatin). THs samples (25 µg) were prepared by dilution with 
assay buffer, loaded and the zymogram run, renatured and developed under conditions identical 
to those of casein zymography (section 2.7) 
2.9 Anticollagen type-II (Anti-CII) autoantibodies determination by ELISA 
The anti-CII autoantibodies were estimated in serum using a commercial ELISA kit (Catalogue 
#2044T; Chondrex, USA) as per the manufacturer's instruction with minor modifications to 
optimise sample dilutions and incubation timings. The serum samples were thawed on ice, 
centrifuged in a pre-cooled centrifuge (4 ℃); the supernatants were then collected and diluted 
(1:30,000) in dilution buffer prior to loading  100 µL into pre-blocked (1 hour at room 
temperature) 96 well plates pre-coated with collagen type-II. Standards were prepared as per 
manufacturer protocols and as per the layout (Figure 2.5). The plates were then incubated for 
2.5 hours, followed by a wash step. The secondary antibodies (in 100 μL) were added into the 
wells and incubated for 1 hour at room temperature, followed by a 15-minute incubation with 
TMB solution (100 μL) for colour development. Stop solution (50 μL) was then added to the 
wells, and the absorbance was read at 490/630 nm. The standard was constructed, and unknown 





Figure 2.5: Plate layout for assessment of CII autoantibodies in rat serum samples. The 
serum samples (denoted as S1 – S39, orange circles) and standards (purple circles, units of 
values shown are units/mL) were run in duplicate. B (white circles) represents blank wells 
containing dilution buffer only for background subtraction. 
  
2.10 Enzyme activity assays 
Urokinase plasminogen activator (uPA) activity assays in tissue homogenates were performed 
as previously described using fluorometric (Buckley et al., 2018) or chromogenic substrates 
with minor modifications (Whyte and Mutch, 2020, Jiang et al., 2016). For the fluorogenic 
assay, the TH samples were thawed on ice and diluted to make a final concentration of 2.5 
µg/µL in HEPES reaction buffer (20 mM HEPES, pH 7.6, 100 mM NaCl, 0.5 mM EDTA, 
0.01% (v/v) Tween-20, 400 nM aprotinin) 10 µL of the diluted TH samples were added to 
wells of a black Greiner CELLSTAR® 96-well plate (Greiner Bio-One GmBH, Kremsmünster, 
Austria), containing a final concentration of 0.25 mM uPA fluorescent substrate III (Z-Gly-
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Gly-Arg-AMC, Calbiochem Cat # 672159, Merck Millipore, Massachusetts, USA). 
Fluorescence was measured kinetically in a pre-warmed (37℃) POLARStar fluorescence 
reader (BMG-Labtech, Ortenberg, Germany) (excitation 355nm, emission 460nm, Gain 
900nm) over 1 hour. Homogenisation buffer blanks for samples and HEPES buffer blanks for 
standard uPA blank subtraction as well as substrate blank controls were used. The activity was 
then determined against a human low molecular weight uPA (LMWuPA) standard (Cat # 
U4010, Sigma-Aldrich, St. Louis, MI, USA) diluted to 0.75 nM. Changes in fluorescence over 
a 10 minute period from the linear portion of the reaction progress curve were used to analyse 
the activity after correcting the data for appropriate blanks.  
 
Figure 2.6: Inhibitory assay layout in the presence or absence of inhibitor as shown. Blank 
wells represent the well containing all the reaction components except the sample. LMWuPA 
(0.75 nM) was used as a positive control for the assay. The final assay contained aprotinin (200 
nM) and 1% DMSO. 
 
For chromogenic assays, the samples and assay set up were prepared in an identical way to the 
fluorimetric assay except for clear Greiner CELLSTAR® 96-well plates (Greiner Bio-One 
+ inhibitor sample 1 sample 1 sample 1 blank 
-inhibitor sample 1 sample 1 sample 1 blank 
+ inhibitor sample 2 sample 2 sample 2 blank 
-inhibitor sample 2 sample 2 sample 2 blank 
+ inhibitor sample 3 sample 3 sample 3 blank 
-inhibitor sample 3 sample 3 sample 3 blank 
+ inhibitor sample 4 sample 4 sample 4 blank 
-inhibitor sample 4 sample 4 sample 4 blank 
+ inhibitor sample 5 sample 5 sample 5 blank 
-inhibitor sample 5 sample 5 sample 5 blank 
+ inhibitor LMWuPA LMWuPA LMWuPA blank 
-inhibitor LMWuPA LMWuPA LMWuPA blank 
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GmBH, Kremsmünster, Austria) and a chromogenic substrate pyro-Glu-Gly-Arg-pNa.HC 
(catalogue # BIOPHEN CS-61(44)CoaChrom Diagnostica) was used. Change in colour was 
measured kinetically in a pre-warmed (37℃) SpectroMaxplate reader (BMG-Labtech, 
Ortenberg, Germany) (405 nm) over 3 hours. Homogenisation buffer blanks for samples and 
HEPES buffer blanks for standard uPA blank subtraction as well as substrate blank controls 
were used. The activity was then determined against a human LMWuPA standard diluted to 5 
nM. Changes in absorbance over a 10 minute period from the linear portion of the reaction 
progress curve were used to analyse the activity after correcting the data for appropriate blanks. 
For inhibitory assays, 10 µL of the uPA inhibitors BB2-30F (synthesised in-house (Buckley et 
al., 2018)), PAI-1(Cat # HPAI-R76E-I91L, Novi, USA)  and PAI-2 ( (human PAI-2 Isoform 1 
expressed in E. coli, Biotech Australia (Roseville, Australia)) at 20× final concentration in  
20% DMSO/HEPES buffer were added to wells resulting in the final desirable concentration 
with 1% DMSO. In these inhibitory assays, the initial volume of HEPES (1% DMSO) buffer 
was reduced to 90 µL to accommodate the  10 µL inhibitor or buffer control addition (Figure 
2.6).  
2.11 Cytokines multiplex assay 
The LegenplexTM 13 inflammation cytokines kit for rat (BioLegend, Cat. No. 740401) was 
used to measure 13 cytokines in serum, including IL-6, IL-10, IL-12p40, IL-17A, IL-17F, IL-
21, IL-22, IL-23p19, IFNγ and TNFα. The assay was performed according to the 
manufacturer protocols with some modifications. Briefly, the entire kit was diluted to double 
the volume of the reagents. The plate layout was designed (Figure 2.7), samples and 
standards were prepared and loaded to the plate.  The serum samples were diluted 4 times by 
adding 25 µL of the sample with 75 µL of assay buffer.  
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2.11.1.1 Performing the assay Using a V-bottom 96-wells Plate  
 All the reagents were allowed to warm to room temperature before use. The plate was kept 
upright throughout the assay to avoid losing beads. During the incubation steps, the plate was 
wrapped with aluminium foil. The samples and standard were run in duplicate in a vertical 
plate layout (Figure 2.7).  
 
Figure 2.7 Legendplex 13 rat inflammation cytokines plate layout. c0-c7 and sample1-
sample40 represent standard and samples (in duplicates), respectively. The layout is sourced 
from the LegengPlex user manual.  
 
The plate was sealed with a plate sealer, and no positive pressure was applied to avoid plate 
leaking. The entire plate was then wrapped with aluminium foil and placed on a plate shaker 
for 2 hours at 500 rpm and room temperature. Remove the excess buffer by pipetting out from 
the top or vacuum.  200 µL of wash buffer 1x was added to every well on the plate, and the 
buffer was then removed. The excess wash buffer was blotted gently on a paper towel. The 
washing step was repeated one more time. Detection antibodies (25 µL) were then added to the 
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plate, and the plate was then sealed with a plate sealer. The plate was again wrapped with 
aluminium foil and placed on a plate shaker at 500 rpm for 1 hour at room temperature. At this 
stage, 25 µL SA-PE was added to each well directly, and the plate was sealed, wrapped in 
aluminium foil, and placed on a plate shaker at 500 rpm and room temperature for 30 minutes. 
The plate was then rewashed again with wash buffer 1x twice, and any excess buffer was 
blotted on a paper towel. Wash buffer (150 µL) was then added to each well, and beads were 
resuspended by shaking the plate on a plate shaker for 1 minute. The flow cytometer was set 
up, and the voltages were optimised with set up beads, and the plate was read. The data was 
analysed by LegenplexTM data analysis software provided by the manufacturer (BioLegend). 
The standard curves were created, and unknown concentrations were calculated accordingly. 
2.12 Graphical presentation and Statistical analysis 
Statistical analyses of data were performed using GraphPad Prism v7. For 2 groups of multiple 
time data, a 2-way ANOVA followed by Sedak and Tukey's tests were done. For 2 groups, one 
point time data, an unpaired, two-tailed student t-test followed by Welch's test were performed. 
Linear regression accompanied by Spearman correlation was performed to determine the 




























Various experimental models of spontaneous and immunogen-induced arthritis developed to 
study RA were described in Chapter 1, section 1.4. Collagen-induced arthritis (CIA) model is 
one of the most commonly used polyarthritis models (Trentham et al., 1977, Myers et al., 1997, 
Kannan et al., 2005). To recap, the CIA is induced in rats by injecting type II collagen (CII) 
emulsified either in CFA or IFA (Cathcart et al., 1986). In susceptible strains of mice, CII/CFA 
emulsion causes the development of severe polyarthritis that starts appearing between day 21-
23 and symptoms typically lasts for 2-3 weeks before a resolution phase starts (Courtenay et 
al., 1980). The CII used in immunisation can be either from the murine origin, i.e., from mouse 
to immunise mouse or from rats to immunise rats or from other species, such as pig, chicken, 
and cow to immunise mice and rats (Larsson et al., 1990, Holmdahl et al., 1985, Rosloniec et 
al., 2010, Williams, 2004b). The CIA induced with autologous collagen has a delayed onset, 
low penetrance, but arthritic symptoms last longer (Larsson et al., 1990, Holmdahl et al., 1985).  
CIA in rodents, in general, recapitulates the fundamental features of human RA, such as 
cartilage and bone destruction, peripheral joints involvement, pannus formation, symmetrical 
joints involvement, hyperplastic synovia, involvement of MHC as well as non-MHC genes 
(Griffiths et al., 2000, Becker et al., 1998, Gregersen et al., 1987, Stuart et al., 1985) and the 
predominant role of autoreactive B-cells, which produce arthritogenic antibodies (Holmdahl et 
al., 1994, Moudgil et al., 2011). Rat CIA has more features in common with human RA than 
mouse CIA, such as the presence of rheumatoid factor, higher susceptibility in females and 
responsiveness to NSAIDs (Figure 3.1). These features make rat CIA a better choice for 
pharmacological testing of investigational therapeutic interventions than in mouse CIA.  
Other similarities of CIA in rodents to human RA include fibrin deposition in the synovium, 
infiltration of monocytes into inflamed synovia, periosteal bone formation, hyperplasia of 
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Figure 3.1: Characteristic features of CIA models and their relevance to human RA.  
Venn diagram showing the hallmarks of CIA in mouse (red) and rat (grey), with overlaps 
showing their similarities and differences to human RA disease (blue). Adapted from (Tuncel 
et al., 2016). 
 
As outlined above and in Chapter 1, the rationale for using the CIA model in rats in this thesis 
was based on 1) the rat CIA model bearing a closer resemblance than murine CIA to human 
RA, 2) more favourable plasma pharmacokinetic properties of uPA targeting compound BB2-
30F in rats compared to mice (Buckley et al., 2021), 3) higher potency of BB2-30F against rat 
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uPA than mouse uPA (see Chapter 4).  Thus, in order to use the rat CIA model for analysis of 
uPAS in this model (described in Chapter 4), this chapter describes the in-house development 
and characterisation of the rat CIA model with the additional aim of optimising the parameters 
used to measure drug treatment outcomes (described in Chapter 5).  
3.2 Material and Methods 
The CII immunogenic emulsion preparation and immunisation of rats, clinical score 
assessments, measurements of autoantigens and cytokines, as well as histological and microCT 
analyses were carried out as described in Chapter 2.    
3.3 Results 
3.3.1 Pilot experiments 
To establish a workable CIA model, two pilot experiments (n = 5 rats each) were carried out 
to assess the tolerability of the disease induction. In Pilot-I, 8-week-old rats (average body 
weight at Day 0 = 145.7 g) were used as described by Chondrex and previous reports. All the 
immunised rats developed visible signs of arthritis, including redness, and swelling in the rear 
paws. The disease started appearing between days 12-15 of the first immunisation and showed 




Figure 3.2: Arthritis progression in paws of young rats.  Representative photographs from 
an arthritic rat on day 0, day 13 and day 23 after primary immunisation. Day 0 photographs 
show no sign of inflammation; day 13 shows moderate swelling and redness in multiple joints, 
and day 23 photographs show gross swelling of the paw and redness in multiple joints. The 
booster immunisation was given on day 7 of the primary immunisation.  
 
There was no significant change in serum anti-CII autoantibodies from day 0 to day 9 (p = 0.59 
Dunnett's t-test), but a significant increase was seen at endpoint compared to day 0 (p= 0.00032 
ANOVA test followed by Dunnett's) (Figure 3.3 A).  
Animal 0001-1 showed moderate arthritic signs on day 12 and progressed to severe arthritis, 
reaching humane endpoint (HEP) on day 27. The moderate inflammation started progressing 
in forepaws from day 15 onwards. The rat with deteriorated body condition could not maintain 
her body weight and stopped eating and drinking water. A subcutaneous Hartman's solution (6 
mL) was injected to improve hydration status. The nutritional and hydration support did not 
help, and the rat reached the pre-determined HEP and was euthanised (Figure 3.3 B). To rule 
out possible vital organs damage to the rat, samples were sent to the COMPATH Lab at South 
Australian Health and Medical Research Institute (SAHMRI). No significant findings were 
observed as a potential cause of the deteriorated condition (see Appendix B) for the detailed 
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report). With the progression of the disease, the arthritic paw scores increased with clinical 
scores in all rats (Figure 3.3 B-C). Once arthritis progressed, bodyweight loss was a significant 
concern as the bodyweight of all animals started decreasing from day 15 and continued until 
day 25 (Figure 3.3 D).  Dehydration and loss of appetite were other factors contributing to the 
worsening condition and severe deterioration of the animals. As these young rats (8-9 weeks 
old at model onset) were unable to tolerate the model well in our hands, we hypothesised that 
older rats with improved strategies for food and water intake and relatively mature immune 
systems may tolerate the disease better. 
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Figure 3.3: Anti-CII autoantibodies in sera and clinical features of CIA in rats. A) Graph 
shows the concentration of anti-CII autoantibodies in serum on day 0, day 9 and endpoint (Data 
shown represent mean ± SEM (n=5, *** p<0.001). B) The clinical scores of individual animals 
after immunisation. The red coloured line indicates HEP. C) Arthritic paw scores and D) 





Pilot-II experiment was thus carried out on relatively older rats (10-12 weeks old, n=5). The 
animals exhibited arthritic symptoms comparable to those observed in the Pilot-I experiment 
(Figure 3.4). One of the arthritic rats developed a slowly progressing disease, initially affecting 
the rear paw unilaterally and then progressed to severe arthritis. One of the rats, coded as 0005-
1, exhibited mild disease with an arthritic paw score of 1 and did not progress to severe disease 
until day 28.  Of the 5 rats, 3 showed onset of moderate arthritis in hind paws at day 12-14, 
observed as an increase in arthritic scores (Figure 3.5A). Animal 0005-2 showed delayed onset 
with the first moderate symptoms observed on day 12. Symptoms were confined to the rear left 
paw with no swelling in the right rear paw. Swelling in the affected paw progressed steadily 
over the next seven days, reaching the highest severity (4/4) observed from either study, 
reaching HEP on day 26. It was found that sc 0.9% saline or Hartman’s solution administration 
helped improve hydration status in moderate to severe dehydration. Although weight loss was 
observed with the older rats, it was evident that they tolerated the model better than younger 





Figure 3.4: Progression of CIA in rats. Representative photographs show the progression of 
redness and swelling in rear paws in CIA rats. Of the five rats immunised, one rat remained 
symptoms-free. 
 
3.4 Validation of anti-CII autoantibodies in rat serum from Pilot-II experiment 
There was a statistically significant increase in autoantibodies concentration in immunised rats. 
Even the rat with the lowest scores (coded as 0005-1) showed an increase in serum CII-
autoantibody titre at the endpoint, indicating the immunisation was carried out successfully but 
did not elicit inflammation. There are many factors involved in the immune response to the 
immunisation ranging from the environmental factors to the normal gut flora of the immunised 
animal. The other possibility is that the animal was still in the subclinical disease state and 
could have progressed to the clinical phase if allowed further.  The highest concentration was 
seen for animal coded as 0004-2 and lowest for 0005-2. The severely diseased had a moderately 
elevated autoantibodies concentration at the endpoint, indicating that the autoantibodies titre is 
a good indicator of the disease induction and immunisation but not of the disease severity 
(Figure 3.5 C).  
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Figure 3.5: Monitoring of CIA in rats. Graphs show A) clinical scores of individual animals; 
B) Bodyweight (ATM = all-time maximum); and C) concentration of anti-CII autoantibodies 
day 0 and endpoint for individual animals, bilateral arthritis. The same rat developed a severe 
form of arthritis and was sacrificed upon reaching HEP based on arthritis score (cumulative 
arthritis score>10 or single paw scoring >4).  
 
 
The endpoint serum concentration of anti-CII autoantibodies was significantly higher than the 
baseline values in CIA rats (median fold change was 19.28, CI 95% and p<0.0045). The 
correlation of autoantibodies concentration with clinical scores and histological scores were 
weak (r= 0.01756 and 0.01089 with CI 95%). 
Overall, these pilot studies revealed that even though RA severity in the older rats was of a 
similar nature to that of the younger rats, the older rats generally coped better with the disease. 
Thus, 10-12 weeks old rats were used for further CIA model characterisation and intervention 
studies. 
3.5 Full scale optimised experiment of CIA characterisation in rats Mean clinical scores 
and serum autoantibodies validation 
Consistent with the pilot experiments, the clinical signs of arthritis started appearing between 
day 12 and 15 of primary immunisation. Swelling and redness in rear paws were considered 
macroscopic indicators of arthritis in the immunised animals. A linear increase in mean clinical 
scores and paw thickness was seen in the symptomatic rats (Figure 3.6 A). The linear 
regression showed a strong correlation between time after immunisation and the mean clinical 
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scores in CIA rats during the symptomatic period (r = 0.94, slope= 0.34 ± 0.038, CI 95%) 
(Figure 3.6 B). Similarly, mean paw thickness increased as the disease progressed (Figure 3.6 
C), and the linear regression correlation showed a strong correlation with time after 
immunisation (r =1) (Figure 3.6 D). As expected, arthritis symptoms were not observed in the 
sham controls (sham control animals underwent the process of immunisation, but instead of 
CII/IFA emulsion, they were administered with saline). Similar to the pilot experiments, serum 
CII-autoantibodies in CIA rats increased from baseline with mean ± SEM 24.97 ± 9.635-fold 
from baseline (p-value 0.018, CI 95%, Welch's one-tailed unpaired t-test) (Figure 3.7 A), 
which indicates the successful immunisation and the immune response to the immunisation. 
However, the autoantibodies titre did not correlate with the severity of the disease, clinical 
scores, and histological scores, implying that the antibody titre was not a good indicator of the 
disease severity in the study (R2= 0.205 and 0.0875 for mean clinical scores and histology 
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Figure 3.6: Characterisation of CIA in rats. Graphs show A) clinical scores vs days after 
immunisation; B) scatter plot showing a relationship between clinical scores versus time (in 
days) after the initial immunisation; C) an increase in paw thickness (mm) during the 
symptomatic phase of the disease, and D) scatter plot showing a relationship between mean 
paw thickness and day after the initial immunisation. R2 indicates the goodness of fit of linear 
regression analysis.  Data points in panel A) and C) represent mean ± SEM (CIA n=9 and sham 
n=3). Data points in panel B) and D) represent the mean for each parameter for all 9 CIA rats 





























































































































Figure 3.7: Validation of anti-collagen autoantibodies in serum. A) The graph shows fold change in serum anti-CII autoantibodies at the 
endpoint relative to baseline. Data points represent mean ± SEM (n=9 and 3 for CIA and sham control, respectively). Scatter plots show linear 
regression analysis between anti-CII autoantibodies titre (x1000 unit/mL) at the endpoint and B) endpoint clinical score, and C) histology scores 
in CIA rats. B-C) Data points represent each replicate staggered across the y-axis, where “r” indicates the Spearman coefficient and “p” represents 
the level of significance of the interaction between endpoint scores clinical and histological and endpoint anti-CII autoantibodies. * p-value <0.01 
Welch’s unpaired two-tailed t-test.  
72 
 
3.5.2 Serum inflammatory cytokines  
The BioLegend multiplex assay measured a set of 13 inflammatory baseline and endpoint 
cytokines in CIA and sham control cohorts. The results showed cytokines in serum from sham 
control except for MCP1 were below the detectable limit. The endpoint serum of CIA rats, 
however, had variable concentrations of the different cytokines (see Appendix C). The 
endpoint serum concentrations of IL-10 (110 ± 63.47), TNF-α (132.1 ± 52.18) and IL-18 (96.33 
± 53.56) were not statistically significant different in CIA relative to sham control (p>0.05, CI 
= 95%). The endpoint concentrations of IFN-γ (96.42 ± 34.83, p-value 0.0122), CXCL1 (83.18 
± 33.54, 0.0190), MCP1 (13055 ± 5733, p = 0.0497), GM-CSF (55.18 ± 13.15, p = 0.0291), 
IL-12p (148.1 ± 61.56, p = 0.0206), IL-1β (603.6 ± 282.7, p = 0.0423), and IL-6 (127.9 ± 
29.99, p = 0.0018) were statistically different in CIA vs sham control, suggesting the 
upregulation of these cytokines in the disease. IL-17A and IL-33 were undetectable in both the 
cohorts (Figure 3.8). The Spearman correlation analysis of the concentrations of serum 
cytokines to mean clinical scores at the endpoint showed a strong and significant correlation 
for IL-6 (r = 1 and slope 19.04, CI 95%), IFN (r =0.775, slope = 17.89, CI 95%) and IL-12p 
(r = 0.828, slope = 30.28, CI 95%). Correlations were strong to moderate but did not reach 
significance for IL-1a (r = 0.724, slope =22.67, CI 95%), GM-CSF (r = 0.428, slope =4.23, CI 
95%), IL-1B (r =0.661, slope =124.2, CI 95%), and MCP1 (r = 0.657, slope = 2301, CI 95%). 
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Figure 3.8: Serum inflammatory cytokines. The graphs show serum inflammatory cytokines 
at the endpoint (most of these were not detectable at day 0 and hence not shown here). Data 
represent mean and error ± SEM of concentration of the respective cytokines in serum collected 
at endpoint (p-values < 0.05 and ** p-value < 0.001 analysed by Welch's unpaired one-tailed 
t-test, n=9 for CIA and n=3 for sham control). The CIA group is indicated by red colour, and 
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Figure 3.9: Serum inflammatory cytokines versus clinical scores. The scatter plots show 
between levels of serum inflammatory cytokines and endpoint clinical scores in CIA rats. Data 
represent the mean and error of concentration of the respective cytokines in serum collected at 
endpoint on y-axis and endpoint clinical scores on the x-axis. “r” represents the Spearman 
correlation coefficient, and “p” represents the level of significance of the interaction between 





Knee and paw joints from age and litter-matched sham controls showed healthy joint 
morphology with no hyperplasia, immune cells infiltration and cartilage destruction. On the 
other hand, the CIA rats showed extensive bone erosion, cartilage degradation, and pannus 
formation (Figure 3.10 and Figure 3.11). Safranin-O Fast Green staining revealed the 
complete loss of knee cartilage in the CIA group compared to sham controls (Figure 3.12). 
Histology scores in knees and paws were significantly higher for the CIA group compared to 
shams, (Mean ± SEM of 5.444 ± 1.26 for knees and 4.444 ± 1.492 for paws, p-values 0.0013 
and 0.0088, respectively (Unpaired t-test with Welch's correction)) (Figure 3.13 A, B). Linear 
regression analysis showed moderate linear relation between endpoint clinical scores and 
histological scores with R2 values of 0.6 and 0.4393 for knees and paws, respectively (Figure 




Figure 3.10: Histological features of CIA in the knee. Representative images of H&E-
stained sections of knees from sham control and CIA rats. All sections (4-7 µm in thickness) 
were made in the sagittal plane and harvested at the endpoint.  CIA rats showing pannus 
formation and invasion (red arrowheads), bone erosion (black arrowheads) and immune cells 




Figure 3.11: Histological features of the paw. Representative images of H&E-stained 
sections of knees from sham control and CIA rats. All sections (4-7 µm in thickness) were 
made in the sagittal plane and harvested at the endpoint.  CIA rats showing pannus formation 
and invasion (red arrowheads), bone erosion (black arrowheads) and immune cells infiltration 






Figure 3.12: Safranin-O fast green staining of the knee. Representative images of safranin-
O fast green stained sections of knees of sham control and CIA rats. All sections (4-7 µm in 
thickness) were made in the sagittal plane and harvested at the endpoint. The Safranin-O-
stained proteoglycan in the knee joint from a sham animal indicates the intact cartilage. There 
is no safranin-O stainable cartilage (red) visible in the diseased joints. The scale bars represent 






























































































































Figure 3.13: Histological scoring of CIA in rats. Graphs show cumulative histology scores 
in A) knee and B) paw joints. Data represent mean ± SEM (n = 9 for CIA and n=3 for sham 
control). The data were analysed by Welch's non-parametric two-tailed t-test (** p-values < 
0.001). The scatter plots show the relationship between cumulative histology scores and 




3.5.4 MicroCT analysis of knee joints 
The microCT is an X-ray-based technique used to visualise the bone and soft tissues and see 
the morphological changes resulting from trauma or disease. A 3D volume reconstruction from 
x-ray radiographs helps determine the changes on the surface of joints. The 3D volume 
reconstructed images show intact joint morphology in sham animals (Figure 3.14 A); in 
contrast, extensive pitting and bone surface erosion can be seen in tomograms from a 
representative severely diseased CIA rat (Figure 3.14 B).  
 
Figure 3.14: Miro-CT images of knee joints. Longitudinal 3D volume reconstructed images 
from μCT cross-sectional X-ray. Images were taken and processed by Bruker microCT. Images 
from representative animals from (A) Sham control and (B) CIA model group. There is no 
evidence of pitting on the joint surface (black arrows) in sham animal (A), while there is 




3.6 Discussion and conclusions 
This study showed a successful generation of CIA in Lewis rats with an overall disease 
penetrance rate of 75% after immunisation with a stable emulsion of CII in IFA. Many factors 
affect the model induction in rats ranging from uncontrollable variables, such as microbial 
flora, to controllable variables; examples include but are not limited to immunisation 
techniques, source and quality of collagen used, the quality of emulsion prepared, and animal 
husbandry (Werb, 1997, Miyoshi and Liu, 2018). Getting a stable emulsion is the first and one 
of the most important steps towards successful immunisation. To make a stable emulsion that 
allows consistent immunogenicity, highly purified commercially available immunisation grade 
CII and IFA should be used (Miyoshi and Liu, 2018). The technique of homogenisation and 
mixing should be well optimised and robust to get the emulsion of consistent immunogenic 
potential. 
The source of collagen used to immunise rats is another important variable in CIA induction 
(Joe and Wilder, 1999, Holmdahl et al., 1989, Asquith et al., 2009). Although CII from various 
species, including CII from bovine, chicken, porcine, mice and rats, have been used to elicit 
the CIA pathologies, the heterologous CII causes a relatively severe form of CIA, while 
autologous immunisation generally causes a slower onset but longer-lasting RA-like pathology 
(Joe and Wilder, 1999, Williams, 2004a).  
In pilot-I experiments, the arthritic symptoms appeared between day 12 and 15 following initial 
immunisation. Maximum severity was reached between day 20 and 25. All of the immunised 
rats developed symptoms to a comparable extent except one rat, which initially had a moderate 
inflammation and then progressed to a severe form of arthritis and reached HEP. The anti-CII 
autoantibodies titre was used to validate the immunisation. An increase in the concentration of 
serum anti-CII autoantibodies indicates an immune response triggered by immunisation which 




thought of grouping animals based on autoantibodies titre on day 9. Still, the results indicated 
no significant increase in the titre on day 9 from day 0. Therefore, the determination of day 9 
autoantibodies was excluded to minimise the impact on animal well-being. Clinical scores and 
arthritic scores were relatively more reliable in this context.  
The anti-CII autoantibodies have been shown to play key roles in the CIA model and joint 
destruction (Brand et al., 2003, Nandakumar et al., 2004). The autoantibodies titre was 
significantly higher at the endpoint, indicating the immune system had successfully responded 
to the stimulus, i.e., exogenous collagen. The production of anti-CII autoantibodies validated 
that the arthritic symptoms were due to the response of the immune system to the administered 
CII and not to the IFA, which may cause arthritic symptoms of its own devoid of 
autoantibodies. The increase in clinical scores was representative of the macroscopic features 
of the disease. It was also observed that the arthritis progression negatively impacted overall 
animal well-being in such dehydration, loss of appetite, and body weight loss. With the onset 
of macroscopic arthritis symptoms, a decrease in body weight was seen. The reasons for 
bodyweight loss may be attributable to the systemic inflammatory response, as it has been 
previously reported that inflammation causes cachexia (loss of appetite) and, or secondary to 
their inability to eat the food, dehydration, restricted and painful locomotion due to inflamed 
joints (Tracey et al., 1988, Walsmith and Roubenoff, 2002). As the antibody titre was not a 
better indicator of disease severity and even some asymptomatic rats had increased antibody 
titre, grouping based exclusively on antibodies would undermine the subclinical cases and 
would include the asymptomatic rats in the diseased group. Therefore, a more reliable 
parameter, i.e., arthritis scores, was used to group the animals, as this included all the clinically 
diseased animal with no ambiguities of subclinical pathologies.  
With the lessons learnt from the pilot-I, the pilot-II experiment with improved food and water 




maintaining hydration by Hartmann’s solution 0.9% saline in moderate to severely dehydrated 
animals resulted in better outcomes. It was hypothesised that 7-8 weeks old rats were too young 
to tolerate the disease; therefore, the older (10-12 weeks old) rats were chosen.   
The findings from the current study shows that the antibodies titre was significantly higher in 
all the immunised animals than sham control indicating the CII/IFA emulsion triggered the 
immune response. Interestingly, the mildly symptomatic and asymptomatic rats from the CIA 
cohort also showed a high titre of autoantibodies, suggesting that the immunisation was 
successful and that the asymptomatic rats had a subclinical disease or immune response. The 
mildly diseased had moderately raised autoantibodies titre. The severely diseased rat had mild 
to moderately elevated autoantibodies suggesting the lack of direct correlation of 
autoantibodies titre with disease severity.  
Following the appearance of arthritic signs, the clinical score and paw arthritic scores increased 
and correlated to the progress of the disease. The interventions, including improved access to 
water and food and saline supplementation, helped improve the animal’s activity level. Overall, 
the two pilot experiments helped in optimisation and understanding the nature of the CIA 
model as well as optimising conditions that decreased the impact of the disease induction on 
animal welfare. 
Using the optimised conditions, the rat CIA model was further characterised and compared to 
control (sham immunised) rats. The endpoint cytokines analysis showed that immunisation 
causes variable effects on the concentration of multiple cytokines in rat CIA serum. The 
inflammatory cytokines IFN-γ, CXCL1, GM-CSF, IL-18, MCP1, TNFα, IL-12p, IL-1b, IL-6 
and IL-10, were raised significantly in immunised rats vs the sham controls and were in 
agreement with previous reports indicating their importance in the model (Chen et al., 2017, 
Kimura and Kishimoto, 2010, Sasai et al., 1999, Mu¨ Ssener et al., 1997). IL-17A has been 




et al., 2010). The role of various inflammatory cytokines in experimental arthritis have been 
reviewed (Luuberts and Berg, 2013). This study also revealed correlation between disease 
severity and concentration of various serum inflammatory cytokines. It was found that IL-6, 
IL-12a and IFN serum concentration have strong correlation with endpoint clinical scores 
suggesting their pathogenic role in the model. Previously these inflammatory cytokines have 
been shown to play roles in CIA but were not studied to its correlation to the disease severity. 
IL-1a, IL-1B and MCP were higher in CIA than sham with a moderate correlation to the disease 
which did not reach to statistical significance. These cytokines have previously been shown to 
increase in CIA in various species, but their correlation have not been established with disease 
severity (Tsubaki et al., 2015, Kimura and Kishimoto, 2010, Lee et al., 2009, Joosten et al., 
1997). Accumulating evidence indicates the involvement of the IL-17 family in orchestrating 
inflammatory events in RA (Ruddy et al., 2004, Witowski et al., 2004). The IL-17A deficiency 
in mice abrogated CIA pathology and was hypothesised to be linked with increased interferon 
expression (Chu et al., 2007, Nakae et al., 2003). 
Moreover, IL-17A has been investigated as a potential target in experimental RA models (Chao 
et al., 2011). IL-17A, interestingly, was undetectable in all animals, irrespective of 
immunisation, although previous reports have shown that IL-17A is crucial in RA and different 
CIA models and RA (Nakae et al., 2003, Ye et al., 2015, Baek et al., 2012, Furuzawa-
Carballeda et al., 2007). This may be due to the difference in phase of inflammation, 
immunisation, and animals’ microbial flora. A report in an acute gut mucosal inflammation 
characterised that IL-17A/F was not involved in the early stage of inflammation, which is not 
a directly relevant model but may explain how the cytokine may play its role differently at 
different phases of inflammation (Songhet et al., 2010). The hypothesis is further supported by 
a clinical report showing that the cytokine IL-17A was not detectable in all diagnosed arthritic 




Similarly, IL-33 was not detectable contrary to previous reports for its strong arthritis and CIA 
model implication. IL-33 and its receptor ST2 are expressed in T-cells and macrophages, and 
activation of the ST2 pathway has been shown to play critical roles in inflammatory processes 
by inducing several other pro-inflammatory cytokines and chemokines (Kakkar and Lee, 
2008). However, there are reports suggesting a dual role of IL-33 as a traditional cytokine and 
an intranuclear regulator (reviewed recently as a potential novel member of alarmin) 
(Haraldsen et al., 2009). The IL-33/ST2 has also been shown to have anti-autoimmune 
bioeffects (Liu et al., 2019). In addition, the total absence of these cytokines, in general, may 
be attributable to the methods used to quantify the cytokines. The methods used in previous 
reports were not similar to the one used in this study, and, therefore, the results may not be 
comparable as previously mRNA quantitation was used (Amsen et al., 2009). As expected, on 
the critical inflammatory cytokines, IL-1a was moderately elevated in immunised rats from its 
baseline (Marinova-Mutafchieva et al., 1997, Williams, 2005). 
In conclusion, this chapter describes the induction and characterisation of CIA in Lewis rats 
and the challenges associated with the model and different characterisation parameters. The 
autoantibodies in this study were not a good predictor of disease severity. Instead, histological 
scores, clinical scores, arthritic paw thickness and scores and inflammatory cytokines can be 

















In addition to its essential role in fibrinolysis, the role of the PAS in the extracellular matrix 
(ECM) degradation and tissue remodelling makes it a possible therapeutic target for multiple 
diseases, including but not limited to cancer and inflammatory diseases (Chapter 1.6).  We 
previously reviewed the clinical and experimental evidence of the various components of the 
uPAS system and their implication in arthritis, and the opportunities they present to develop 
new drugs for RA (Buckley et al., 2019).  
However, most of the experimental work on the system has been undertaken in mouse models 
of arthritis. One of the major pieces of experimental evidence for the pathogenic nature of uPA 
arises from the development of anti-uPA monoclonal antibodies and their effectiveness in 
alleviating CIA symptoms (Almholt et al., 2018). The pathogenic roles of the system in the 
experimental model are not simple and are model-dependent (Almholt et al., 2018, Almholt et 
al., 2020). Considering the clinical and experimental evidence in mouse CIA models and the 
lack of studies in the rat CIA model, an investigation into the role of uPA in rat CIA is highly 
relevant. Thus, the aims of this chapter were to:  
1. compare uPA activity levels in serum and diseased joints versus controls 
2. compare uPAR levels and the activity of key MMPs in the diseased joints versus control 
joints 
3. assess fibrin(ogen) deposition in the diseased joints versus control joints 






4.2  Methods 
All methods used in this chapter are described in Chapter 2 and 3.  
4.3 Results 
4.3.1 Characterisation of natural uPA inhibitors and BB2-30F in fluorogenic uPA 
substrate assays in biological samples  
The utility of the naturally occurring uPA inhibitors PAI-1 and PAI-2 as positive controls for 
serum and tissue homogenate (TH) uPA proteolytic activity was first tested using recombinant 
human proteins (rat PAIs are expensive and not readily available) in biochemical assays. 
Human PAI-1 treatment completely inhibited the activities of purified human, rat and mouse 
uPA at PAI-1: uPA molar ratios of 1:1, 20:1 and 50:1, respectively (Figure 4.1), with 
preferential inhibition seen for mouse uPA over the rat homologue. Human PAI-2 was equally 
effective at inhibiting human and mouse uPA, with complete inhibition at PAI-2: uPA molar 
ratios between 2:1 and 5:1) but was unable to inhibit rat uPA at molar ratios as high as 100:1 
(Figure 4.1). This indicated that human PAI-1 but not PAI-2 would be useful as a positive uPA 
inhibitor control for any subsequent experiments using rat derived tissue homogenates.  
Next, we used BB2-30F as a small molecule highly selective inhibitor of uPA for fluorogenic 
assays (see Chapter 1.7). BB2-30F inhibited purified human uPA in a concentration-dependent 
manner with an IC50 value of 120.8 ± 8 nM (Figure 4.2 A), in line with previous findings 
(Buckley et al., 2018).  BB2-30F was similarly effective against purified rat uPA with an IC50 
of 192.5 ± 7 nM (Figure 4.2 B) but less effective against purified mouse uPA with an IC50 of 
1650 ±8 nM (Figure 4.2 C), indicating significant species selectivity for BB2-30F.  However, 
in this fluorescence-based assay, BB2-30F did not completely inhibit protease activity in THs 
even at a concentration as high as 10 µM, with only complete inhibition observed at 50 µM 
(Figure 4.3).  At 1 µM, BB2-30F caused 50% inhibition. This suggested the contribution of 




PAI-1 (200 nM) to inhibit these activities in BB2-30F treated THs. As the fluorogenic substrate 
used in this assay (Z-Gly-Gly-Arg-AMC) can also act as a substrate for trypsin, thrombin, and 
tPA, and it is likely that thrombin and trypsin, but not tPA (primary target for PAI-1), 
contributed to the residual protease activity in the presence of BB2-30F. It should be noted that 
while BB2-30F is highly selective for uPA, at > 20-fold excess concentrations above the IC50 
for uPA, it will inhibit other serine proteases (Buckley et al., 2018) potentially explaining the 
almost complete inhibition of fluorogenic activity with 10 and 50 µM BB2-30F.  As the 
fluorogenic assay was not sufficiently selective for uPA quantitation in THs, a relatively more 
specific chromogenic uPA substrate (BIOPHEN CS-61(44)) (pyro-Glu-Gly-Arg-pNa.HCl) 












































Figure 4.1: Validation of PAI-1 and PAI-2 inhibition. Graphs show PAI-1 versus PAI-2 
inhibitory activity assays against purified A) human low molecular weight uPA (LMWuPA), 
B) rat high molecular uPA (HMWuPA), and C) mouse HMWuPA in a fluorescence-based 
assay. Molar ratios of PAI:uPA are shown as 1 = 0.75nM or 15 nM uPA for human and 
rat/mouse, respectively. Data represent mean ± SEM of per minute change in fluorescence 
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Figure 4.2: BB2-30F inhibitory assays. The graphs show inhibitory curves from the fluorogenic assay of BB2-30F compound against A) 
human low molecular weight uPA (LMWuPA), B) mouse uPA and C) rat high molecular weight uPA (HMWuPA). Data points indicate mean 
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Figure 4.3: PAI-1 and BB2-30F inhibition of fluorogenic assay in THs. Inhibitory potential 
of BB2-30F in rat THs (200 µg total protein) in the absence and presence (200 nM) of PAI-1. 
A representative experiment from paw THs of an arthritic rat with a high clinical score at the 
endpoint showing the mean ± SEM of per minute change in fluorescence (n=3 technical 
replicates). No differences in the ability of BB2-30F to inhibit overall fluorogenic activity were 
observed between knee and paw homogenates or between other arthritic or sham control rats. 
 
4.3.2 Specificity of uPA chromogenic substrate assay in biological samples and validation 
of rat uPA selectivity of BB2-30F  
BB2-30F treatment inhibited the activities of purified rat uPA and human uPA with IC50 values 
of 120.1+/- 12 and 105.2+/- 9 nM, respectively (Figure 4.4 A and B) in these assays. Similarly, 




inhibition observed at 1 µM (Figure 4.4 C). Unlike the fluorogenic assay, there were no 
residual protease activities seen in the BB2-30F treated THs. The absence of protease activities 
in THs treated the highly selective uPA inhibitor, i.e., BB2-30F, demonstrated that the 
chromogenic uPA substrate assay was sufficiently selective for the determination of uPA 
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Figure 4.4: BB2-30F inhibitory activity in the chromogenic substrate assay. Graphs showing inhibitory curves of effect of BB2-30F against 
A) human and B) rat uPA., Data points represent the mean of per minute change in ODu at 405 nm ± SEM (%of maximum uninhibited control) 
(n = 3). C) Shows the inhibitory effects of BB2-30F in THs. Representative data from paw THs of an arthritic rat with a clinical score 8 at the 




4.4 Characterisation of protease activities in CIA versus sham rats 
Although not specific for uPA, fluorogenic assays were carried out to see the protease activity 
in THs. The fluorogenic assay showed apparent activity in serum and TH from paws and knees. 
No difference in serum activity was found between CIA and sham at either baseline (day 0) or 
endpoint. (p>0.99, two-way ANOVA followed by Bonferroni's test of multiple comparisons). 
Rear paw homogenates from CIA rats showed increased fluorogenic activities, approximately 
two-fold that of sham with mean ± SEM of 70.07 ± 4.87 for CIA and 36.62 ± 2.41 for sham 
(p-value<0.001, Welch's unpaired non-parametric two-tailed t-test). A trend toward decreased 
proteolytic activity was seen in knee homogenates from CIA rats relative to sham; however, 
the difference was not significant (mean± SEM 43.88±4.83 for CIA and 65.46±9.21 for sham 





































































































Figure 4.5: Fluorogenic activities in biological samples. A) serum at baseline and study endpoint and B, C) THs at endpoint from B) paws and 
C) knees. The data points represent mean ± SEM (n = 9 for CIA and n=3 for sham control).  ** p<0.01, ns = non-significant (p>0.05). The 




Spearman correlation revealed a weak correlation between fluorogenic activities and endpoint 
clinical scores for paws (r= 0.48) and knees (r= 0.21). However, when the group was sub-
categorised into mild-moderate and moderate-severely diseased animals, a moderate negative 
correlation was found for mild-moderately diseased animals suggesting the downregulation of 
the proteases causing the fluorogenic activities; and a strong positive correlation was seen in 
moderate-severely diseased animals showing the upregulation of the proteases in diseased 
paws. A similar phenomenon was seen in rear knees as well. For the rats with endpoint clinical 
scores below 5, the protease activities were negatively correlated (r= -0.51 for paw and r =-
0.96 for knee), but for the moderate to severely diseased rats (endpoint clinical >5), the 
correlation was positive between protease activity and endpoint clinical scores (r= -0.99 for 
and r = 0.98 for paws for animals with clinical score <5 and >5, respectively) (Figure 4.6 A-
F).  These interactions were not statistically significant except for uPA activities in knees 
versus endpoint clinical scores for animals with endpoint clinical scores less than 5 and more 
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Figure 4.6: Fluorogenic activities in THs versus disease severity. Scatter plots show activities in paw THs versus A) overall endpoint clinical 
scores B) mild to moderate disease severity (clinical score < 5) and C) severely diseased animal (clinical scores > 5). D-F) Activities in knee THs 
versus D) overall endpoint clinical scores E) mild to moderate disease severity (clinical score < 5) and F) severely diseased animal (clinical scores 





4.4.1 uPA activities in tissue homogenates using chromogenic substrate assay 
As characterised above, this assay is more specific toward uPA than the fluorogenic assay using 
biological samples, such as THs.  The chromogenic activities in THs from paws and knees 
were significantly higher in CIA than in sham control rats with mean values of 0.094 ± 0.0035 
ODu (p-value= 0.0150) and 0.0142 ± 00.0035 ODu (p-value= 0.0019), respectively, versus 
completely no activities in sham control animals (Figure 4.7 A and D). The correlation 
analyses showed that uPA activities in THs from both paws and knees positively correlate to 
cumulative clinical scores (Spearman coefficient r = 0.8286 and 0.9429 for paws and knees, 
respectively) (Figure 4.7 B and E). These findings are different to the mixed protease activities 
measured in the fluorogenic assay. 
The correlation between uPA activities of the paws and knees also moderately correlated with 
histological scores (as shown in chapter 3, CIA rats have higher histological scores) of the 
corresponding joints (Spearman coefficient r = 0.632 and 0.775 for paws and knees, 
respectively), indicating a positive correlation between increasing uPA activities and joint 
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Figure 4.7: uPA determination by chromogenic activity assay. The graphs show uPA 
chromogenic activities in tissue homogenates from A) paws in sham and CIA rats. B) scatter 
plot between uPA chromogenic activities and endpoint clinical scores, and C) histology scores. 
Similarly, D) represents uPA chromogenic activities in tissue homogenates from knee from 
CIA and sham rats. E) scatter plot between uPA chromogenic activity and endpoint clinical 
scores, and F) histology scores. “r” indicates the Spearman correlation coefficient and “p” 
represents the level of significance of interaction between uPA activity and clinical/histological 
scores. The activities are normalised to µg of total protein in THs. A, D) Data points indicate 
mean ± SEM, **p<0.001 and *p<0.05 (Welch's unpaired non-parametric two-tailed t-test, n=9 
for CIA and n=3 for sham control). 
 
4.4.2 Caseinolytic/plasminogen activities of tissue homogenates 
Zymography is another sensitive technique for quantifying proteolytic enzymes in biological 
samples and is based on gel electrophoresis (Gogly et al., 1998). Thus, uPA activities in THs 
were further characterised by casein/plasminogen zymography, whereby activation of 
plasminogen to plasmin acts as is an indirect indicator of plasminogen activator activities in 




CIA than sham control at molecular weight 50-55 kDa, representing uPA. Other proteases 
activities bands were also detectable at 75-80 (tPA) and 30 kDa (LMWuPA) (Figure 4.8A). 
Interestingly, the tPA caseinolytic/plasminogen activities (corresponding to the 70kDa band) 
were lower in all samples than uPA activities and relatively unaffected by disease, suggesting 
that uPA plays a more prominent role CIA than these other proteases.  Densitometric analysis 
of zymograms from across the cohorts confirmed that uPA activities were significantly higher 
in CIA rat knees (95.35± 45.2 ODu) and paws (95.25 ±35.25 ODu) than sham control knees 
(23± 2.25 ODu) and paws (27.18 ± 3.1 ODu) with mean differences of 71.73 (p-value=0.0067) 
and 62.42 (p-value=0.0179), respectively (2WAY ANOVA followed by Bonferroni's test) 
(Figure 4.8 B).  
 
Figure 4.8: Caseinolytic/plasminogen activities of rat knee and paw TH. A) Representative 
image of casein-plasminogen zymogram with THs from rat knee (K) and paw (P) joints from 
CIA and sham control (SC) rat. B) Densitometric analysis of caseinolytic activities of all THs 
from sham control vs arthritic rats. Data points are the mean of optical densitometric units 
(normalised to µg of protein loaded) ± SEM (n=9 for CIA and n=3 for sham control). **p-
value<0.001, * p-value <0.05 compared to corresponding sham control. 
 
4.4.3 uPAR in diseased joints 
The expression of the uPA receptor uPAR and subsequent uPA/uPAR complexation is required 
for activation of colocalised plasminogen and is often also upregulated in RA (See Chapter 1, 




was carried out to localise uPAR in the joints in relation to the pannus formation and immune 
cell infiltrates.  
Western blot analysis showed significantly higher band intensities for diseased CIA joint than 
sham control (Figure 4.9 A). Densitometry analysis of blots from THs across the cohort 
confirmed that uPAR levels were significantly increased in CIA rat knee (5.426± 2.40 ODu) 
and paw (2.76± 1.32 ODu) THs compared to sham control knee 1.162± 0.281 ODu and paw 
1.07± 0.148 ODu (p-value <0.01) (Figure 4.9 A, B and D). Additionally, the uPAR expression 
in knee joints showed a moderate correlation with disease severity (r= 0.7424 with p-value = 
0.045) but a very weak correlation was seen between paw uPAR expression and disease 
severity (r= 0.535 with p-value = 0.235) 
To pinpoint cellular localisation of uPAR expression, IHC was carried out. The rear knees from 
CIA rats showed brown staining when incubated with anti-uPAR antibodies, but staining was 
absent in identical section treated with irrelevant IgG isotype antibodies. Similarly, the joints 
from sham control animals did not show brown staining under the same conditions, indicating 
the absence of uPAR antigen within the detection range for the rear knee samples. The cells in 
the synovial space are most likely the immune cells infiltrate as they are absent in sham control, 
and they are the ones staining dark for uPAR expression, suggesting immune cells have 
increased uPAR expression (Figure 4.10) 
These results, together with the observed increase in uPA activity seen in CIA joints, suggest 
that there is likely to be higher uPA/uPAR colocalisation at the cell surface of synovial 
fibroblasts and immune cells, causing increased plasminogen to plasmin conversion, which in 
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Figure 4.9: Immunoblotting of uPAR Expression in tissue homogenates from knee and paws. A) Representative image of immunoblot probed 
for uPAR expression. The graphs show a comparison of fold change relative to sham control for uPAR expression in CIA and sham control B) 
paw and D) knee tissue homogenates. Data represent the mean ± SEM of optical densitometric units (n=9 for CIA and n= 3 for sham control) 
(**p<0.01). C) and E) The scatter plots show a relationship between uPAR expression and clinical scores for C) paw and E) knee tissue 






Figure 4.10: IHC for uPAR in knee joints. Representative images of a formalin-fixed, 
processed and paraffin-embedded section of the knee joint, stained for uPAR using anti-uPAR 
antibodies and commercial IHC kit. Brown stained (red arrows) synovial tissues in CIA 
represent uPAR expression in the diseased joint, while an identical method with irrelevant IgG 
isotype did not show any staining. Sham control did not show identifiable stained areas above 
non-sepecific background staining. Bars represent 50 µm. 
 
4.4.4 IHC for fibrin(ogen) deposition in diseased joints 
Inflamed joints in RA and CIA show fibrin deposits (Kwieciński et al., 2011, Weinberg et al., 
1991, Orange et al., 2020). By fibrin(ogen) IHC tissues, joint sections from CIA animals 
showed increased fibrin(ogen) staining compared to sham rat joints (Figure 4.11). The 
inflamed joints exhibited fibrin(ogen)-positive structures on IHC slides, indicating the 
fibrin(ogen) meshwork formation in the diseased joint. The serial sections did not show any 




joints did not show any fibrin(ogen) meshwork staining under the identical protocols 
suggesting that fibrin(ogen) deposition is a phenomenon that takes place in CIA similar to RA.  
 
Figure 4.11: IHC for fibrin(ogen) in knee joints. Representative images of formalin-fixed, 
processed and paraffin-embedded section of the knee joint, stained for fibrin(ogen) using anti-
fibrin(ogen) antibodies and commercial IHC kit. Brown stained (red arrows) synovial tissues 
in CIA represent fibrin(ogen) deposition in the diseased joint, while an identical method with 
irrelevant IgG did not show any staining. Sham control did not show identifiable stained areas 
above son-specific background staining. Bars represent 50 µm. 
 
4.4.5 Gelatinolytic Activity in THs  
Gelatin zymography is one of the sensitive techniques used to determine the activity of MMPs 
of collagenases and gelatinases class such as MMP2 and MMP9 in biological samples. THs 
from both the CIA and sham rats gelatinolytic bands of similar intensity at 92 kDa and ~85 
kDa, representing pro-MMP9 and MMP9, respectively (Figure 4.12 A). Other gelatinolytic 
bands visible were at molecular weight 72 kDa and 67 kDa, most likely representing pro-




Densitometry of zymograms from each cohort confirmed that the putative MMP2/9 but not 
pro-MMP2/9 activities were significantly increased in CIA rat knee and paw THs compared to 
sham control THs. The mean band intensities for CIA were 38.4± 18.1 and 39.1 ± 21.5 for 
MMP2 and MMP9, respectively. Sham control band mean band intensities were 5.1 ± 2.1 ODu 
and 13± 8.20 ODu for MMP2 and MMP9, respectively (Figure 4.12 B and C). The increased 
MMPs potentiate the ECM remodelling seen in arthritic joints. This demonstrates the expected 
increase in conversion of pro-MMPs to MMPs in arthritic joints and explains the downstream 
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Figure 4.12: Gelatin zymography for MMPs. A) Representative image of gelatin 
zymography showing the activities of TH (under non-reducing condition) from CIA and sham 
control animals. The graphs show the optical densitometric units (ODu) normalised to the 
protein-loaded in µg in B) knee and C) paw THs. Horizontal lines represent mean ± SEM (n = 
9 For CIA, n=3 for sham) (**p-value<0.01, 2-way ANOVA followed by Tukey’s multiple 





4.5 Discussion and conclusions  
As discussed in chapter 1, the role of uPAS in experimental arthritis is variable across various 
animal models, and no such characterisation has been previously done in rats; therefore, a 
comprehensive characterisation of uPAS was carried out in rat CIA. This study is the first to 
characterise the uPAS in rats and its association with disease severity. Overall, the study 
showed higher uPA activities, uPAR expression and its correlation with the disease severity 
and MMPs in CIA than sham control suggesting the potential implication of the system in the 
disease.  
In the first set of experiments, we tested the utility of human PAI-1 and PAI-2 (the natural 
inhibitors of uPA) against rat uPA using the fluorogenic assay. In this study human PAIs were 
used, as rat PAIs were very expensive. Interestingly, human PAI-2 effectively inhibited mouse 
and human uPA but was ineffective against rat uPA even at large molar excess to the enzyme 
ratios. This has not been previously reported. On the other hand, PAI-1 was effective in 
inhibiting uPA across the 3 species. The species-specific nature of PAI-2 excluded its use here 
as a rat uPA inhibitor, and PAI-1 was used instead in enzyme assays using the CIA and sham 
rat biological samples (i.e., serum and THs).  
To test the utility of BB2-30F (highly selective small-molecule uPA inhibitor) in the rat 
biological samples, different concentrations (50, 10 and 1 µM) of BB2-30F were added to the 
fluorogenic assay. The buffer system contained aprotinin (200 nM) to inhibit trypsin, plasmin, 
plasma kallikrein, and tissue kallikrein present in the biological system. However, BB2-30F 
did not completely inhibit fluorogenic substrate conversion, indicating that TLSPs other than 
uPA, plasmin, trypsin and kallikreins were contributing to the measured protease activity. The 
inability of PAI-1 to inhibit the residual activities of BB2-30F further suggested that proteases 
other than uPA were involved and that the fluorogenic assay was not sufficiently uPA-specific. 




inhibited chromogenic activities of purified human and rat uPA with comparable IC50 values 
to those obtained from the fluorogenic assay. Unlike the fluorogenic assay, BB2-30F inhibited 
chromogenic activities in THs in a concentration-dependent fashion and at much lower 
concentrations (complete inhibition was observed at 1 µM), supporting the specificity of the 
assay for uPA in the samples. Aprotinin in the assay buffer again excluded the possibility of 
plasmin and trypsin originated activities in the samples. In conclusion, the fluorogenic assay 
was not uPA-specific for biological samples and possibly captured other TLSP that BB2-30F, 
PAI-1 and aprotinin could not inhibit. In contrast, the chromogenic assay was sufficiently uPA-
specific for the biological samples.  
Although the fluorogenic assay was not particularly selective for uPA, THs and serum from all 
the CIA and sham rats were tested using the assay to determine the overall trend of protease 
activity. The serum activities were not significantly different between the two cohorts 
suggesting that the systemic proteases in the vascular compartment may not be directly affected 
during the disease course. The paw THs, however, had higher activities in CIA rats than in 
sham control. The correlation between protease activities and disease severity was variable; in 
animals with endpoint clinical scores below 5, the correlation was negative, indicating that 
proteases were downregulated.  In moderate to severely diseased animals (endpoint clinical 
score above 5), the activities were positively correlated, suggesting that proteases were 
upregulated in CIA joint THs.  
In contrast, under the conditions of the uPA chromogenic substrate assay, THs from sham 
control animals did not show any detectable activities, suggesting the balance between pro and 
active uPA with the natural inhibitors, as uPA activity was not detectable. In contrast, the THs 
from diseased knee and paws showed significantly higher activities, suggesting the 




between uPA activities and disease severity in terms of clinical and histological scores, 
confirming the upregulation of the uPA in CIA animals. 
Casein-plasminogen zymography further confirmed the uPA activities in CIA joint THs. The 
lytic bands observed at a molecular weight ~55 kDa represent in situ activation of the 
embedded plasminogen predominantly by uPA and, to some extent, other proteases, such as 
active plasmin and tPA in the sample. This study also revealed significantly higher activities 
in arthritic rats, both in paws and knees than in sham control. Interestingly, uPA was 
undetectable in sham control in chromogenic assay but was detectable in casein-plasminogen 
zymography. This could be attributable to the presence of pro-uPA in sham control animals. 
As the chromogenic assay did not have exogenous plasmin; therefore, the pro-uPA present in 
the samples did not convert to active uPA and did not show activity in the assay. However, the 
casein-plasminogen zymography had exogenous plasminogen embedded in the gel, which may 
have activated the pro-uPA to uPA. The inability of the chromogenic assay to detect the pro-
uPA may underestimate a large amount of pro-uPA present in the CIA as well, and 
theoretically, there should be more uPA than seen in the assay. Casein-plasminogen 
zymography does not face this issue, as the proteins are denatured and renatured only after 
electrophoresis. The proteins in biological samples are electrophoresed in the gel, and only 
defined protease can degrade casein (mostly uPA and, to some extent, tPA at 55 kDa and 70 
kDa, respectively). During the assay, the protein is reversibly denatured (just prior to the 
loading) with SEMS in the gel and remain denatured till after the electrophoresis is done and 
then renatured. The denatured protein and enzymes are less likely to undergo autolysis in the 
gel. In contrast, the chromogenic assay where no denaturation of protease inhibition can be 
incorporated into the assay and the proteases are kept at 37ºC for the entire assay period 
(usually 1-3 hours depending on assay reaching the saturation point) may undergo autolysis 




expression in CIA rats than sham controls suggesting overexpression of the receptor in the 
disease.  The uPAR expression was positively correlated with disease severity.  These findings 
are in agreement with previous studies in clinical RA, CIA and inflammation (Dinesh and 
Rasool, 2018, Mondino and Blasi, 2004, Almholt et al., 2018, Junge et al., 2008), with high 
expression of uPAR and uPA in the diseased joints suggesting an involvement in the 
progression of inflammation. The increased uPAR provides a platform for uPA anchoring on 
the cell surface to activate colocalised plasminogen to plasmin which in turn causes further 
activation of uPA, latent growth factors and MMPs, providing a medium for ECM degradation. 
The uPAR is anchored to the cell surface via a glycosylphosphatidylinositol (GPI) linker. 
Interestingly, having no intracellular or transmembrane domain, uPAR is capable of cell-
mediated signalling due to its association with integrin and uPAR-associated protein (Yuan 
and Huang, 2007). uPA's role independent of its proteolytic activity involves its interaction 
with uPAR and the cell signalling through uPA/uPAR, resulting in many intercellular 
biological changes such as cell proliferation, adhesion, differentiation, and migration (Odekon 
et al., 1992). It has been shown that activated neutrophils in inflammatory exudates in synovia 
act as an essential source of soluble urokinase plasminogen activator receptor (suPAR) (Chu 
et al., 2006). The activated neutrophils release the chemotactically active form of suPAR, 
which may contribute to the recruitment of formyl peptide receptor-expressing leukocytes at 
the site of inflammation and promoting inflammatory progress and joint destruction RA (Pliyev 
and Menshikov, 2010). The higher expression of uPAR and uPA in the diseased joints thus 
also suggests their involvement in inflammation progress. As excessive immune cells 
infiltration and fibrin deposition in the joints was evident on histological examination, IHC was 
carried out to see where uPAR expression was abundant in the joint. Increased uPAR 
expression was evident at locations identified as immune cells infiltrate in HE-stained sections 




in immunopathogenesis as has recently been shown in several inflammatory diseases and 
COVID19 patients (D'Alonzo et al., 2020, Kokkinos et al., 2021, Rosso et al., 2011, Paysant 
et al., 1998). Although a significant portion of the research is dedicated to the proteolytic side 
of the uPAS involvement in cancer and inflammation, uPAR signalling may contribute to the 
pathologies in these diseases (Zhang et al., 2007, Koga et al., 2011) by uPA/uPAR-mediated 
signalling promoting cell adhesion, migration, and proliferation. In fact, uPAR knockdown in 
mice showed total amelioration of CIA similar to uPA knockdown (Thornton et al., 2017).  
MMPs are a group of proteolytic enzymes with varying substrate specificities and cause ECM 
remodelling through proteolytic degradation of various ECM components (Emonard and 
Grimaud, 1990). MMPs are synthesised as zymogens (pro-MMPs) and require proteolytic 
activation. uPA activates colocalised plasminogen to plasmin which in turn causes activation 
of the pro-MMPs (Buckley et al., 2018, Emonard and Grimaud, 1990, Lombard et al., 2005). 
Therefore, uPA indirectly plays an essential role in the activation of MMPs. Gelatin 
zymography is a sensitive semi-quantitative technique used to measure MMP activity in tissue 
samples (Snoek-van Beurden and Von den Hoff, 2005). Once resolved under non-denaturing 
conditions, MMPs proteolytically degrade gelatin leaves non-stained light bands corresponding 
to their molecular weights upon reactivation. In this study, gelatin zymography revealed that 
THs from CIA rats had significantly higher amounts of gelatinolytic activities and, therefore, 
MMPs and in the active form, these were significantly higher in CIA than in the sham control. 
It was noted that pro-MMPs and MMPs were detectable both in CIA and sham control animals. 
The molecular weight corresponding to the proteolytic bands suggests that pro-MMP2, MMP2, 
pro-MMP9 and MMP9 were present in the samples with higher active MMPs (MMP2 and 
MMP9) were seen in CIA than sham control suggesting the activation of a large amount of pro-




to MMPs and therefore causing ECM remodelling and joint destruction seen in RA and in the 
model (Bruno et al., 1998, Rohani and Parks, 2015, Corbel et al., 2000). 
Fibrin deposition in inflamed joints is a critical feature of RA and the CIA (Li et al., 2005a, 
Koizumi et al., 1999). Fibrin deposits in the joints act as a chemoattractant for inflammatory 
cells to the diseased joint, increasing local inflammation that further potentiates ECM 
remodelling. IHC with fibrin-specific antibodies showed significant fibrin deposits in inflamed 
joints while similar were absent in joints from sham control animals. The serine protease tPA 
may help dissolve the fibrin deposits and, therefore, may have a protective role as previously 
reported in RA and experimental arthritis models (Buckley et al., 2018). The fibrin deposition 
may trigger an inflammatory response by attracting immune cells to clear the deposits (Jeon et 
al., 2002). The upregulated uPA in the joint may be beneficial in this context, but the damage 
caused by uPA may overweight the benefits offered by fibrin dissolution in the inflamed joints. 
Altogether, the upregulated uPA, uPAR and fibrin in the model implicate the role of uPAS in 


























CHAPTER 5 In vivo efficacy of uPA inhibitor BB2-30F versus 





As discussed in (Chapter 1, section 6) and from the results shown in Chapter 4, the uPAS plays 
a vital role in the pathogenesis/severity of human RA, which can be observed in both murine 
and rat CIA models.  
As described previously, rat CIA models better reflect the human CIA and represent a relevant 
model for testing uPAS targeted therapeutics. The enzyme inhibitory assays indicated that the 
compound BB2-30F was more potent against rat uPA than mouse uPA, with IC50 values of 126 
nM and 1657 nM, respectively (Chapter 4). Furthermore, BB2-30F blocked uPA activity in 
the CIA rat biological samples. These findings supported the use of the rat CIA model to assess 
the in vivo effects of BB2-30F. The specific aims of the experiments presented in this chapter 
were to: 
1. determine the in vivo efficacy of BB2-30F in rat CIA models 
2. characterise BB2-30F as a pharmacological tool in rat CIA model 
3. demonstrate the in vivo efficacy of methotrexate as a positive control 
5.2 Material and Methods 
The rat CIA model and evidence for uPAS upregulation were described in chapters 3 and 4, 
respectively.  The CII immunogenic emulsion preparation and immunisation of rats, clinical 
score assessments, measurements of autoantigens and cytokines, as well as histological and 
microCT analyses were carried out as described in Chapter 2. All drug administration 
experiments were approved by the University of Wollongong animal ethics committee 
(AE18/02). The CIA group (described in chapter 3 and 4) served as a historical control for 
vehicle treatment as the animals had received an inert vehicle.  
5.2.1 Administration of BB2-30F and Methotrexate 
Rats were administered either BB2-30F at a dose of 7.5 mg/kg ip once-daily or MTx at a dose 




reached the HEP before SEP (Figure 5.1). The dose of BB2-30F was calculated based on the 
dose previously used in mouse using the allometric scaling method using the following formula 
(Nair et al., 2016) 











= 7.32 mg. kg−1 = 7.5 mg. kg−1 rounded up 
A safe and moderate dose of MTx, i.e., 0.75 mg/kg, was chosen based on the pharmacokinetics 
and efficacy in rat CIA (Liu et al., 2013). Treatments were initiated when the arthritic score of 






Figure 5.1: Induction of CIA in rats. The rats were acclimatised to the animal house and 
handling procedures for 7 days prior to immunisation. A stable emulsion was prepared on the 
day of immunisation by mixing an equal volume of CII (0.5M acetic acid) and IFA adjuvants 
and homogenising. Under general anaesthesia, blood was collected, and the 200 µg of CII was 
injected intradermally at the base of the tail, followed by another booster immunisation on day 
7 of the first immunisation with 100 µg of CII, the same route and technique as of primary 
immunisation. The baseline photographs were taken, and the rats were monitored, and any sign 
of arthritis was recorded on a spreadsheet. The treatment was started once the rat reached an 
individual arthritic score of 2 and was continued till the endpoint. At the endpoint, animals 
were sacrificed in a CO2 chamber and blood, and tissues were collected for further analysis. 








5.3.1 The effect of BB2-30F and MTX treatment on anti-CII autoantibodies in serum  
The ELISA analysis of baseline serum, i.e., before immunisation showed no difference in anti-
CII levels among all the cohorts. Animals were randomly assigned to treatment and control 
groups. Anti-CII antibodies in serum at endpoint were vehicle control (113927 ± 3832 u/mL; 
mean ± SEM), BB2-30F (241005 ±5739 u/mL; mean ± SEM) and MTx (248758 ±45030 u/mL; 
mean ± SEM) treated groups. The One-Way ANOVA analysis followed by multiple 
comparison test showed no significant difference between vehicle and BB2-30F treated groups 
(p 0.132) and vehicle and MTx treated group (p 0.0741). The increase in serum anti-CII 
antibodies only suggested the induction of arthritis, and essentially the treatment (BB2-30F and 
MTx) did not affect the titre (Figure 5.2). 
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Figure 5.2: Anti-CII autoantibodies validation in serum. The graph shows serum 
concentration of anti-CII autoantibodies (in units/mL) in vehicle control, BB2-30F and MTx 
treated groups. The data points indicate mean ± SEM, ns indicates non-significant, and p> 0.05. 





5.3.2 Effect of BB2-30F treatment on clinical scores and paw thickness 
The clinical scores for the BB2-30F cohort showed no difference to vehicle control; the scores 
progressed in a similar fashion to the vehicle control (Figure 5.3 A). The linear regression 
showed that clinical scores increased linearly during the symptomatic period (R2=0.8665) 
(Figure 5.3 B). Similarly, paw thickness was not different between the BB2-30F cohort and 
the vehicle control (Figure 5.3 C), with the increase in paw thickness over time was linear 
(R2=1) during the symptomatic period of the disease (Figure 5.3 D). The linear increase in 
clinical scores and paw thickness and no difference between vehicle control and BB2-30F 
treated group suggest the lack of any in vivo effect of the compound on these parameters in the 
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Figure 5.3: Effect of BB2-30F on clinical scores and paw thickness in CIA. The graphs 
show A) Clinical scores and B) scatter plot between mean clinical scores and days after 
immunisation during the symptomatic phase of the disease, C) Paw thickness measurements 
and D) scatter plot linear regression and correlation between mean paw thickness and days after 
immunisation during the symptomatic phase of the disease. A and C) Data points indicate the 
mean ± SEM (n=9 for each group).  B and D) data points indicate means of data staggered at 
the y-axis. The “R2” value indicates the goodness of fit of the linear line. Red and blue colours 
indicate vehicle control and BB2-30F treated groups, respectively.  
 
5.3.3 Effect of BB2-30F treatment on serum inflammatory cytokine profiles  
The LegendPlexTM analysis measures a panel of 13 rat inflammatory cytokines, including IL-
10, IFN, CXCL1, MCP1, TNFα, GM-CSF, IL-18, IL-12p, IL-1B, IL-17A, IL-33 and IL-6. The 
concentrations of 11 cytokines increased variably across the two groups, but IL-17A and IL-
33 were undetectable in serum in both groups (Figure 5.4).  For all the detectable cytokines, 
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Figure 5.4: Serum inflammatory cytokine concentration. The graphs show the 
concentrations of inflammatory cytokines in serum at the study treatment endpoint. Data points 
indicate mean ± SEM; ns indicates no significant difference between the group, p> 0.05. n=9 
for both the groups. Red and blue colours indicate vehicle and BB2-30F treatment groups, 
respectively.  
 
5.3.4 Effect of BB2-30F treatment on histological scoring 
The important microscopic features of CIA, including joint erosion, immune cell infiltration 
and pannus formation, were visible in both groups (Figure 5.5). The cumulative histological 
scores of H&E-stained sections showed no statistically significant difference between vehicle 
control and treatment groups. The mean histological score for vehicle control was 5.44± 3.77, 
and the treatment group was 4.27± 4.47. For paws, the mean histological score for vehicle 
control was 4.44± 4.47, and for the BB2-30F-treatment group was 3.455± 3.29 (Figure 5.6 A 





Figure 5.5: Effects of BB2-30F on histology of knee and paw. Representative images of 
H&E-stained sections of the knee (left panels) and paw (right panels) joints from vehicle 
control and BB2-30F treatment group. The arrowheads show features of CIA, hyperplasia 
(black arrowhead), immune cells infiltration (red arrowhead) and surface erosion (yellow 





























































Figure 5.6: Histological analysis of BB2-30F treatment in rat CIA. The graphs show a 
comparison of cumulative histology scores of A) knee and B) paw of vehicle control 
(represented by red colour) and BB2-30F (represented by blue colour). Data points represent 




5.3.5 Effect of BB2-30F treatment on bone erosion as measured by MicroCT 3D imaging 
The 3D volume reconstruction of selected representative samples showed severe pitting and 
erosion of the surfaces of joints. Qualitatively, there was no difference between vehicle control 
and treatment group in terms of surface roughness and pitting (Figure 5.7).  
 
Figure 5.7: Effect of BB2-30F of joint. Images are representative of animals from vehicle 
control and treatment groups. The surface erosion and pitting are evident on 3D reconstructed 
images microCT imaging of knee joints. 
  
5.3.6 Effect of BB2-30F treatment on uPA chromogenic substrate activities in THs 
The chromogenic assay was used to measure activities in THs from paws and knees from 
vehicle control and BB2-30F treatment groups. The normalised mean per minute change in 
colour at 405 nm in wells for THs from paws were 0.00941±0.0035 ODu for vehicle control 
and 0.01307± 0.0023 ODu for the BB2-30F treatment group (p = 0.203) (Figure 5.8 A). 
Similarly, for THs from knees, the mean per minute change in colour at 405 nm were 0.0093± 
0.0029 ODu for vehicle control and 0.0112± 0.0033 ODu for BB2-30F (p = 0.3408) (Figure 
5.8 B). There was also no difference between the uPA activities in endpoint serum from vehicle 
control and BB2-30F treatment groups (0.000325±0.0000211 ODu/min/mL for BB2-30F vs. 
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Figure 5.8: Effect of BB2-30F on uPA THs and serum. The graphs show uPA chromogenic activities in A) knee, B) paw, and C) endpoint 
serum. The data points represent a change in colour as an increase in absorbance at 405 nm normalised to the amount of protein loaded for THs 




5.3.7 Effect of BB2-30F treatment on uPA-caseinolytic activities in rat CIA 
Caseinolytic activities were detected in treatment endpoint THs from vehicle control and 
treatment groups. The zymogram showed light bands against the dark-stained background at 
50 kDa representing uPA, and a similar band was seen for rat HMWuPA suggesting the 
corresponding bands in the samples were uPA (Figure 5.9 A). The normalised band intensities 
were determined by densitometry. There was no difference between the band intensities 
corresponding to uPA in the vehicle control and BB2-30F treatment groups. The band 
intensities for knee and paw THs in the vehicle control were 142.68 ± 5.96 ODu and 130.19 ± 
6.33 ODu, respectively. For the BB2-30F treatment group, the band intensities for knee and 
paw THs were 128.56 ± 12.7 ODu and 115.6 ± 10.2 ODu, respectively. The statistical 
difference between the two groups was not significant (p>0.05). Overall, the assay showed no 





Figure 5.9: Effects of BB2-30F treatment on uPA-caseinolytic activities in THs. A) A 
representative image of the casein-plasminogen zymogram showing uPA-digested light bands 
on dark background. The light bands at a molecular weight around 55 kDa represent high 
molecular uPA and are similar to the positive control high molecular rat uPA on the right lane. 
The other two bands at 70-75 kDa and 30-35 kDa are likely tPA and low molecular weight 
uPA, respectively. B) The graph shows the comparison of optical densitometric units 
(normalised to the amount of protein loaded) between the two groups for knee and paw THs as 
mean ± SEM (n = 9 each group, ns= non-significant and p > 0.05). VC represents vehicle 
control, TG represents BB2-30F treatment group, K denotes knee, and P denotes paw.   
 
5.3.8 Effect of BB2-30F treatment on uPAR expression 
The western blot analysis showed no difference for uPAR expression between vehicle and 




normalised to the band intensities of Ponceau S stain as a protein loading control and then 
normalised to sham control as baseline control to see the change relative to sham control 
(Chapter 4).  
The mean increase (relative to sham control) in THs from knees was 5.426± 0.849 ODu for 
vehicle control and 6.71± 1.389 ODu for the BB2-30F treatment group. However, the 
difference between the two groups was statistically not significant, indicating no effect of BB2-
30F on uPAR expression (Figure 5.10 B and D). Additionally, the uPAR expression had a 
similar correlation with endpoint clinical scores for knee and paw, with r values of 0.857 and 
0.886, respectively (p<0.05) (Figure 5.10 C and E). Besides, formalin-fixed sections from the 
BB2-30F treatment group stained positive for uPAR on IHC (Figure 5.11). The uPAR 
expression was prominent in the structures identified through histology as hyperplastic tissues 
and immune cells infiltrate, suggesting the upregulation of uPAR in these cell types. Overall, 







Figure 5.10: uPAR immunoblot analysis on THs from paws and knees. A) A representative 
image of western blot probed for uPAR and normalised to Ponceau-S for protein loading 
control. The graphs show uPAR band intensity relative to sham control in the vehicle control 
and treatment groups in THs from B) knee and D) paw. The data points indicate mean ± SEM 
(n=9 for each group, ns= non-significant, p> 0.05). The scatter plots show correlation between 
endpoint clinical scores and mean uPAR band intensity for THs from C) knee and E) paws. 
The “r” indicates the Spearman correlation coefficient. VC= vehicle control, TG= BB2-30F 






Figure 5.11: IHC staining for uPAR in the BB2-30F treatment group. Representative 
images of formalin-fixed sections probed for uPAR through IHC. The upper panel shows 
sections incubated with uPAR antibodies, and the lower panel shows images of sections 
incubated with IgG isotype as a control for non-specific bindings. The black arrows indicate 
uPAR positive cells and tissues in the joint space. Bars represent 50 µm.  
 
5.3.9 Effect of BB2-30F on fibrin(ogen) in the diseased joint 
The IHC of formalin-fixed and paraffin-embedded sections showed the presence of 
fibrin(ogen)-positive bodies in synovial spaces as described in chapter 4 (Figure 5.12). The 
qualitative pattern of fibrin(ogen) deposits in the representative samples from vehicle control 
and BB2-30F treatment did not differ, suggesting that there was no effect of BB2-30F treatment 
on the fibrin(ogen) deposits. 
 
Figure 5.12: IHC staining for fibrin(ogen) in the BB2-30F treatment group. Representative 
images of formalin-fixed sections probed for fibrin(ogen). The black arrows indicate the 




section probed with IgG isotype antibodies did not show staining. The bars represent 50.38 
µm.  
 
5.3.10 The effect of BB2-30F treatment on MMPs in rat CIA 
The gelatinolytic activities in THs were detected in THs from vehicle control and treatment 
groups.  Multiple light gelatinolytic bands were observed on gelatine zymograms. Two light 
bands were detected between 100 and 80 kDa, representing pro and active forms of MMP9 and 
2 light bands were detected between 50 and 60 kDa representing pro and active forms of MMP2 
(5.13 A). The band intensity between the two groups was not statistically significant (p > 0.05) 
in paws and knees THs, indicating no effect of in vivo treatment of BB2-30F in rat CIA (5.13 
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Figure 5.13: Effects of BB2-30F on MMPs in rat CIA.  A) The representative image of 
gelating zymogram. B) Graph shows normalised band intensity of gelatine zymogram of THs 
from knee and paw joints. The data points indicate mean ± SEM (n=6, ns= non-significant and 
p > 0.05). 
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5.3.11 Effect of MTx treatment on clinical scores and paw thickness 
The clinical scores for MTx showed no difference to the vehicle control; the scores progressed 
similarly to the vehicle control (Figure 5.14 A). The linear regression showed between time 
(the day after immunisation), and the mean clinical score showed a linear increase (R2=0.873) 
(Figure 5.14 B), indicating the progress of the disease overtime during the symptomatic period 
and indicates that MTx did not have an effect on clinical scores of the model. Similarly, MTx 
did not change the increase in paw thickness, and the increase in paw thickness showed a linear 
increase over time in MTx-treated animals (R2= 0.7231) (Figure 5.14 C and D). These findings 
suggest that MTx at the given dose and treatment duration did not alter any of these 
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Figure 5.14: Clinical assessment of MTX treatment on rat CIA. The graphs show A) 
clinical scores after immunisation B) scatter plot of linear regression between mean clinical 
scores and time (in days after initial immunisation), C) change in paw thickness (in mm) and 
D) scatter plot of linear regression between mean paw thickness (in mm) and time (in days after 
initial immunisation) during the symptomatic phase of the disease. Data points for A and C 
indicate mean ± SEM (n=9 for vehicle control and n= 11 for MTx treatment groups represented 
by red and purple colours, respectively. Data points for B and D indicates mean, R2 indicates 
goodness of fit of linear regression line. Red and purple colours represent vehicle control and 
MTx-treated group, respectively. 
 
5.3.12 Effects of MTx on serum inflammatory cytokines analysis  
The LegendPlexTM analysis measures a panel of 13 rat inflammatory cytokines, including IL-
10, IFN, CXCL1, MCP1, TNFα, GM-CSF, IL-18, IL-12p, IL-1B, IL-17A, IL-33 and IL-6. 




cytokines increased variably across the two groups, but IL-33 was undetectable in serum in 
both groups.  Methotrexate treatment caused a significant decrease in concentrations of CXCL1 
and IFN-ɣ with statistically significant effects (p<0.05). The other cytokines with a trend of 
reduction but no statistical significance include IL-10, TNF-α, GM-CSF, IL-18 and IL-12p 
(p>0.05). Although there were no statistically significant differences, a trend of reduction is 
apparent in the MTx group. Interestingly, methotrexate caused an increasing trend in IL-6 
which was statistically not significant (p>0.05) (Figure 5.15). These findings suggest the 
possible pharmacodynamic effects of MTx on the immune system in reducing symptoms of 
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Figure 5.15: Endpoint serum inflammatory cytokines analysis. Graphs represent concentrations of inflammatory cytokines in endpoint 
serum from vehicle control (represented by red) and MTx (represented by purple) treatment group. Data points indicate mean ± SEM 





5.3.13 Effect of MTx on histological scores 
The important microscopic features of inflammation, including joint erosion, immune cell 
infiltration and pannus formation, were visible in both the groups but to a lesser extent in the 
MTx treatment group than vehicle control (Figure 5.16). The cumulative histological scores 
of H&E-stained sections showed a decreasing trend in the MTx-treated group, but the 
difference was not statistically significant (p>0.05). In knees, the mean histological score for 
vehicle control was 5.44± 3.77 and for the MTx treatment group was 4.15± 3.25. For paws, the 
mean histological score for vehicle control was 4.44± 4.47, and for the treatment, the group 
was 3.2± 1.29 (5.17 A and B).   
 
Figure 5.16: Histological analysis of knee joints.  Representative H&E-stained knee (left 
panel) and paw (right panel) sections from vehicle control and MTx treatment groups. Bone 
and cartilage destructions (yellow arrowheads) is evident as pitting in of the joint surface, and 
pannus formation can be seen as multilayer synovial hyperplasia (black arrowheads) and 
immune cells in the synovial space (red arrowheads). The images were taken 4x, 20x, 40x 
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Figure 5.17: Histological analysis of formalin-fixed sections of joints. The graphs show 
cumulative histological scores of A) knee and B) paw joints. Data points indicate mean ± SEM 
(n=9 for vehicle control and n= 11 for MTx treatment groups). ns =p>0.05. 
 
5.3.14 Effects of MTx on microCT 3D volume reconstructed images 
The 3D volume reconstruction of selected representative samples showed severe pitting and 
erosion of the surface of joints in vehicle control. Qualitatively, there was less pitting and 
erosion on the surface of the bone in the MTx treated group than the vehicle-treated group, 
suggesting MTx efficacy in reducing the joint destruction (Figure 5.18).  
 
Figure 5.18: 3D volume reconstructed microCT imaging. Images are representative samples 
from vehicle control and MTx treatment group. The surface erosion and pitting are evident on 




5.3.15 Effect of MTx treatment of uPA chromogenic substrate activities 
The chromogenic assay showed similar uPA activities in THs from paws and knees from 
vehicle control and MTx treatment groups. The normalised mean per minute change in colour 
at 405nm in wells for THs from paws were 0.00941±0.0035 ODu for vehicle control and 
0.0081± 0.0011 ODu for the MTx treatment group (p 0.21). Similarly, for THs from knees, the 
mean per minute change in colour at 405 nm were 0.0093± 0.0029 ODu for vehicle control and 
0.0102± 0.0025 ODu (p= 0.39) (Figure 5.19 A and B). 
 






























Figure 5.19: Analysis of chromogenic activity in THs. The graphs show chromogenic 
activity in A) THs from paw joints and B) THs from knee joints.  Data points indicate mean ± 
SEM (n=9 for vehicle control and n= 11 for MTx treatment) ns = p>0.05. 
 
5.3.16 Effect of MTx treatment on uPA-caseinolytic activity in THs 
The caseinolytic activities in THs were detected in THs from the vehicle control and treatment 
group.  The light caseinolytic bands on casein zymograms showed around 50 kDa and parallel 
to active rat HMWuPA representing HMWuPA (Figure 5.20 A). The MTx treated group had 
significantly lower band intensities on the zymogram than vehicle control. The band intensities 
for knee and paw THs in the vehicle control were 142.68 ± 5.96 ODu and 130.19 ± 6.33 ODu, 




ODu 1 (p<0.001) and 103.22 ± 3.5 ODu (p<0.01), respectively (Figure 5.20 B). These findings 







5.3.17 Effect of MTx on uPAR expression 
The western blot analysis showed an increase in uPAR expression normalised to sham control 
Figure 5.21 A). The vehicle control and MTx treatment groups have high uPAR expression 
Figure 5.20: Casein-plasminogen zymography analysis in CIA rats treated with MTx. A) 
Image represents light caseinolytic bands on blue background at molecular weight around 55 
kDa representing high molecular weight uPA. B) Graph shows band intensity normalised to 
the amount of protein for vehicle control and MTx-treated animals. Data points represent mean 





relative to sham control. The mean increase (relative to sham control) in THS from knees was 
5.426± 0.849 for vehicle control and 4.82± 1.14 for the MTx treatment group (Figure 5.21 B). 
In THs from paws, western blot showed increased uPAR relative to sham control in both 
cohorts. The mean increase in band intensity relative to sham control for vehicle control was 
2.76± 0.397 and 4.79± 1.36 for the MTx treatment group (p 0.0889). Besides, formalin-fixed 
sections from the MTx treatment group stained positive for uPAR on IHC (Figure 5.22). 
However, the uPAR-stained structures were less prominent in the MTx treatment group was 
prominent. Overall, these findings suggest that MTx treatment had a modest effect on uPAR 
expression, particularly in knee joints, which was seen as a decrease in western blot (though 
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Figure 5.21: Western blot analysis of uPAR in rat CIA treated with MTx. A) The 
representative image of western blot probed for uPAR shows bands around 55-60 kDa 
representing uPAR. The graphs show uPAR band intensity normalised to sham control in THs 
from A) paw and B) knee joints. The data points indicate the mean ± SEM (n=9 for vehicle 














Figure 5.22: Effect of MTx on uPAR expression. Representative images of formalin-fixed 
sections probed for uPAR through IHC. The upper panel shows sections incubated with uPAR 
antibodies, and the lower panel shows images of sections incubated with IgG isotype as a 
control for non-specific bindings. The black arrows indicate uPAR positive cells and tissues in 
the joint space. Bars represent 50 µm.  
 
5.3.18 Effect of MTx on fibrin(ogen) in the diseased joint 
The IHC of formalin-fixed and paraffin-embedded sections for fibrin(ogen) showed the 
presence of fibrin(ogen)-positive bodies in synovial spaces (Figure 5.23). The qualitative 
pattern of fibrin(ogen) deposits in the representative samples from MTx treatment showed 
fewer fibrin(gen)-positive bodies than the vehicle control. This suggests the effect of MTx on 






Figure 5.23: IHC staining for fibrin(ogen) in the MTx treatment group. Representative 
images of formalin-fixed sections probed for fibrin(ogen). The black arrows indicate the 
presence of fibrin(ogen)-positive structures in the synovial space (upper panel), while a serial 
section probed with IgG isotype antibodies did not show staining. The bars represent 50.38 
µm.  
 
5.3.19 Effect of MTx treatment on MMPs in THs in rat CIA 
The gelatinolytic activities in THs were detected in THs from the vehicle control and treatment 
group (Figure 5.24 A).  Multiple light gelatinolytic bands were visible on gelatine zymograms. 
Two light bands were detected between 100 and 80 kDa, representing pro and active forms of 
MMP9 and 2 light bands were seen between 50 and 60 kDa representing pro and active forms 
of MMP2. The optical densitometry showed that the intensity of bands representing active 
forms of MMP2 and MMP9 were significantly lower in the MTX treated group than the vehicle 




Similarly, MMP9 band intensity was significantly lower in the MTX group than in the vehicle 
control (22.05± 2.94 versus 51.04 ± 3.01, mean ± SEM, respectively p <0.0001). Pro-MMP2 
and pro-MMP9 were not statistically different in MTX versus vehicle control groups (p>0.05) 























































































Figure 5.24: Effect of MTx on MMPs. A) Representative image of gelatin zymogram. 
VC and MTx indicate vehicle control and methotrexate groups. K and P represent knee 
and paw THs. The graphs indicate band intensities in B) knee and C) paw THs. Data 
points indicate mean ± SEM (n=9 for vehicle control and n=11 for MTx group. Red and 


















5.4 Discussion and conclusions 
The potential of uPAS as a new drug target to regress joint destruction and alleviate arthritic 
symptoms has been previously reviewed (Chapter 1, (Buckley et al., 2019). Others have shown 
that mAbs against the active site of uPA ameliorate the CIA in mice (Almholt et al., 2018), but 
no small molecule-based uPA inhibitor had been explored in CIA models until now. It was, 
therefore, of interest to test the uPA active site inhibitor BB2-30F in the CIA in rats, a better 
model of human RA than mouse CIA, and compare this to MTx as a positive control standard 
of care intervention in the model (Wang et al., 2018). 
 Although the compound was active against rat uPA both in THs and serum (chapter 4), BB2-
30F did not ameliorate CIA symptoms in the model. Apparently, higher autoantibodies titre in 
the treatment group was seen; the difference was not statistically different. This suggests two 
possibilities, the treatment did not alter the antibodies production, or anti-CII autoantibodies 
are not a good predictor of the disease severity and poor outcome parameter of the therapeutic 
intervention (as shown in chapter 3). The analysis showed that clinical scores in the vehicle 
versus the treatment group were overlapping, indicating no effects of BB2-30F at the given 
dose and frequency on clinical scores. There was a strong correlation between time (in days) 
and clinical scores, which indicate that the disease had progressed linearly in the diseased 
animals. 
Similarly, paw thickness increased as the disease progressed during the symptomatic phase 
regardless of the intervention. The treatment effect on serum inflammatory cytokines was 
negligible as there was no statistical difference between vehicle and treatment groups. The 
enzyme activity assays, measured using both chromogenic assays and casein-plasminogen 
zymography, also revealed no difference between the groups indicating no in vivo effects of 
the compound on these parameters. However, uPA activity in the serum of the treatment group 




the inhibitory effects of BB2-30F on serum uPA activities. Apart from that, the histological 
scores and microCT revealed no effect of the treatment on the diseased joint indicating failure 
of the compound to alter any of the CIA parameters. Theoretically, inhibition of surface-
localised uPA leads to a reduction in plasmin generation and subsequent downstream effects 
resulting in decreased ECM remodelling and joint destruction otherwise seen in RA (Buckley 
et al., 2019, Green and Lund, 2005, Arroyo and Iruela-Arispe, 2010). To explore the 
downstream effects of uPA on MMP activities by the compound, gelatin zymography was 
carried out; however, there was no difference between the vehicle control and treatment group. 
There are several possible explanations for the lack of in vivo efficacy of BB2-30F under the 
given dosage regimen in this model. Firstly, although preferred for several reasons, the rat CIA 
model is a very aggressive model, and inflammation progresses faster (in days) than clinical 
disease, typically taking months to go from subclinical to clinical phase (Heidari, 2011, 
Williams, 1998). In this study, the deteriorated animal wellbeing and distress secondary to the 
severe inflammation caused by disease progression raised ethical concerns with our AEC, who 
would not allow the study period to continue for longer. This limitation restricted the study to 
test the compound during the acute phase of the disease and over a short period of 10 days 
only. Another possibility could be a lack of drug target-site exposure. Although BB2-30F has 
been previously validated in rat plasma (Buckley et al., 2021), the onsite concentration has 
never been validated. It can be hypothesised that the compound may have faced hindrances in 
distributing to the synovial joints, the actual site of action in CIA.  Therefore, in addition to the 
in vitro potency against the target enzyme, i.e., uPA, sufficient target site drug concentration is 
required to cause clinically visible effects in the disease. 
Moreover, the half-life of the compound is essential in sustaining the concentration well above 
the IC50 value, especially in inflammatory diseases. The IC50 of the compound is 126 nM with 




approach in the mouse lung metastatic model was effective as a uPA inhibitor with 
antimetastatic effects (Buckley et al., 2018). However, the dose to IC50 values in metastatic and 
inflammatory disease may not be comparable. For instance, the anti-uPA antibodies previously 
tested in mouse CIA had IC50 values below 1 nM. The dose regimen of 60 mg/kg three times 
a week had a therapeutic effect in mouse with an initial loading dose of 120 mg/kg to achieve 
steady-state concentration in mouse CIA (Almholt et al., 2018, Almholt et al., 2020). 
Similarly, the half-life of the antibodies was much longer than BB2-30F (42 hours and 6.8 
hours, respectively). The loading dose followed by such a high dose of highly selective anti-
uPA monoclonal antibodies resulted in the abrogation of CIA in mice (Almholt et al., 2018, 
Almholt et al., 2020). Taking into account the ability of the compound to inhibit pure rat uPA 
and uPA in the complex tissue homogenates at a reasonably lower concentrations, it can be 
hypothesised that the inability of the compound to alter disease pattern could be a 
pharmacokinetic or dosage regimen issue instead of a pharmacodynamic issue.  In addition to 
this, inhibition of uPA using BB2-30F may paradoxically exacerbate the symptoms due to the 
impaired fibrin clearance. As in the introduction chapter of the thesis, fibrin deposition is one 
of the important driving forces for inflammation in the joints and therefore inhibition of uPA 
may further potentiate the inflammatory flare. However, in the current study, there is no 
qualitative or quantitative evidence suggesting that the disease was potentiated after the 
administration of uPA inhibitor in the treatment group. Nonetheless, when inhibiting uPA to 
treat inflammation, the potential of exacerbation of the disease due to averted fibrin clearance 
should always be considered.  
To explore these possibilities, more experiments were planned to determine the site of action 
(i.e., synovium) pharmacokinetics of the compound by liquid chromatography-mass 
spectrometry (LC-MS) in order to detect and quantify the compound in synovial aspirates. 




to the unavoidable circumstances during the COVID19 pandemic, investigations were not 
commenced but should be considered in future studies.  
Due to the perceived efficacy, safety, and low cost, MTx is the drug of choice in uncomplicated 
cases of RA with a long history of clinical use (see Chapter 1 section 1.3.2) (Braun, 2011).  In 
this study, MTX treatment was ineffective in decreasing clinical scores and paw thickness 
compared to the vehicle control group for the given dose and treatment period. The effect of 
the MTx treatment on serum cytokines was variable, and a significant decrease in endpoint 
serum cytokines was seen for IFN-ℽ and CXCL1, where the concentrations were significantly 
lower than the vehicle group, recapitulating previous finding (Luo et al., 2013). IFN-ℽ and 
CXCL1 are important cytokines involved in clinical RA, and therefore decrease in these 
cytokines due to MTx treatment explains, in part, the improved clinical outcomes in the CIA 
model (Szekanecz et al., 2010). On the other hand, there was a trend of a statistically non-
significant decrease in the concentration of cytokines IL-10, TNF-α, GM-CSF, IL-18, IL-12p 
and IL-1B. Among these cytokines, TNF-α and IL-18 have been shown to play significant roles 
in disease initiation and joint destruction in clinical RA (McInnes and Schett, 2007). The non-
significant reduction in the concentration of the systemic cytokine in the MTx treatment group 
is interesting but not surprising, as previously it has been shown that MTx significantly 
decreased synovial cytokines but was less effective in reducing systemic cytokine 
concentrations (Issekutz et al., 1994, Williams et al., 1995a, Chang et al., 1992, Williams et al., 
1995b); the spatial differences may be due to MTx 10 fold higher concentration in synovial 
fluids than in plasma (Bologna et al., 1994). 
Interestingly, IL-17 was detectable only in the MTx treatment group. IL-17 has been shown to 
overexpress in RA and has been linked with Th17 mediated immune response to autoantigen 
in joints (Jain et al., 2015). Previously, MTx has been shown to reduce IL-17 in experimental 




difference in the quantitation technique used. The IL-17 mRNA expression previously used to 
quantitate the IL-17 in RA and CIA may not necessarily correlate with the systemic increased 
IL-17 protein.  
On the other hand, IL-6 was modestly increased in the MTx group without statistical 
significance. Previously, ex vivo studies in U937 cell lines showed that MTx increases IL-6 in 
a concentration-dependent manner and does not change serum IL-6 in mouse CIA (Olsen et 
al., 2014, Neurath et al., 1999). Furthermore, IL-6 has pro-and anti-inflammatory properties. 
In mouse models of systemic inflammation, IL-6 was shown to act as an anti-inflammatory 
through the classic signalling pathway by inhibiting cell proliferation (Su et al., 2017). 
However, IL-6 trans-signalling pathway acts as pro-inflammatory in RA by facilitating the 
recruitment of monocytes to the site of inflammation (Scheller et al., 2011). The no or 
increasing effects on some cytokines may be the reason why MTx usually has better efficacy 
and outcomes when combined with other biological and non-biological DMARDs than as a 
monotherapy (Van der Heijde et al., 2008, Fagerli et al., 2014, Breedveld et al., 2006, Tak et 
al., 2011, Katchamart et al., 2009). The modest or no effects of MTx on certain cytokines in 
short term treatment may explain the poor efficacy of this historical drug in macroscopic 
measures of the disease in the model. The low efficacy of MTx in terms of clinical scores and 
paw thickness raises the concern of the drug administration protocols. However, looking at the 
molecular and histological pattern of the MTx treatment group, it is evident that MTx was 
effective in altering some of these features, indicating that MTx was present in the system and 
was performing an antiarthritic action in the model, as shown by decreases in certain cytokines, 
MMPs and decreasing trend in the histological scores. One of the important findings is a similar 
significant decrease in MMPs and histological scores in knees but not paws. This shows a joint-
specific effect of MTx treatment at the given doses and duration in rat CIA. As both the 




and redness in the paw, this can undermine the molecular changes seen in knees. To date, there 
are no reported joint-specific arthritic scorings; therefore, in future, a more joint-specific 
approach can be undertaken to overcome this issue.  
The decrease in the cytokines and histological scores is indicative of the modest effects of in 
vivo MTx administration. The clinical effects of MTx in human RA have been studied over a 
period of weeks, and therefore, a short-term monotherapy with MTx in acute CIA disease may 
not reflect the actual efficacy (Bello et al., 2017). The MTx treatment in this study did not have 
effects that can be seen macroscopically in the form of a reduction in disease severity and 
arthritis scores; however, the treatment improved disease tolerance. Better disease tolerance 
can be defined as the subjective analysis of animal behaviour, mobility and activity assessed 
by the investigators, animal house staff and AEC officials. The subjective improvements may 
be due to the subclinical effects of the treatment. 
Another aspect of the work was to observe the effects of MTx treatment on uPAS in CIA rats. 
However, no difference in uPA activity in paws and knee joint THs were observed. 
Interestingly, the findings from casein-plasminogen zymography showed that uPA levels in 
THs from knee and paw joints were significantly lower in MTx treated animals than in the 
vehicle-treated group. This contradictory finding may be due to the differences in the 
sensitivity and characteristics of the assays.  
Gelatin zymography, a sensitive technique used to determine MMPs (particularly collagenases 
and gelatinases) in biological samples (Kupai et al., 2010), showed lower gelatinolytic 
activities in THs from MTx treated animals in knees. MMP2 is expressed constitutively under 
normal physiological conditions and increases during inflammation, and MMP9 is 
predominantly expressed in inflammatory diseases (Hannocks et al., 2019, Corbel et al., 2002). 
As discussed earlier (chapter 1, section 6), MMPs are downstream effectors in inflammatory 




many other diseases (Xue et al., 2014, Catalán et al., 2009).  The reduction in the active MMPs 
in MTx treated animals may be attributable to the anti-inflammatory effects of MTx and 
subsequent effects downstream. Previously, MTx has been shown to reduce intestinal damage 
in the intestinal mucositis model in rats through various mechanisms, including MMP2 and 
MMP9 (Araújo Júnior et al., 2014, Natarajan et al., 2018). The reduced caseinolytic activity 
accompanied by reduced gelatinolytic activity in THs by MTx is suggestive that reduced uPA 
activity may partly be responsible for lower MMPs in the joints.  The cytokines, such as IL-10, 
IL-1B, and IFN and MMPs interact and cause the disease progress in RA (Lin et al., 2007b, 
Morel and Berenbaum, 2004, Di Girolamo et al., 2006). Taken together, the overall minimal 
effects of MTx on the model suggests that the duration of therapy may not have been sufficient 
for both new interventions (BB2-30F) as well as for standard care MTx treatment.  
In conclusion, this study investigated the -uPA inhibitor BB2-30F for the first time in a CIA 
model. At the given doses and for the given treatment duration, BB2-30F and MTx were 
ineffective in decreasing the symptoms of CIA; however, MTx treatment showed effects on 
histological indices and MMPs indicating a positive effect of the treatment.  Further studies are 

























RA is one of the most debilitating chronic medical conditions causing pain and swelling in 
synovial joints (ACR guidelines, 2002). The uPAS has been shown to play a major role in 
tissue remodelling by mediating proteolytic ECM degradation and facilitating immune cells 
infiltration to the site of inflammation. There is strong clinical evidence showing that the 
expression of uPA is higher in diseased compared to healthy joints. This is seen in mouse CIA 
models, which further implicates uPA overexpression as a pathogenic factor. Other arthritis 
models of localised trauma or immunisation, such as AIA, have suggested a protective role that 
uPA plays against inflammation (Buckley et al., 2019), indicating that the roles of PAS in 
arthritis may be model-dependent. 
The mouse CIA model closely recapitulates RA (Brand et al., 2007). Rat CIA also shows many 
of the fundamental features of RA, such as pannus formation, bilateral joint destruction, and 
anti-CII antibodies production. While CIA has been studied extensively in rats, previous work 
has not measured uPA activity in the model. Also, uPA small molecule inhibitors have not been 
studied in rat CIA models. In the current study, the CIA model was established in Lewis rats 
as described previously (Lon et al., 2011).  
The disease progressed rapidly following the onset of limb swelling, and younger rats were 
unable to tolerate the model and reached the humane endpoint. In contrast, older rats with a 
comparable disease severity tolerated the model well, with some challenges inherent to the 
model, such as the impact of the disease on body weight, body condition, hydration, and overall 
wellbeing. The measurement of serum CII autoantibodies by commercial ELISA validated 
immunisation and the model.   
Investigation of PAS components in the rat CIA model yielded several interesting results. 
Firstly, uPA activities in tissue homogenates measured by chromogenic activity assays and 
casein-plasminogen zymography were higher in the diseased joints relative to sham controls. 




causes increased MMP activation, growth factor activation and ECM remodelling (Serhan and 
Savill, 2005). Increased putative MMP2 and MMP9 activities were observed by gelatin 
zymography in diseased joints relative to sham control, likely due to increased uPA activities 
in the joints. Efficient cell localisation and activation of pro-uPA requires the binding of uPAR, 
expressed on the surface of immune cells. uPAR expression was higher in diseased joints, 
supporting increased uPA binding, likely leading to increased plasmin and consequent 
proteolytic remodelling of the ECM. This was confirmed by histological analysis of tissues 
showing extensive bone and cartilage destruction in the joints. 
The amiloride analogue BB2-30F effectively inhibited uPA activities as measured by 
chromogenic assay in all tissue samples in a concentration-dependent manner.  
This in vitro inhibition thus validated the potential of the compound to inhibit uPA in complex 
biological samples supporting the investigation of its efficacy in the CIA model. BB2-30F 
inhibition inhibits uPA-mediated plasminogen-to-plasmin conversion and potentially inhibits 
its consequent effects, such as MMP activation, growth factors and proteolytic degradation of 
ECM components. However, BB2-30F was not effective in alleviating CIA symptoms in the 
rats under the dose regimen used. The in vivo failure of BB2-30F in reducing CIA symptoms 
in rats may be a consequence of the poor distribution of compound to the target site due to less-
than-optimal pharmacokinetics, causing sub-optimal concentration in the inflamed joints. The 
presumed low tissue exposure may be a result of the inherent physicochemical properties of 
the compound or maybe a result of the dose regimen administered for the duration of therapy 
in the model or a combination of the two (and many other factors as well). Therefore, to address 
these issues, further studies will be required to confirm the concentration of compound present 
within the synovium throughout treatment. Such information would allow the selection of a 
rational dose regime that may achieve therapeutically active concentrations of the inhibitor for 




One efficient approach would be to determine the exposure at target sites first to see if a 
potential therapeutic concentration is achievable for sufficient time. A dose-escalation and 
extended (e.g., 6 weeks) treatments will be necessary to confirm whether this represents a 
viable therapeutic approach.  
The nature of the CIA disease is highly aggressive. Once the inflammatory phase is initiated, 
it may be hard to reverse the damage due to sustained inflammation as the overall body 
condition deteriorate. The issue of aggressiveness of the disease can be addressed using a 
prophylactic intervention where the treatment is initiated before the symptoms appear and can 
reduce the progression of the disease in the treatment group as previously seen with other 
therapeutic approaches (Lin et al., 2007a, Mould et al., 2008). Therefore, it would be interesting 
to see the effect of prophylactic inhibition of uPA in CIA using BB2-30F or similar modalities.  
Furthermore, it would also be interesting to evaluate the efficacy of the compound in other 
arthritis models. The outcomes may be inflammation phase-dependent as in cyclosporine 
(CSA), a potent immunosuppressant with established efficacy in RA. Multiple reports have 
suggested that CSA is more effective in the chronic inflammatory phase of the disease than in 
the acute phase when tested in different experimental arthritis models (Phadke et al., 1982, 
Cannon et al., 1993, Takagishi et al., 1986, Wilder et al., 1987). RA is a chronic version of the 
inflammatory disease; therefore, testing the compound in a model that more closely represents 
the prolonged or sustained state of chronic inflammation as seen in RA may have produced 
different results. However, this was not a possibility in the current study due to time, resource, 
and ethical constraints. 
MTx treatment effectively improved the model tolerability, histological scores and radiological 
finding in diseased joints but did not change paw thickness and arthritis scores significantly. 
This indicates that for the microstructural and molecular changes taking place as a result of 





A systematic approach is under consideration to investigate the in vivo efficacy of the highly 
selective uPA inhibitor in the rat CIA model. Although the compound previously has shown 
reasonable pharmacokinetics in rats (Buckley et al., 2021), the target site concentration in 
synovial joints has not been determined. Future studies should focus on determining the 
concentration of the compound in the synovium. This can be done using the LC-MS technique. 
LC-MS has seen enormous growth in clinical and pharmacological laboratories. The LC-MS 
based techniques are superior to immunoassay or other conventional high 
performance/pressure liquid chromatography (HPLC) due to its specificity for low molecular 
weight analytes (Grebe and Singh, 2011). In future studies, rats would be administered with 
different doses of BB2-30F, and the synovial aspirates collected at different time points after 
the treatment. This would allow the determination of the concentration in synovial fluid relative 
to the IC50 values of the compound against pure rat uPA and the time period for which these 
concentrations are sustained in the synovia. Thus, future studies that fully characterise the 
pharmacokinetics of BB2-30F in rat CIA and utilise dose-escalation together with prophylactic 
(discussed further below) treatment with the compound and by studying the compound in the 
chronic phase of the disease which may be more effective also will help further understand 
why the selective and potent uPA inhibitor BB2-30F failed to show in vivo efficacy in the rat 
CIA model employed in this study. The Kelso lab is currently working on improving BB2-30F 
analogues with improved PK properties (e.g., decreased plasma clearance and metabolic 
stability), which could be tested in vivo to treat RA in the future. 
Another approach would be to test the effect of the long-term treatment with the same dose or 
an escalated dose. As discussed earlier, the current model has ethical constraints secondary to 
its impact on animal wellbeing, and long-term in vivo studies could not be executed. In future, 




wellbeing of the animal while preserving the characteristic hallmarks of the model. This can 
be achieved by showing that analgesics with no anti-inflammatory effects are administered 
with no impact on key parameters of the models, such as swelling, paw thickness, inflammatory 
cytokines, and histology, but is effective in reducing the pain component of inflammation. This 
may allow for the study to continue for the long term with minimal impact on animal wellbeing. 
In addition to this, studies with other uPA inhibitors, such and anti-uPA mAbs and PAIs, 
administered as a positive control to determine in vivo effects of uPA inhibition in the model 
in rats may provide a better understanding of the outcomes of uPAS inhibition in the model. 
Approaches other than pharmacological inhibition may also be attempted to further validate 
the pathogenic roles of the uPAS in rat CIA. Unlike in mouse models (see section 1.6.2), to 
date, no studies have been conducted addressing the impact of uPAS genetic manipulations in 
rat CIA. Among a variety of options, homozygous and heterozygous deletion of uPAS 
components (uPA, uPAR and fibrin, using traditional knock-down and or contemporary 
CRISPR technologies) in isolation and in combination would be helpful in pinpointing the 
interplay between these components in the inflammatory models. Subsequently, injecting the 
animal with exogenous components (uPA and fibrin, for example) in their respective 
genetically modified models against control would be of interest to show how the presence or 
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Appendix A: Zymography buffers and protocols 
Renaturation Buffer  
Final concentration For 250 mL 
2.5% Triton X-100               6.25 mL of 100% 
50 mM Tris HCl 12.5 mL of 1 M stock 
5 mM CaCl2                        625 μL of 2 M stock 
1 μM ZnCl2                       2.5 μL of 0.1 M stock 
H2O 228 mL + 2 mL 2% NaN3 
 
Incubation Buffer 
Final concentration For 250 mL 
1% Triton X-100             2.5 mL of 100% 
50 mM Tris-HCl 12.5 mL of 1 M 
5 mM CaCl2    625 μLof 2 M 
1 µM ZnCl2             2.5 μL of 0.1 M 










5X non-reducing sample buffer (pH 6.8) 
 
Final concentration For 250 mL 
4% SDS 10 g 
20% glycerol 50 mL of 100% 
0.01% bromophenol blue 0.025 g 
125 mM Tris-HCl 4.91 g 
H2O 200 mL 
 
Casein 1% solution preparation 
✓ Take 60 mL MilliQ water 
✓ Add 1 gram of casein 
✓ Soak for 20 minutes 
✓ Add 1 mL of CaCl2 (2M) 
✓ Place on magnetic stirrer  
✓ Stir with magnetic stirrer at 60°C 
✓ Add few drops of 10M NaOH, continue till a clear solution is obtained. Adjust pH 
with HCL 10M to 8.5. Make up the volume to 100 mL. Add 0.02% Azide and filter 
the solution with 0.22 µm membrane. Store in cold room. 
 
Gel preparation 
Resolving Gel (1 mm)  
    MilliQ H2O: 4.8 mL 
    Tris 1.5 M (pH8.8): 2.5mL 
     Acryl/Bis 40%: 2.5mL 




      Plasminogen: (final concentration 20 µg/mL) 
     SDS 10%: 100 µL 
     APS 10%: 50 µL 
     TEMED: 15 µL 
 
Stacking Gel 
 MilliQ H2O: 3.075 mL 
 Tris 0.5M (pH6.8) buffer: 1.25 mL 
 Acryl/Bis 40%: 0.670 mL 
SDS 10%: 50 µL 
APS 10%: 50 µL 
TEMED: 10 µL 
Sample preparation and loading 
✓ Take the suitable amount of protein/whole cell lysates, add and mix loading buffer 5x 
(1:5) 
✓ Incubate on ice for 5-10 minutes 
✓ “DO NOT HEAT” sample should be loaded under non reducing conditions 
✓ Load protein standard molecular weight marker 
✓ Load sample (20-30 µl) 
Running SDS-PAGE 
✓ After loading samples, initially run gel at 65v (constant voltage) 
✓ When stacked, gel can be run at 75-85v (constant voltage) 
✓ When the dye front reaches/leaves the gel at bottom, stop electrophoresis 
✓ Take out gel of the cassette and take image using Gel Imager 
✓ Chop the molecular weight marker and place that in PBS1x in cold room 
Renaturation  
✓ Wash gel with renaturation buffer twice for 30 minutes each 
Developing zymogram 
✓ Incubate the zymogram overnight at 37°C (18-20 hours) 
✓ Stain gel commassie blue stain for 5-7 hours (overnight preferred) 
✓ Destain gel till light band appear against dark background 




✓ Preserve gel in 5% glycerol, 30% methanol solution 
 
Gelatin Zymography 
Gelatine 1% solution preparation 
✓ Take 60 mL Milli-Q water 
✓ Add 1 gram of gelatine 
✓ Soak for 30 minutes 
✓ Place on magnetic stirrer  
✓ Stir with magnetic stirrer at 65°C 
✓ Add few drops of 10M NaOH, continue stirring till a clear solution is obtained. Add 
0.02% azide and filter the solution with 0.22 µm membrane. Store in cold room. 
Resolving Gel   
    MilliQ H2O: 4.8 mL 
    Tris 1.5 M (pH8.8): 2.5mL 
     Acryl/Bis 40%: 2.5mL 
     Gelatine 1%: 0.5 mL (final concentration 0.5mg/mL) 
     SDS 10%: 100 µL 
     APS 10%: 50 µL 
     TEMED: 15 µL 
 
Stacking Gel 
 MilQ H2O: 3.075 mL 
 Tris 0.5M (pH6.8) buffer: 1.25 mL 
 Acryl/Bis 40%: 0.670 mL 
SDS 10%: 50 µL 
APS 10%: 50 µL 
TEMED: 10 µL 
 
Sample preparation and loading 




✓ Incubate on ice for 5-10 minutes 
✓ “DO NOT HEAT” sample should be loaded under non reducing conditions 
✓ Load protein standard molecular weight marker 
✓ Load sample (20-30 µl) 
Running SDS-PAGE 
✓ After loading samples, initially run gel at 65v (constant voltage) 
✓ When stacked, gel can be run at 75-85v (constant voltage) 
✓ When the dye front reaches/leaves the gel at bottom, stop electrophoresis 
✓ Take out gel of the cassette and take image using Gel Imager 
✓ Chop the molecular weight marker and place that in PBS1x in cold room 
▪ Renaturation  
✓ Wash gel with renaturation buffer twice for 30 minutes each 
▪ Development  
✓ Incubate the zymogram overnight at 37°C (18-20 hours) 
✓ Stain gel commassie blue stain for 5-7 hours (overnight preferred) 
✓ Destain gel till light band appear against dark background 
✓ Take image of the gel 
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History: AE1802 Rhematoid arthritis model rats. Female Lewis (LEW/CrlArc) Inbred rats - approx 7 weeks old at induction of 
arthritis with Bovine collagen. Rat developed severe arthritis on 18/8 with wt loss, inappetance and dehydration. Rats had collagen 
injection on D1 30/7/18, and D7 under GA. This rat was slow to recover from GA at second collagen injection on the 6/8/18 was 
given s/c fluids and was ok next day. Arthritis was slow onset compared to others but very severe and rat unable to maintain weight 
and hydration despite fluids and nutritional support. Concerned about kidney function possible immune mediated glomerulonephritis 
or other pathology. 
 
Results: The only significant lesion is seen within the lungs of this animal. There are multifocal small nodular aggregates of 
macrophages that have foamy cytoplasm containing lipid-type vacuoles. This may represent so-called histiocytosis which refers to 
a continuum of lesions ranging from small foci of alveolar macrophages to mixed inflammatory cell infiltrates in which 
macrophages predominate, sometimes associated with fibrosis. This can be an incidental lesion in aged rodents, especially in the 
subpleural regions of rat lung. Intra-alveolar accumulation of lipid-containing macrophages (alveolar phospholipidosis) can also be 
seen due to alteration of endogenous lipid metabolism associated with certain cationic amphophilic drugs. 
 
DDx might include a foreign body response to inhaled material (e.g. bedding) although this would not typically be associated with 
macrophages containing lipid vacuoles. Similarly, an infectious aetiology is unlikely. Special stains have been requested to further 
rule out the presence of microorganisms (PAS, ZN) with results to follow in a supplementary report. However, the lung lesions are 
suspected to be subclinical and probably not related to the previous signs of clinical illness seen in this animal. 
 
There were no lesions to suggest immune-mediated glomerulonephritis in the kidneys. Mild hepatocellular vacuolation is probably due 
to glycogen accumulation. No other lesions were seen in the liver or other organ
 
101 Blacks Road 
Gilles Plains SA 5086 T 
+61 8 8128 4617 
info@compath.com.au www.compath.com.au 





H-EXAM results for sample: 1 
 
Lung: Multifocally, the alveolar interstitium is expanded by vacuolated macrophages forming small 
nodular aggregates or more loose infiltrates. Macrophages have pale eosinophilic cytoplasm and contain 
one or more round clear vacuoles resembling lipid. A few lymphocytes, plasma cells and scarce 
granulocytes are present within and around the periphery of the nodules. There is mild thickening of the 
alveoli septa in affected regions. Mild to moderate, patchy atelectasis is present (non-perfused formalin 
fixation artefact). Multifocally, there are minimal perivascular eosinophilic infiltrates. 
 
Liver: Diffusely, hepatocytes exhibit mild pallor and have feathery to finely granular cytoplasmic 
vacuolation (glycogen- type vacuolation). Lobular architecture is otherwise intact, with no significant 
findings. 
 
Kidney: There is mild congestion. Glomeruli appear within normal limits. 
 














Appendix C: Serum cytokines concentrations 
 




  A4.IL-10 A5.IFN-g A6.CXCL1 A7.MCP-1 
  pg/mL pg/mL pg/mL pg/mL 
  Day 0 End Point   Day 0 
End 
Point   Day 0 End Point 
1-1 1 1 1 22.46893 1 42.43221 1803 2246.903 
  1 1 1 21.54949 1 37.20745 1744 1920.419 
1-2 1 1 1 19.66536 1 1 1701 1966.536 
  1 1 1 15.97321 1 1 1692.5 1879.202 
1-3 1 1 1 14.01684 1 1 1709.42 1629.865 
  1 1 1 18.08253 1 1 1700.85 1503.361 
2-1 1 1 1 18.19944 1 1 1717.5 1598.87 
  1 1 1 13.06921 1 1 1709.29 1742.561 
2-2 1 1 1 32.21125 1 48.71438 1726 2722.208 
  1 1 1 25.17063 1 41.02867 1717.5 2106.329 
2-3 1 58.24805 1 36.00704 1 76.39912 1734.93 18729.59 
  1 48.21225 1 36.33897 1 69.21444 1726 15502.58 
3-1 1 1 1 22.20492 1 19.17734 1743.5 1600.65 
  1 1 1 31.36397 1 25.5865 1734.8 1426.322 
3-2 1 29.69809 1 41.72863 1 44.53831 1752 2846.71 
  1 32.74961 1 49.76564 1 49.96398 1743.39 16408.89 
3-3 1 92.44309 1 58.1125 1 50.3075 1760.82 8220.178 
  1 118.3098 1 61.46899 1 53.0825 1752.02 12364.44 
4-1 1 1 1 1 1 1 1769.54 1653.369 
  1 1 1 1 1 1 1760.69 3024.197 
4-2 1 1 1 1 1 1 1778.3 1607.075 
  1 1 1 1 1 1 1769.41 1709.928 
4-3 1 1 1 1 1 1 1787.1 3419.855 
  1 1 1 1 1 1 1778.16 331.042 
5-1 1 1 1 1 1 1 1795.95 4424.376 
  1 1 1 1 1 1 1786.97 12825.37 
5-2 1 50.53406 1 29.91646 1 22.91695 1804.84 14886.75 
  1 78.19116 1 23.83646 1 18.66383 1795.81 7135.634 
5-3 1 100.6907 1 53.11469 1 45.70147 1813.77 18673.94 
  1 87.90441 1 65.53871 1 55.92783 1804.7 17690.4 
6-1 1 1 1 1 1 1 1822.75 1804.53 
  1 1 1 1 1 1 1813.63 1846.32 
6-2 1 1 1 1 1 1 1831.77 3554.964 
  1 1 1 1 1 1 1822.61 4513.658 
6-3 1 1 1 1 1 1 1840.84 1654.302 
  1 1 1 1 1 1 1831.63 3972.019 
7-1 1 49.54204 1 1 1 22.97185 1849.95 5188.421 
  1 41.02735 1 1 1 21.91938 1840.7 4297.472 
7-2 1 1 1 1 1 1 1859.11 1663.538 
  1 1 1 1 1 1 1849.81 227.7198 




  A4.IL-10 A5.IFN-g A6.CXCL1 A7.MCP-1 
  pg/mL pg/mL pg/mL pg/mL 
  Day 0 End Point 
Day 
0 End Point 
End 
Point   Day 0 End Point 
7-3 1 1 1 1 1 1 1868.31 1639.583 
  1 1 1 1 1 1 1858.97 4679.167 
8-1 1 78.59557 1 80.31145 1 69.5185 1877.558 14748.14 
  1 87.39215 1 70.3097 1 66.5048 1868.17 4468.942 
8-2 1 1 1 1 1 1 1886.85 3530.551 
  1 1 1 1 1 1 1877.42 2159.748 
9-1 1 1 1 1 1 1 1896.19 1641.408 
  1 1 1 1 1 1 1719.5 1805.549 
9-2 1 1 1 43.0859 1 1 1767.77 294.9364 
  1 1 1 40.79361 1 1 1769.53 3026.048 
10-1 1 1 1 1 1 26.6706 1771.303 31920.43 
  1 1 1 1 1 29.79753 1773.075 31868.74 
10-2 1 56.47888 1 18.80089 1 51.06706 1774.85 6849.698 
  1 84.6061 1 16.68603 1 53.97308 1951 55404.97 
10-3 1 1 1 1 1 1 1257.5 14732.16 
  1 1 1 1 1 1 1601 8769.364 
11-1 1 1 1 1 1 1 1156 7975.506 
  1 1 1 1 1 1 1507.5 28001.24 
11-2 1 1 1 21.04269 1 39.59641 1492.43 33017.71 
  1 1 1 20.82549 1 44.23065 1493.92 11987.5 
11-3 1 1 1 1 1 1 1477.19 31162.11 
  1 1 1 1 1 1 1624.9 6128.366 
12-1 1 1 1 1 1 1 1641.15 1996.096 
  1 1 1 1 1 1 1624.74 2235.628 
12-2 1 43.09887 1 25.63713 1 49.6359 1626.37 1327.963 
  1 36.77179 1 23.87136 1 50.54461 1608.15 10868.05 
12-3 1 130.7583 1 21.36464 1 44.13641 1768.97 32374.25 
  1 142.5138 1 18.82115 1 46.36418 1786.66 31065.15 
13-1 1 1 1 1 1 1 1768.79 7496.85 
  1 1 1 1 1 1 1770.56 32746.32 
13-2 1 139.7943 1 18.3162 1 44.33946 1750.73 16792.94 
  1 119.1727 1 20.48738 1 47.02795 1925.8 15793.76 
13-3 1 1 1 1 1 1 1945.06 17373.14 




  A8.TNF-a A10.GM-CSF B2.IL-18 B3.IL-12p70 
  pg/mL pg/mL pg/mL pg/mL 
  Day 0 End Point   Day 0 End Point   Day 0 End Point 
1-1 1 1 1 11.48565 1 1 1 44.90885 
  1 1 1 14.54905 1 1 1 40.81851 
1-2 1 1 1 12.74902 1 1 1 26.41648 
  1 1 1 13.97753 1 1 1 23.57584 
1-3 1 1 1 13.21512 1 1 1 16.50678 
  1 1 1 12.30023 1 1 1 0 
2-1 1 1 1 14.24736 1 1 1 0 
  1 1 1 15.84146 1 1 1 0 
2-2 1 1 1 22.47695 1 54.42 1 53.08078 
  1 1 1 17.2336 1 48.2 1 51.34786 
2-3 1 557.955 1 20.13934 1 66.78 1 106.8886 
  1 488.7145 1 15.16557 1 29.41 1 101.0915 
3-1 1 1 1 14.26322 1 1 1 37.12513 
  1 1 1 12.8369 1 1 1 39.81163 
3-2 1 500.5823 1 1.69447 1 48.2 1 67.33465 
  1 556.4356 1 17.08026 1 48.2 1 64.02825 
3-3 1 553.1125 1 24.49666 1 1 1 103.8575 
  1 561.3537 1 30.54745 1 1 1 107.2354 
4-1 1 1 1 14.88032 1 114.93 1 1 
  1 1 1 27.21777 1 29.41 1 1 
4-2 1 1 1 16.07075 1 1 1 1 
  1 1 1 17.09928 1 1 1 1 
4-3 1 1 1 13.67942 1 1 1 1 
  1 1 1 16.5521 1 1 1 1 
5-1 1 1 1 14.74792 1 1 1 1 
  1 1 1 32.06342 1 1 1 1 
5-2 1 334.1056 1 42.53358 1 35.68 1 45.31737 
  1 207.3631 1 17.83908 1 20.45 1 50.33625 
5-3 1 517.6661 1 38.11009 1 29.41 1 97.03401 
  1 737.2987 1 15.69839 1 25.35 1 112.1511 
6-1 1 1 1 14.76434 1 1 1 28.955 
  1 1 1 13.8474 1 1 1 36.87 
6-2 1 1 1 31.99468 1 1 1 1 
  1 1 1 40.62292 1 1 1 1 
6-3 1 1 1 14.88872 1 1 1 1 
  1 1 1 35.74817 1 1 1 1 
7-1 1 1 1 16.21382 1 54.42 1 40.39812 
  1 1 1 13.86281 1 54.42 1 43.916 
7-2 1 1 1 16.63538 1 48.2 1 1 






  A8.TNF-a A10.GM-CSF B2.IL-18 B3.IL-12p70 
  pg/mL pg/mL pg/mL pg/mL 
  Day 0 End Point   Day 0 End Point   Day 0 End Point 
7-3 1 1 1 14.75624 1 1 1 1 
  1 1 1 42.1125 1 1 1 1 
8-1 1 714.9222 1 46.08792 1 32.31 1 61.8158 
  1 628.1464 1 14.46259 1 45.1 1 55.1614 
8-2 1 1 1 49.77496 1 1 1 1 
  1 1 1 19.43773 1 1 1 1 
9-1 1 1 1 14.77267 1 1 1 1 
  1 1 1 16.24994 1 1 1 1 
9-2 1 377.3048 1 1.769618 1 122.75 1 1 
  1 321.2608 1 14.33391 1 132.31 1 1 
10-1 1 242.4735 1 57.45677 1 1 1 48.12808 
  1 210.223 1 69.95577 1 1 1 45.86508 
10-2 1 467.401 1 15.41182 1 1 1 58.28646 
  1 518.0687 1 61.56108 1 92.41 1 56.82465 
10-3 1 1 1 16.78347 1 32.31 1 1 
  1 1 1 14.34987 1 45.1 1 1 
11-1 1 1 1 17.94489 1 1 1 1 
  1 1 1 56.00249 1 1 1 1 
11-2 1 337.186 1 49.52657 1 1 1 76.02141 
  1 352.7192 1 17.68648 1 1 1 87.2144 
11-3 1 1 1 53.93443 1 1 1 44.76848 
  1 1 1 15.75866 1 1 1 46.16392 
12-1 1 1 1 17.96487 1 1 1 1 
  1 1 1 20.12065 1 1 1 1 
12-2 1 553.1314 1 1.770617 1 1 1 55.58575 
  1 429.6846 1 17.52911 1 1 1 61.17149 
12-3 1 316.3665 1 62.25817 1 1 1 44.13641 
  1 489.6144 1 60.91205 1 1 1 46.36418 
13-1 1 236.348 1 18.74213 1 32.23 1 35.01372 
  1 256.1472 1 81.8658 1 33.4 1 31.36658 
13-2 1 496.188 1 16.79294 1 41.789 1 55.31625 
  1 584.0685 1 17.54863 1 30.21 1 49.60252 
13-3 1 1 1 17.37314 1 1 1 1 





  B4.IL-1B B5.IL-17A B6.IL-33 B7.IL-1a B9.IL-6 
  pg/mL pg/mL pg/mL pg/mL pg/mL 
  
Day 








0 End Point 
1-1 1 122.8314 1 1 1 1 1 1 1 22.91841 
  1 126.2652 1 1 1 1 1 1 1 15.36335 
1-2 1 172.1702 1 1 1 1 1 1 1 22.13258 
  1 142.1887 1 1 1 1 1 1 1 24.96425 
1-3 1 91.9961 1 1 1 1 1 1 1 13.92822 
  1 80.19 1 1 1 1 1 1 1 15.20261 
2-1 1 0 1 1 1 1 1 1 1 17.38849 
  1 0 1 1 1 1 1 1 1 14.89641 
2-2 1 164.1644 1 1 1 1 88.38 1 1 50.26826 
  1 161.3195 1 1 1 1 71.91 1 1 37.16783 
2-3 1 230.6572 1 1 1 1 55.51 104.37 1 58.24266 
  1 216.9391 1 1 1 1 47.37 31.47 1 69.34765 
3-1 1 226.69 1 1 1 1 39.29 1 1 20.08154 
  1 246.8411 1 0 1 1 43.381 1 1 24.8416 
3-2 1 328.6043 1 1 1 1 1 20.81 1 60.47974 
  1 337.3433 1 1 1 1 1 134.71 1 76.14864 
3-3 1 489.3667 1 1 1 1 31.3 1 1 38.85716 
  1 464.1138 1 1 1 1 55.51 31.47 1 41.84451 
4-1 1 109.326 1 1 1 1 1 279.46 1 20.43066 
  1 130.7058 1 1 1 1 47.37 1 1 17.1008 
4-2 1 1 1 1 1 1 55.51 154.65 1 1 
  1 1 1 1 1 1 1 20.81 1 1 
4-3 1 1 1 1 1 1 63.7 1 1 1 
  1 1 1 1 1 1 39.29 1 1 1 
5-1 1 1 1 1 1 1 47.37 1 1 1 
  1 1 1 1 1 1 47.37 1 1 1 
5-2 1 170.7146 1 1 1 1 55.51 1 1 70.82186 
  1 186.6383 1 1 1 1 39.29 1 1 79.02142 
5-3 1 281.7625 1 1 1 1 47.37 1 1 62.9839 
  1 291.5503 1 1 1 1 1 1 1 83.26544 
6-1 1 1 1 1 1 1 1 1 1 38.33884 
  1 1 1 1 1 1 1 1 1 45.25784 
6-2 1 1 1 1 1 1 80.14 1 1 75.52803 
  1 1 1 1 1 1 47.37 1 1 87.82937 
6-3 1 1 1 1 1 1 1 1 1 35.14663 
  1 1 1 1 1 1 39.29 20.81 1 23.24739 
7-1 1 1 1 1 1 1 1 52.61 1 53.20652 
  1 1 1 1 1 1 39.29 124.65 1 62.52167 
7-2 1 1 1 1 1 1 37.02 55.83 1 32.51813 









  B4.IL-1B B5.IL-17A B6.IL-33 B7.IL-1a B9.IL-6 
  pg/mL pg/mL pg/mL pg/mL pg/mL 
  
Day 
0 End Point  Day 0 
 End 
Point Day 0 
 End 




0 End Point 
7-3 1 1 1 1 1 1 41.52 41.52 1 32.77174 
  1 1 1 1 1 1 24.49 50.93 1 46.55105 
8-1 1 252.012 1 1 1 1 55.83 24.49 1 68.44159 
  1 242.8262 1 1 1 1 28.49 158.62 1 55.21315 
8-2 1 1 1 1 1 1 28.49 50.93 1 1 
  1 1 1 1 1 1 46.16 24.49 1 1 
9-1 1 1 1 1 1 1 87.43 37.02 1 1 
  1 1 1 1 1 1 104.4 76.52 1 1 
9-2 1 1 1 1 1 1 32.67 127.96 1 33.22603 
  1 1 1 1 1 1 37.02 46.16 1 25.95909 
10-1 1 1 1 1 1 1 32.67 55.83 1 141.5616 
  1 1 1 1 1 1 87.43 158.62 1 137.0412 
10-2 1 78.20186 1 40.6505 1 1 28.49 98.67 1 144.7032 
  1 69.3946 1 26.9082 1 1 41.52 91.94 1 188.0775 
10-3 1 1 1 24.72267 1 1 127.96 13.71 1 288.5257 
  1 1 1 26.69357 1 1 20.68 50.93 1 242.5158 
11-1 1 1 1 1 1 1 50.93 41.52 1 156.1969 
  1 1 1 1 1 1 41.34 60.85 1 143.1648 
11-2 1 115.8321 1 61.92626 1 1 1 1 1 210.4986 
  1 130.4038 1 64.10154 1 1 1 1 1 218.5278 
11-3 1 1 1 1 1 1 1 1 1 156.9283 
  1 1 1 1 1 1 1 1 1 144.3528 
12-1 1 1 1 1 1 1 1 1 1 1 
  1 1 1 1 1 1 1 1 1 1 
12-2 1 163.7168 1 46.1939 1 1 1 1 1 146.4144 
  1 178.1494 1 69.59859 1 1 1 1 1 190.7584 
12-3 1 135.8913 1 49.61938 1 1 1 1 1 121.9618 
  1 141.3625 1 46.19391 1 1 1 1 1 126.3448 
13-1 1 95.8734 1 26.55561 1 1 1 1 1 175.8662 
  1 98.72143 1 33.86593 1 1 1 1 1 135.2094 
13-2 1 482.2093 1 46.16325 1 1 1 1 1 151.1363 
  1 425.1862 1 31.98061 1 1 1 1 1 135.2701 
13-3 1 1 1 1 1 1 1 1 1 214.978 




Appendix D: Histology scores 
Animal ID 

















Cage No Animal RRK RRP RRK RRP RRK RRP average cumulative average cumulative 
1 1 1 0 1 0 1 0 1 3 0 0 
  2 2 1 1 1 1 1 1.333333 4 1 3 
  3 1 0 1 1 1 0 1 3 0.333333 1 
2 1 1 1 1 1 1 0 1 3 0.666667 2 
  2 2 2 2 2 1 1 1.666667 5 1.666667 5 
  3 2 2 1 2 1 1 1.333333 4 1.666667 5 
3 1 1 1 1 1 1 1 1 3 1 3 
  2 5 5 4 4 5 5 4.666667 14 4.666667 14 
  3 3 3 3 2 2 2 2.666667 8 2.333333 7 
4 1 1 0 1 0 0 0 0.666667 2 0 0 
  2 0 0 0 0 0 0 0 0 0 0 
  3 0 0 0 0 0 0 0 0 0 0 
5 1 0 0 0 0 0 0 0 0 0 0 
  2 0 1 2 1 1 1 1 3 1 3 
  3 5 4 5 3 5 3 5 15 3.333333 10 
6 1 2 2 1 1 1 2 2 2 2 2 
  2 1 1 1 1 1 1 1 3 1 3 
  3 0 0 0 0 0 0 0 0 0 0 
7 1 2 1 2 2 1   1.666667 5 1.5 3 
  2 0 0 0 0 0 0 0 0 0 0 
  3 1 0 1 1 0 0 0.666667 2 0.333333 1 





Appendix D : Histology scores (continued) 
Animal ID 




















l RRK RRP RRK RRP RRK RRP average cumulative average cumulative 
  2 0 0 0 0 0 0 0 0 0 0 
9 1 1 0 1 0 0 0 0.666667 2 0 0 
  2 2 3 2 2 3 3 2.333333 7 2.666667 8 
10 1 1 1 1 1 1 1 1 3 1 3 
  2 3 2 2 2 2 2 2.333333 7 2 6 
  3 1 1 1 1 1 1 1 3 1 3 
11 1 0 0 0 0 0 0 0 0 0 0 
  2 3 3 3 2 2 2 2.666667 8 2.333333 7 
  3 1 1 1 1 1 1 1 3 1 3 
12 1 0 0 0 0 0 0 0 0 0 0 
  2 3 2 2 2 1 1 2 6 1.666667 5 
  3 1 1 1 1 1 1 1 3 1 3 
13 1 2 1 2 2 1 1 1.666667 5 1.333333 4 
  2 3 2 2 2 2 1 2.333333 7 1.666667 5 




Appendix E: Histology scoring criteria 
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